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Attention deficit hyperactivity disorder, or ADHD, is a common childhood 
disorder with the prevalence rate of 5-10%. The prevalence rate in Taiwan is 
around 7-8%. There have been many theories proposed to explain ADHD, and 
one of them focuses on the deficiency of essential fatty acids (EFA), particularly 
omega-3 polyunsaturated fatty acids (n-3 PUFAs). Studies have shown that there 
is a positive correlation between EFA deficiency severity and ADHD symptoms 
and a negative association between blood PUFAs levels and ADHD symptoms, 
but not all studies have shown consistent findings. Moreover, although there have 
been some clinical trials showing that n-3 PUFAs, commonly a combination of 
docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), are effective in 
ADHD, the findings continue to remain controversial. Indeed, there is limited 
research on the effect of n-3 PUFAs on cognitive functions in children with 
ADHD. In addition, the mechanism underpinning the link between PUFAs, and 
ADHD is still unclear, although a role for cortisol and inflammation has been 
suggested.  
My PhD has addressed these research questions in a number of ways. First, I have 
performed systematic reviews and meta-analyses on the cortisol levels and 
PUFAs levels in ADHD, including both children and adolescents, and a 
systematic review and meta-analysis on the effects of n-3 PUFAs 
supplementation on ADHD symptoms and cognitive function in children with 
ADHD. Second, I have conducted a cross-sectional study comparing ADHD and 




blood inflammatory biomarkers, neurotrophins and PUFAs levels. Next, I 
conducted a double-blind randomized controlled study (RCT) of n-3 PUFAs 
(EPA) in children with ADHD, and conducted cognitive function assessments, 
including Weschler Intelligence Scale for Children-Fourth Edition Digit Span 
Subtest (WISCDS) and Continuous Performance Test (CPT) measures, as the 
primary outcome; moreover, I have studied other ADHD severity measures and 
blood levels of inflammatory biomarkers and neurotrophins as secondary 
outcomes.  
In the systematic reviews and meta-analyses, children with ADHD had lower 
salivary cortisol levels (g = -.77, p = .04) and lower morning salivary cortisol 
levels (g = -1.21, p = .02), as well as lower levels of docosahexaenoic acid (DHA, 
g = -.76, p = .0002), EPA (g = -.43, p = .0002) and total n-3 PUFAs (g = -.58, p 
= .0001); moreover, n-3 PUFAs supplementation improved ADHD clinical 
symptoms scores (g = .38, p < .0001) and cognitive measures associated with 
attention (g = 1.09, p = .001).  
In the cross-sectional study, I have enrolled 98 with ADHD youth (mean age 9.32 
+ 3.05 years, 86% males) and 21 TD youth (mean age 9.19 + 2.96 years, 71% 
male). The ADHD youth have lower levels of bedtime salivary levels (p = .030), 
brain-derived neurotrophic factor (BDNF, p < .0001), tumor necrosis-factor alpha 
(TNF-α, p = .009), Linoleic acid (LA) (p = .003) and DHA (p = .018), and higher 
levels of high-sensitivity C- reactive protein (hs-CRP, p < .0001) and interleukin 




In the RCT of n-3 PUFAs (EPA 1.2g) supplementation, I have enrolled 105 
children and adolescents with ADHD, and 98 had completed the 12-week RCT. 
The n-3 group with the lowest baseline EPA level has a greater improvement in 
the CPT measures, hit reaction time (HRT, p = .009), HRT standard deviation 
(HRTSD, p = .043) and HRT interstimulus interval changes (HRTISIC, p = .005); 
such findings are not present in the group with moderate and high baseline EPA 
levels. Moreover, n-3 group with the highest baseline hs-CRP has a greater 
improvement on WISCDS longest digit span backward score (p < .001), 
WISCDS digit span backward score (p = .001), WISCDS total score (p = .026) 
and prosocial behavior (p = .021). There were no significant changes in the 
parent-, teacher- and youth-reported ADHD symptoms, emotional symptoms, and 
blood levels of inflammatory and neurotrophin biomarkers between n-3 and 
placebo group. 
In conclusion, my findings provide evidence that ADHD youth have lower 
PUFAs, cortisol and BDNF levels, and a higher state of inflammation than TD 
youth. My findings further supported the efficacy of n-3 PUFAs, especially EPA, 
in improving inattention and vigilance associated cognitive measures in ADHD 
with a low EPA level at baseline; and improving working memory and prosocial 
behavior in ADHD with high baseline inflammation status. Further research is 
needed to explore the effects of EPA on the clinical symptoms of ADHD 
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1.1 Attention deficit hyperactivity disorder (ADHD)- symptoms and 
prevalence 
Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental 
disorder that has been under-recognized. Children with ADHD often have 
profound manifestations of inattention, hyperactivity and impulsivity and have 
impairment in school, social, and daily functions (American Psychiatric 
Associaiton, 2013). The prevalence rate of ADHD is around 5-10% (Biederman 
& Faraone, 2005), while about two-thirds of children with ADHD will have 
persistent symptoms into adulthood (Hechtman, 1999). The Diagnostic and 
Statistical Manual of Mental Disorders-Fifth Edition (DSM5) criteria for ADHD 
include 1) symptoms of inattention, hyperactivity, and impulsivity need to appear 
before 12 years of age, 2) had significant functional impairments in social 
interactions, academic performances, and daily living in more than 2 settings 
(e.g., at home, school or work; with friends or relatives; in other activities), and 3) 
the symptoms do not happen only during the course of schizophrenia or another 
psychotic disorder. The symptoms are not better explained by another mental 
disorder (e.g. Mood Disorder, Anxiety Disorder, Dissociative Disorder, or a 
Personality Disorder) (APA, 2013).  
The DSM5 inattention criteria includes:  
• Often fails to give close attention to details or make careless mistakes in 




• Often has trouble holding attention on tasks or play activities. 
• Often does not seem to listen when spoken to directly. 
• Often does not follow through on instructions and finish schoolwork, 
chores, or duties in the workplace (e.g., lose focus, side-tracked). 
• Often has trouble organizing tasks and activities. 
• Often avoids, dislikes, or is reluctant to do task that require mental effort 
over a long period of time (such as schoolwork or homework). 
• Often loses things necessary for tasks and activities (e.g. school materials, 
pencils, books, tools, wallets, keys, paperwork, eyeglasses, mobile 
telephones). 
• Is often easily distracted. 
• Is often forgetful in daily activities. 
The DSM5 hyperactivity and impulsivity criteria includes: 
• Often fidgets with or taps hands or feet, or squirms in seat. 
• Often leaves seat in situations when remaining seated is expected. 
• Often runs about or climbs in situations where it is not appropriate 
(adolescents or adults may be limited to feeling restless). 




• If often “on the go” acting as if “driven by a motor.” 
• Often talks excessively. 
• Often blurts out an answer before a question has been completed. 
• Often has trouble waiting his/her turn. 
• Often interrupts or intrudes on others (e.g., butts into conversations or 
games). 
Based on the types of symptoms, there are three kinds of presentation of ADHD. 
The Combined Presentation is when the child presents enough symptoms of both 
criteria for inattention and hyperactivity-impulsivity for the past 6 months. The 
Predominantly Inattentive Presentation is when the child presents enough 
symptoms of inattention but not hyperactivity-impulsivity for the past 6 months. 
The Predominantly Hyperactive-Impulsive Presentation is when the child 
presents enough symptoms of hyperactivity-impulsivity but not inattention for the 
past 6 months. 
My PhD will investigate the omega-3 polyunsaturated fatty acids (n-3 PUFAs) in 
ADHD with a variety of approaches, including meta-analyses, a cross-sectional 





1.2 ADHD- Aetiology 
Many environmental factors may play a role in the pathophysiology of ADHD. 
For example, the risk of ADHD is doubled or tripled among offsprings of mothers 
who smoked during pregnancy (Froehlich et al., 2009). Children with mothers 
who had obesity or diabetes during pregnancy also have a higher risk of ADHD 
(Buss et al., 2012; Rodriguez et al., 2008). Other prenatal and perinatal factors 
associated with ADHD include low birth weight and prematurity (Bhutta, Cleves, 
Casey, Cradock, & Anand, 2002), and in-utero exposure to maternal stress, 
alcohol, prescribed drugs such as paracetamol and illicit substances (Liew, Ritz, 
Rebordosa, Lee, & Olsen, 2014; Thapar, Cooper, Eyre, & Langley, 2013; 
Thompson et al., 2014); and in-utero or early childhood exposure to 
environmental toxins such as lead, organophosphate pesticides and 
polychlorinated biphenyls (Thapar et al., 2013). The nutritional surplus of sugar 
and artificial food coloring and nutritional deficiencies of zinc, magnesium and 
polyunsaturated fatty acids (PUFAs) have also been associated with ADHD 
(Lange et al., 2017; Millichap & Yee, 2012). 
ADHD is a multifactorial disorder, involving the gene-environmental interactions 
(Figure 1). More discussion on ADHD and genetics will follow in section 1.3.5. 
My PhD will focus on the following two theories: the deficiency of omega-3 
polyunsaturated fatty acids (n-3 PUFAs) (Stevens et al., 1995) and inflammation 
(Leffa, Torres, & Rohde, 2018) in ADHD.  
My PhD will investigate the effects of n-3 PUFAs in ADHD with a variety of 




controlled trial. My PhD will also focus on the inflammation mechanisms that 






Figure 1 Multiple factors contributing to the development of ADHD  




1.3 Main biological systems involved in ADHD 
There have been many theories proposed to explain ADHD, and in this section, I 
will focus on the findings of the following biological systems involved in ADHD: 
1) Hypothalamic-Pituitary-Adrenal (HPA) axis and cortisol levels, 2) 
inflammation, 3) neurotrophins, 4) brain image studies and 5) genetic studies.  
ADHD often co-occur with allergic diseases and the correlation between ADHD 
and streptococcus-mediated neuropsychiatric disorders suggest the participation 
of the immune system in ADHD pathogenesis (Verlaet, Noriega, Hermans, & 
Savelkoul, 2014). It has been argued that a sustained and exaggerated release of 
inflammatory cytokines in atopic eczema (AE) affected children may impact 
ADHD relevant brain circuits and affecting behaviour and motor control, 
emotional regulation, or motivational mechanisms (Verlaet et al., 2014). For 
example, children suffering from atopic disease may have increased levels of pro-
inflammatory cytokines, like interferon- gamma (IFN-γ) and interleukin- 6 (IL-6), 
which may pass through the blood-brain-barrier (BBB), bind to the receptors on 
vagal sensory nerves and stimulate the HPA axis (Verlaet et al., 2014). Thus, 
exaggerated cytokine release during the early years of AE may lead to an initial 
hyperactivity of HPA axis but followed by a down-regulation of HPA axis 
response in the later years as AE becomes a chronic condition (Verlaet et al., 
2014). Malfunctioning of the HPA axis may be a symptom of AE in infancy, but 
later contribute to ADHD development in adolescents with susceptibility (Buske-
Kirschbaum et al., 2013). This theory is further supported by studies showing 




In addition, studies of neurotrophin levels such as brain-derived neurotrophic 
factor (BDNF), beta-nerve growth factor (bNGF), glial cell line-derived 
neurotrophic factor (GDNF) and neurotrophin factor 3 (NT-3) (Tsai, 2017) and 
brain image studies (Shaw et al., 2007) have suggested that ADHD and typically 
developing youth (TD) are different not only in the brain structure but also in 
brain function. Moreover, genetic studies have also attempted to identify potential 
genes involved in ADHD (Faraone & Mick, 2010).  
1.3.1 Hypothalamic-Pituitary-Adrenal (HPA) axis 
HPA axis regulates homeostasis via the production of cortisol when the body 
encounters stress. When the body is under stress, Corticotrophin Releasing Factor 
(CRF), the main activator of HPA axis, is synthesized in the hypothalamus and 
then travels to reach the anterior pituitary to stimulate the release of 
Adrenocorticotrophic Hormone (ACTH). ACTH then reaches the adrenal cortex 
to stimulate the synthesis and secretion of cortisol. The cortisol then binds to 
either the mineralocorticoid receptors and the glucocorticoid receptors, and 
suppress the immune system. On the other hand, the level of cortisol is crucial for 
the negative feedback to terminate HPA axis response to stress. The negative 
feedback can be either made to the pituitary (inhibition of synthesis and release of 
ACTH) or the hypothalamus (inhibition of the synthesis and release of CRF) 
depending on the concentration of the cortisol (Dallman & Yates, 1969; Gjerstad, 
Lightman, & Spiga, 2018). However, several inflammation-associated disorders 
have been associated with impaired negative feedback of the HPA axis, such as 




ADHD has also been associated with dysfunction of the HPA axis (Ryan, 1998), 
but with inconsistent results. In the first study to suggest abnormalities of the 
HPA axis in children with ADHD, Steingard et al described a higher rate of 
dexamethasone nonsuppression in children with ADHD when compared with 
controls (22.7% vs 0%) (Steingard, Biederman, Keenan, & Moore, 1990); which 
indicated that children with ADHD who received dexamethasone, or synthetic 
cortisol, continued to have higher cortisol levels than control group. This further 
suggests that children with ADHD have impaired negative feedback on the 
secretion of hormones of the HPA axis regulating cortisol releases, such as CRF 
and ACTH. Subsequently, Kaneko et al (Kaneko, Hoshino, Hashimoto, Okano, & 
Kumashiro, 1993) found that only around 40% of children with ADHD had 
normal diurnal cortisol rhythm, defined as a diurnal cortisol variation showing a 
maximum level in the morning and a minimum level at night, as compared with 
90% of adult controls and 81% of children with autistic spectrum disorders 
(ASD); moreover, abnormal cortisol rhythms were more frequently found in 
children with severe ADHD compared with children with mild ADHD (Kaneko 
et al., 1993).  
However, subsequent studies have found less consistent findings. For example, 
one study comparing ADHD and TD children reported a lower morning salivary 
cortisol level in children with ADHD (Isaksson, Nilsson, Nyberg, Hogmark, & 
Lindblad, 2012), while another study reported no such differences (van West, 
Claes, & Deboutte, 2009). Moreover, some studies were able to demonstrate a 




1993; Wang et al., 2011) and total ADHD symptoms (Wang et al., 2011), while 
other studies failed to report such an association (Pesonen et al., 2011).  
 1.3.1.1 Behaviour Inhibition System (BIS) 
The relationship between ADHD and the putative HPA axis abnormalities could 
partly be explained by the reduced behavior inhibition in ADHD. According to 
Gray’s reinforcement sensitivity theory (Gray & McNaughton, 2003), the 
Behaviour Inhibition System (BIS) represents sensitivity to punishment. The BIS 
distributes among a number of neural structures controlled by the septo-
hippocampal system and the amygdala, and also represents sensitivity to conflicts 
in general (Gray & McNaughton, 2003; McNaughton & Corr, 2004). Activation 
of BIS tends to lead to behaviours that will decrease the chance of potential 
punishment (i.e., avoidance behavior) (Gray & McNaughton, 2003) and has been 
positively associated with an increase in cortisol levels in healthy children (Blair, 
Peters, & Granger, 2004). Meanwhile, low cortisol levels have been linked with 
novelty seeking in animal study (Short et al., 2014), and novelty seeking has been 
associated with hyperactivity symptom domain of the ADHD symptoms (Yoo, 
2016). Thus, the reduced BIS activity in ADHD may, conversely, lead to reduced 
HPA axis activity and increased hyperactivity manifestations.  
1.3.1.2 Basal cortisol level vs cortisol reactivity 
HPA axis function can be examined with two approaches: measurements of basal 
cortisol levels, or resting cortisol levels to examine changes in the diurnal pattern 
(Weitzman et al., 1971), and measurements of cortisol reactivity, or cortisol 




association between basal levels of cortisol and externalizing behavior has been 
shown in a meta-analysis of basal cortisol levels in children and adolescents 
(Alink et al., 2008), while the association between cortisol reactivity and behavior 
remained inconsistent (Alink et al., 2008). Moreover, meta-analyses showed that 
ADHD youth had lower basal cortisol levels than TD youth (Scassellati, 
Bonvicini, Faraone, & Gennarelli, 2012), but no association between cortisol 
reactivity and ADHD (Kamradt, Momany, & Nikolas, 2018).  
Previous studies on HPA axis in ADHD only used a limited number of time-
points, with only one to three-time points throughout the day or with more time 
points in the morning, for cortisol sample collection. For example, one study used 
one time point for cortisol measurements (Snoek, Van Goozen, Matthys, 
Buitelaar, & van Engeland, 2004), while another study measured cortisol at 3 
different time points (Isaksson et al., 2012); this might not represent the diurnal 
changes of cortisol levels in ADHD. Moreover, the gender distribution of the 
studies may also contribute to the inconsistent findings of cortisol levels in 
ADHD. For example, there were about 45% boys in the study by Maldonado et 
al. (2009), but 100% boys in the study by Jansen et al. (1999). Other differences 
between the studies included medication use of the enrolled subjects. Angeli et al. 
(2018) enrolled drug-naïve patients, while 89% of participants in the study of 
Isaksson et al. (2012) took either central stimulants or atomoxetine or both. 
Moreover, the methods used for saliva collection also vary from study to study, 
where Jansen et al. (1999) used citric acid-induced saliva for sample collection, 
Randazzo et al. (2008) used the passive drool technique, while Isaksson et al. 




The sample source also provides different details of HPA axis activity. For 
example, salivary cortisol tends to reflect the unbound or “free” fraction of 
cortisol, while plasma tends to reflect the total cortisol; and the free cortisol is the 
cortisol that acts on the target tissue (Kirschbaum & Hellhammer, 1994). In 
addition, the collection of saliva sample is a non-stressful and noninvasive 
technique, while the collection of plasma sample can be stressful and confound 
basal cortisol levels.  
My PhD will investigate salivary cortisol levels in ADHD with a meta-analysis 
and a cross-sectional study. 
1.3.2 Inflammation associated biomarkers in ADHD 
Inflammation has been suggested to play a crucial role in the pathogenesis of 
ADHD. Epidemiology and genetic studies have provided support by showing a 
high comorbidity of ADHD with inflammatory and autoimmune disorders and the 
differences in biomarkers between ADHD and TD youth. For example, ADHD 
are more likely to have allergy associated disorders including asthma, rhinitis, 
atopic dermatitis and allergic conjunctivitis (Miyazaki et al., 2017; Schans, Cicek, 
de Vries, Hak, & Hoekstra, 2017) and psoriasis (Hegvik, Instanes, Haavik, 
Klungsoyr, & Engeland, 2018). Moreover, A personal and maternal history of 
autoimmune diseases, such as thyrotoxicosis, type 1 diabetes, autoimmune 
hepatitis, psoriasis and ankylosing spondylitis, has been associated with an 
increased risk for ADHD (Nielsen, Benros, & Dalsgaard, 2017).  
The inflammatory and autoimmune disorders may be associated with the 




cortex (Buske-Kirschbaum et al., 2013), which are often impaired in ADHD 
(Sebastian et al., 2014). Cytokines produced by systematic inflammation may 
pass the blood-brain barrier, affect the synaptic plasticity and neurogenesis, and 
may even induce T-cell mediated neuroinflammation (Buske-Kirschbaum et al., 
2013; Oades, Dauvermann, Schimmelmann, Schwarz, & Myint, 2010), which 
then contribute to the pathogenesis of ADHD. Moreover, ADHD has been shown 
to have a higher comorbidity with T-cell mediated neuroinflammation (Gungor, 
Celiloglu, Ozcan, Raif, & Selimoglu, 2013; Schmitt, Buske-Kirschbaum, & 
Roessner, 2010).  
Furthermore, ADHD has been suggested as the result of an exaggerated central 
nervous system (CNS) inflammatory response in fetus associated with maternal 
inflammation (Leffa et al., 2018). Neonatal infection associated with 
inflammatory responses and systematic inflammation during the first postnatal 
month has been shown to be associated with the risk for ADHD at 10 years of age 
(Allred et al., 2017). As for the genetic studies, De Jong et al (2016) found a 
similar genetic signature between ADHD and depression in genes related to 
inflammation. On the other hand, the studies regarding inflammatory biomarkers 
in ADHD have been inconclusive. For example, some studies reported a higher 
immunoreactivity and higher levels of pro-inflammatory cytokine such as IL-6 
and anti-inflammatory cytokine such as IL-10 in ADHD (Donfrancesco et al., 
2016; Passarelli et al., 2013), while others found no differences in IL-1b, IL-6, 
IL-10 levels between ADHD and TD groups (Corominas-Roso et al., 2017; 




In addition, there had been no studies comparing levels of C-reactive protein 
(CRP) in youth with ADHD and TD youth. In the literature regarding CRP and 
ADHD, there has been one study reporting no association between ADHD 
symptoms and CRP in a non-ADHD sample (Vogel et al., 2017). Meanwhile, 
another study measured levels of IL-6 and CRP after n-3 PUFAs supplementation 
in children with ADHD (Hariri et al., 2012) and found a decrease in IL-6 and 
CRP levels in the n-3 PUFAs group when compared with the placebo group.  
My PhD will investigate the blood levels of the inflammatory biomarkers, 
including IL-1b, IL-6, IL-10, tumor necrosis factor alpha (TNF-α), interferon 
gamma (IFN-γ) and high-sensitivity c-reactive protein (hs-CRP) between ADHD 
and TD children in a cross-sectional study. Furthermore, I will also examine the 
effects of n-3 supplementation on these inflammatory biomarkers in the RCT. 
1.3.3 Neurotrophins and ADHD 
Neurotrophins have been linked to a variety of psychiatric disorders including 
MDD and ASD (de Azevedo Cardoso et al., 2014; Meng et al., 2017), and have 
been suggested to play a role in the pathogenesis of ADHD (Tsai, 2017). 
Neurotrophins are a family of polypeptide growth factors that play an important 
role in neurogenesis, neuronal survival, synaptic connectivity and brain plasticity 
(Aloe, Rocco, Bianchi, & Manni, 2012; Lang, Jockers-Scherubl, & Hellweg, 
2004). Four neurotrophins have been associated with ADHD, they include BDNF 




1.3.3.1 Brain-derived neurotrophic factor (BDNF) 
An animal study had supported the BDNF hypothesis in ADHD by showing that 
BDNF conditional knockout mice display certain ADHD characteristics such as 
learning deficiencies, aggressiveness and locomotor activity (Rios et al., 2001). 
Moreover, an increase in BDNF levels has been reported in children with ADHD 
treated with CNS stimulant medication such as methylphenidate (Amiri et al., 
2013), while a decrease in BDNF levels has been reported in adults with ADHD 
treated with non-stimulant medication such as atomoxetine (Ramos-Quiroga et 
al., 2014).  
1.3.3.2 Beta-Nerve growth factor (bNGF) and Glial cell line-derived 
neurotrophic factor (GDNF) 
Another neurotrophin that may play a role in ADHD pathogenesis is bNGF, since 
bNGF is involved in attentional systems by playing a key role in basal forebrain 
cholinergic neurons (Aloe et al., 2012). Moreover, bNGF gene polymorphism has 
been associated with ADHD (Syed et al., 2007). In addition to BDNF and bNGF, 
recent studies have suggested a potential role for GDNF in ADHD. GDNF is 
broadly expressed in the brain and protects serotonergic and dopaminergic 
neurons from neuroinflammation and oxidative damage (Naumenko, Bazovkina, 
Morozova, & Popova, 2013a; Naumenko et al., 2013b). GDNF has been 
associated with cognitive function including learning and memory in animal 




1.3.3.3 Neurotrophin factor 3 (NT-3) 
NT-3 may also play a role in ADHD, for it has a crucial role in dopaminergic 
neurons in the mesolimbic area, noradrenergic neurons in the locus coeruleus, and 
glutaminergic neurons in the hippocampus (Maness et al., 1994). Moreover, it has 
been associated with ADHD in genetic studies (Conner et al., 2008; Ribases et 
al., 2008).  
Nevertheless, although the functions of these neurotrophins may be closely 
associated with areas in the brain associated with ADHD pathogenesis, the 
findings on BDNF, bNGF, GDNF, NT-3 levels in ADHD have been 
controversial. Some research groups found associations between the 
neurotrophins and ADHD (Amiri et al., 2013; Bilgic, Toker, Isik, & Kilinc, 2017; 
Syed et al., 2007), while others did not find such an association (Scassellati et al., 
2014; Syed et al., 2007).  
My PhD will investigate the blood levels of BDNF, bNGF, GDNF and NT-3 in 
ADHD and TD children. My PhD will also examine the effects of n-3 PUFAs on 
the levels of these neurotrophins in the RCT. 
1.3.4 Evidence from brain image  
I will discuss the structural and functional brain images that have been carried out 
in youth with ADHD, examining the differences from TD youth. Subjects with 
ADHD have an overall reduction of about 3-8% in total cerebral volumes with 
medium effect sizes (.30 to .64) when compared with controls (Castellanos et al., 




Kaufmann, 2002; Seidman, Valera, & Makris, 2005). In particular, children with 
ADHD have decreased volumes in the basal ganglia regions putamen and the 
globus pallidus, and more pronounced on the right hemisphere than TD children 
from a structural magnetic resonance imaging (MRI) study. (Frodl & Skokauskas, 
2012). The changes in the basal ganglia have been associated with the 
dysfunction of frontal-striatal pathways and may be associated with the imbalance 
in dopaminergic and noradrenergic systems in ADHD (Frodl, 2010). On the other 
hand, treatments for ADHD have been shown to affect the brain volumes, 
particularly anterior cingulate cortex (ACC), in ADHD (Frodl & Skokauskas, 
2012). For example, treatment-naïve children with ADHD have a smaller ACC 
and caudate volumes when compared with controls, but this is not the case for 
those with treatment (Semrud-Clikeman, Pliszka, Lancaster, & Liotti, 2006). This 
further implicates a role for ACC in ADHD, since ACC has been associated with 
cognition due to its reciprocal connections with lateral prefrontal cortex (Paus, 
2001), and is crucial in the processing and regulation of emotional information.  
ADHD has been associated with a delay in cortical maturation (Shaw et al., 
2007). ADHD children and TD children had similar maturation process with 
primary sensory areas attaining peak cortical thickness before polymodal, high-
order association areas (Shaw et al., 2007); however, ADHD have a delay in 
attaining peak thickness throughout most of the cerebrum when compared with 
TD children (median age 10.5 years vs. median age 7.5 years) (Figure 2). 
Moreover, the prefrontal regions, areas important for control of cognitive 
processes such as attention and planning, have the most prominent delay in 




with the dysfunction of the prefrontal-striatal circuitry and the frontal-to-parietal 
cortical connections (Castellanos, Sonuga-Barke, Milham, & Tannock, 2006; 
Dickstein, Bannon, Castellanos, & Milham, 2006). Furthermore, functional MRI 
(fMRI) studies were able to identify alterations in several networks, including 
those related to attention and executive function in ADHD (Cortese et al., 2012). 
For example, children with ADHD when compared with TD children have a 
hypoactivation in the frontoparietal network (executive function) and the ventral 
attentional network (attention); and a hyperactivation in the default, ventral 
attention and somatomotor networks (Cortese et al., 2012). In addition, diffusion 
MRI studies reported disturbed white matter integrity in ADHD in the areas 
corresponding to the fronto-striatal-cerebellar neurocircuitry, including the right 
anterior corona radiata, right forceps minor, bilateral internal capsule and left 
cerebellum (van Ewijk, Heslenfeld, Zwiers, Buitelaar, & Oosterlaan, 2012); and 
the fronto-striatal-cerebellar neurocircuitry has been closely associated with 
ADHD (van Ewijk et al., 2012).  
In my PhD, although I will not investigate neuroimaging in ADHD, I will be 
investigating the effects of n-3 PUFAs in ADHD, focusing on the effects of n-3 
PUFAs on cognitive function tasks associated with the frontoparietal network 





Figure 2 The cortical thickness in children with ADHD compared with 
typically developing children in magnetic resonance imaging  
(A) dorsal view of the cortical regions where peak thickness was attained at each 
age (shown, ages 7–12) in ADHD (Upper) and typically developing controls 
(Lower). The darker colors indicate regions where a quadratic model was not 
appropriate (and thus a peak age could not be calculated), or the peak age was 
estimated to lie outside the age range covered. Both groups showed a similar 
sequence of the regions that attained peak thickness, but the ADHD group 
showed considerable delay in reaching this developmental marker. (B) Right 
lateral view of the cortical regions where peak thickness was attained at each age 




Again, the delay in ADHD group in attaining peak cortical thickness is apparent. 





1.3.5 Genetic studies 
ADHD is a familial disorder. The relative risk in first-degree relatives of 
probands with ADHD is about 5-9 (Faraone, Biederman, & Monuteaux, 2000). 
ADHD has a very high heritability of 80%, suggesting that genetic factors would 
account for about 65% of the phenotypic variance. Meta-analyses of candidate-
gene association studies have shown strong associations between ADHD and 
several genes involved in dopamine and serotonin pathways (Faraone & Mick, 
2010). However, a whole-genome investigation has only identified a few genes 
associated with ADHD, while the candidate genes only accounted for 3% of the 
phenotypic variation (Kuntsi, Neale, Chen, Faraone, & Asherson, 2006). ADHD-
associated genomic variants are non-specific with a significant overlap with those 
contributing to schizophrenia and mood disorders (Cross-Disorder Group of the 
Psychiatric Genomics, 2013; Wray et al., 2014). ADHD-associated copy number 
variants (CNVs, duplications secondary to subtle chromosomal mutations) also 
show overlap with the ones associated with schizophrenia, ASD and intellectual 
disability (Lionel et al., 2011; Williams et al., 2010). Thus, this may imply the 
genetic cause of ADHD may include a combination of many unidentified 
common variants with small effects, gene-environment or gene-gene interactions 
and/or rare variants (Zuk, Hechter, Sunyaev, & Lander, 2012). 
Of note, single nucleotide polymorphisms (SNPs) of the FADS1 and FADS2 
(fatty acid desaturase) genes, which code for the enzymes, delta-5 desaturase and 
delta-6 desaturase, responsible for the metabolism of polyunsaturated fatty acids, 




Xu, Taylor, & Asherson, 2006). ADHD has been associated with SNP rs498793 
in the FADS2 gene, while the two SNPs rs174545 and rs174548 in the FADS1 
gene were nominally associated with ADHD in the prenatal alcohol-exposed 
group of children (Brookes et al., 2006). 
Although most cases of ADHD are multifactorial in origin, there are several 
known, rare genetic syndromes, such as fragile X syndrome, tuberculous 
sclerosis, 22q11 microdeletion and Williams syndrome, that have high rates of 
ADHD and ADHD-like presentations (Bastain et al., 2002). These syndromes are 
also associated with ASD (especially tuberculous sclerosis and fragile X 
syndrome) and schizophrenia (22q11 microdeletion syndrome) (Bastain et al., 
2002). 
Based on the association between FADS SNP and ADHD, my PhD will 
investigate the effects of n-3 PUFAs in ADHD with a variety of approaches 





1.4 ADHD and comorbidity 
ADHD has a high comorbidity with other psychiatric disorders (Figure 3), 
including conduct disorders (Biederman, Newcorn, & Sprich, 1991), mood 
disorders (Biederman et al., 1991), anxiety disorders and substance use disorders 
(Wilens & Biederman, 2006). In the following, I will discuss the comorbidities in 
the following order- developmental disorders, behavior disorders and mood 
disorders. 
1.4.1 Developmental disorders 
During childhood, ADHD is more likely to comorbid with ASD, tic disorder and 
learning disorders. The co-occurrence rate of ADHD and ASD is around 20-50% 
(Rommelse, Geurts, Franke, Buitelaar, & Hartman, 2011). Children with ADHD 
tend to have deficits in social interactions, peer relationship problems and 
empathy problems (Hartman, Geurts, Franke, Buitelaar, & Rommelse, 2016), 
while individuals with ASD have a higher risk for ADHD than non-ASD 
individuals (odds ratio (OR) = 22.33, confidence intervals (CIs) = 21.77 to 
22.92)) (Ghirardi et al., 2018). The relatives of individuals with ASD also have a 
higher risk for ADHD than relatives of non-ASD individuals (Ghirardi et al., 
2018). Tic disorder is another common comorbidity of ADHD during childhood, 
it is 5 times as common in children with ADHD than TD children (Cohen, 
Leckman, & Bloch, 2013). The peak age for tic disorder is between 8 and 12 
years of age, and there is usually a marked decline of the disorder during 




Learning problems/disorders are also common in ADHD. For example, about 31 
to 45% of patients with ADHD have reading and writing difficulties (Gray & 
Climie, 2016; Sciberras et al., 2014). Children with ADHD are also more likely to 
have arithmetical disorders than TD children (Hart et al., 2010). Moreover, 
children with ADHD may be 5-10 times more likely to comorbid intellectual 
disability than TD children (Simonoff, Pickles, Wood, Gringras, & Chadwick, 
2007).  
1.4.2 Behaviour disorders 
More than 50% of children with ADHD also meet the criteria for oppositional 
defiant disorder (ODD) and conduct disorder (CD) (Connor & Doerfler, 2008). 
ODD and CD predict a more severe clinical symptomatology, more severe 
functional impairments, higher persistence of ADHD into adulthood and worse 
outcome of the disorders (Biederman et al., 2008). Comorbidity of ODD in 
childhood increases the risk for CD and depression in ADHD later in life, while 
comorbidity of CD predicts a worse outcome of the disorders in adulthood 
(Biederman et al., 2008; Mannuzza, Klein, Abikoff, & Moulton, 2004).  
Substance use disorders (SUD) is another common comorbidity in ADHD during 
adolescence and young adulthood. Childhood ADHD significantly increases the 
risk for nicotine use in middle adolescence with an OR of 2.36 (CIs = 1.71 to 
3.27) and the risk for alcohol use disorder during young adulthood with an OR of 
1.35 (CIs = 1.11 to 1.64) (Charach, Yeung, Climans, & Lillie, 2011). Adolescents 
with ADHD have an earlier onset and an increased use of tobacco, alcohol and 




1993; Milberger, Biederman, Faraone, Chen, & Jones, 1997; Milberger, 
Biederman, Faraone, Wilens, & Chu, 1997). Moreover, adult ADHD have a drug 
abuse and dependence rate of around 9 to 40%. On the other hand, a meta-
analysis controlled for comorbid disorders- particularly CD, could not confirm 
that ADHD increases the risk for SUDs (Serra-Pinheiro et al., 2013). 
1.4.3 Mood disorders 
Depression is common in adolescents with ADHD (Meinzer et al. 2013) and in 
adults with ADHD (Jacob et al. 2007). A 4-year follow-up showed that the 
lifetime rates of comorbid depression in children with ADHD had an increase of 
16% at the average age of 15 (Biederman et al., 1992). A study showed that a 
baseline diagnosis of MDD in ADHD predicted a lower psychosocial functioning, 
a higher rate of hospitalization and impairments in interpersonal and family 
functioning (Biederman et al., 1992).  
Moreover, anxiety disorder is another commonly underdiagnosed comorbidity in 
children with ADHD. Many of the anxiety symptoms including rumination, 
agitation, attention-seeking may be misinterpreted in the context of ADHD and 
overlooked in a hyperactive child. A study has shown that children with ADHD 
comorbid anxiety disorder are associated with increased psychiatric treatment, 
more impaired psychosocial functioning and higher rates of family history of 
anxiety disorders (Biederman et al., 1996).  
In summary, throughout the lifespan, the specific pattern of comorbidities 
changes substantially for ADHD (Taurines et al., 2010). ODD and CD are the 




ADHD, while SUDs become more problematic in adolescence and adulthood. 
Comorbidity with depression and anxiety disorders may further complicate the 
management of ADHD in adolescence and adulthood. 
In my PhD, I will recruit patients with ADHD without comorbidity of major 
psychiatric disorders, including mood disorders, psychotic disorders, substance 
use disorders, conduct disorders and intellectual disability for the cross-sectional 
study and the RCT. 
 
Figure 3 The prevalence of ADHD comorbidity 




1.5 ADHD and outcome 
ADHD has negative impacts on the lives of the affected individual and their 
families. Moreover, untreated ADHD symptoms will not only lead to failures in 
academic performance, but it will also have a great impact on the society, where 
there would be more absenteeism at work, more motor vehicle accidents, more 
substance use problems and lower economic growth of the society as a whole 
(Volkow & Swanson, 2013). People with ADHD are also more likely to drop out 
of school (Barkley, Fischer, Edelbrock, & Smallish, 1990), being absent from 
work (Birnbaum et al., 2005), and have poor interpersonal relationship problems 
(Gau & Chang, 2013; Searight, Burke, & Rottnek, 2000). An 11-year followed-up 
study of 96 girls (baseline mean age of 11 years, follow-up mean age of 22 years) 
with ADHD showed one-third continued to meet the full criteria for ADHD, 
29.2% had partial persistence of the disorder, 10.4% had impaired functions, and 
4.3% were remitted but treated.  
The predictors of persistence included psychiatric comorbidity, family history of 
psychopathology and baseline family and school function (Biederman, Petty, 
O'Connor, Hyder, & Faraone, 2012). Moreover, ADHD is also associated with 
higher risks for accidental or self-inflicted injuries (Nigg, 2013), including 
vehicular accidents (Barkley, 2015), which may result in increased emergency 
room admissions (Cuffe, Moore, & McKeown, 2009). About 40-60% of children 
with ADHD still have persisted ADHD symptoms in adulthood (Rasmussen & 
Gillberg, 2000). Even as adults, patients with ADHD may continue to have 




turning in a project by the deadline (Volkow & Swanson, 2013). Many adults 
with ADHD have difficulties in employment, finance, interpersonal relationships 
with both friends and family, and have comorbid psychiatric disorders including 
anxiety, depression, substance use disorders, self-harm behaviour and suicide 
attempts (Barkley, Murphy, K.R., Fischer, M., 2010; Hinshaw et al., 2012; Weiss, 
1993). A recent study also showed that ADHD combined type or presentation is 
associated with a 9.5-year reduction in healthy estimated life expectancy (ELE), 
and the persistence of ADHD to adulthood is associated with a 12.7-year 
reduction in ELE (Barkley & Fischer, 2018). The variables contributing to the 
reduced ELE included less education, less annual income, greater intake of 
alcohol and tobacco, diminished sleep and poorer overall health status relative to 
the control group (Barkley & Fischer, 2018). 
My PhD aims to investigate the effects of n-3 PUFAs in ADHD, in the hope to 
improve the quality of life and functioning status of children with ADHD so that 





1.6 ADHD and cognitive function 
Children with ADHD often have impairments in the executive functions, or a 
higher level of cognitive skills needed to control and coordinate other cognitive 
abilities and behaviours. Executive functions include activation, effort, regulation 
of emotion, response inhibition, vigilance, working memory and planning 
(Willcutt, Doyle, Nigg, Faraone, & Pennington, 2005) (Figure 4). Children with 
ADHD have been suggested to have impairment of the inhibition control system 
(Barkley, 1997). For example, children have little ability to refrain from acting on 
an impulse or to inhibit their behavior (Barkley, 1997). Young children are more 
likely to ‘act out’ the things that appear in their minds, but this can be controlled 
by external sources, such as the command of the mothers. Moreover, children will 
learn to shift the control from external sources to internal sources, hence called 
self-control, as they grew older. However, such inhibition control or self-
regulation may be impaired in children with ADHD (Barkley, 1997). Such 
impairment in inhibition may further negatively impact other domains of 
executive function, including working memory (Rhodes, Park, Seth, & Coghill, 
2012), reaction time variability (Kofler et al., 2013), time management (Noreika, 
Falter, & Rubia, 2013), internalization of speech and goal-directed behavior 
(Barkley, 1997).  In addition, children with ADHD often also have problems with 
decision making (DeVito et al., 2008). 
Results from meta-analytic studies have also supported the association between 
executive dysfunction and ADHD. For example, a meta-analysis including 83 




impairment of several executive function domains, included planning, vigilance, 
set shifting and verbal and spatial working memory, ranging in the medium effect 
size (EF) from d = .4 to .7 (Willcutt et al., 2005). Moreover, another meta-
analysis comprising of 26 studies and more than 4600 subjects investigating 
working memory in ADHD showed that children with ADHD have greater 
impairment in spatial storage (EF = .85 with CIs = .62 to 1.08), spatial central 
executive working memory (EF = 1.06, CIs = .72 to 1.39), verbal storage (EF 
= .47, CI= .36 to .59) and verbal central executive working memory (EF = .43, 
CIs = .24 to .62) (Martinussen, Hayden, Hogg-Johnson, & Tannock, 2005). 
In my PhD, I will be investigating the effects of n-3 PUFAs on cognitive function 
in ADHD in the RCT; using the Continuous Performance Test (CPT) to assess 
focused attention, impulsivity, sustained attention, and vigilance, and use the 
Wechsler Intelligence Scale for Children-Fourth Edition (WISC-IV) Digit Span 






Figure 4 The executive functions impaired in ADHD 




1.7 ADHD treatment 
The treatment for ADHD includes pharmacotherapy and non-pharmacotherapy 
approaches. The Multimodal Treatment of ADHD study (MTA), the longest trial 
of ADHD treatment (14 months), showed that medication treatment, 
methylphenidate hydrochloride in this study, is superior to behavior therapy for 
reducing core symptoms of ADHD, and the combination of medication and 
behavior therapy was not superior to medication alone for these symptoms (MTA 
Cooperative Group, 1999).  
1.7.1 Pharmacotherapy 
The current medications available include stimulants such as methylphenidate 
(MTA Cooperative Group, 1999), and non-stimulants such as atomoxetine 
(Quintana et al., 2007). Short-term randomized, placebo-controlled trials 
(duration generally less than 4 months in duration) in children with ADHD have 
shown a greater benefit of stimulant medications in reducing inattention, 
hyperactivity and impulsivity (Biederman et al., 2003; Faraone et al., 2002; 
Schachar et al., 2002). Moreover, the long-acting or extended-release form of 
stimulant medications are generally preferred by children and parents because 
they allow administration of a single morning dose to improve symptoms for the 
entire school day without increasing adverse effects (Pelham et al., 2001). The 
common side effects of stimulants include headaches, abdominal pain, decreased 
appetite, and delay onset of sleep (Feldman & Reiff, 2014) (Table 1). 
Non-stimulant medications include atomoxetine and selective alpha 2-adrenergic 




been shown to be effective in reducing core symptoms in short-term placebo-
controlled clinical trials, but they have weaker effects than those reported with 
stimulants (Subcommittee on ADHD, 2011). The side effects of atomoxetine 
include upset stomach, dizziness, fatigue, nausea, mood swings (Feldman & 
Reiff, 2014) (See Table 1). The side effects of selective alpha2-adrenergic 
agonists include somnolence, fatigue, sedation and sleep problems (Feldman & 










Table 1 The pharmacotherapy for ADHD. 





The non-pharmacotherapy treatments for ADHD include behavioural therapy 
(Table 2). Behaviour therapies provide models and opportunities for social 
learning, and enhance motivation by using rewards (Antshel & Barkley, 2008). 
Behaviour therapies include behavioural parenting training, behavioural peer 
interventions and behavioural classroom management. The aim of the behavioural 
parenting training program is to teach the parents to use the techniques developed 
based on the principles of behaviour modification and social learning theory to 
shape their child’s behaviours (Centers for Disease Control and Prevention, 
2009). Parents learn how to promote a positive parent-child relationship by 
learning how to communicate and express their emotions more effectively (CDC, 
2009). Moreover, behavioural peer interventions are often carried out 
simultaneously with the behavioural parent training. Behavioural peer 
interventions often take place during summer schools that provide settings for 
daylong and intensive social-skills training (Pelham & Fabiano, 2008). In 
addition, behavioural classroom management at school has been associated with 
moderate-to-large improvements in academic and behavioural functioning in 
ADHD (DuPaul, et al. 2012). 
Despite the good efficacy of pharmacotherapy around in children with ADHD- 
around 60-80%, about 20-40% of patients with ADHD either respond poorly to 
the current medications available or suffer from medication side effects 
(Childress & Sallee, 2014). Thus, my PhD will investigate n-3 PUFAs as an 




ADHD by examining its effects on the cognitive function and clinical symptoms 






Table 2 The non-pharmacotherapy for ADHD.  




1.8 Omega-3 polyunsaturated fatty acids (n-3 PUFAs)- Introduction 
There are two main types of PUFAs in the human body, the omega-6 
polyunsaturated fatty acids (n-6 PUFAs) from the cis-linoleic acid (LA, 18:2n-6) 
and the omega-3 PUFAs (n-3 PUFAs) from the α-linolenic acid (ALA, 18:3n-3). 
N-3 and n-6 PUFAs are important constituents of all cell membranes; they are 
called the essential fatty acids (EFAs), because they are crucial for the survival 
for the humans and mammals but cannot be synthesized within the body (Das, 
2006). EFAs can only be obtained from diets (Das, 2006). The PUFAs appear to 
be active in the biological function, and some of their functions require their 
conversion into metabolites including eicosanoids. Linoleic acid can be converted 
to gamma-linolenic acid (GLA, 18:3n-6) and GLA can be elongated to form 
dihomo-GLA (20:3n-6), which is the precursor of the prostaglandin (PG)-1s. 
Dihomo-GLA can also be converted to arachidonic acid (AA, 20:4n-6), which is 
the precursor of the PG-2s, thromboxanes (Txs) and the Leukotriene (LT)-4s. On 
the other hand, ALA can be converted to eicosapentaenoic acid (EPA; 20:5n-3) 
and EPA forms the precursor of PG-3s and LT-5s. In addition, EPA can be 
converted to docosahexaenoic acid (DHA; 22:6n-3) (Figures 5 and 6). Both PGs 
and LTs are highly biologically active, have proinflammatory action and are 
known to be involved in the pathophysiology of inflammation-associated 
disorders, such as atherosclerosis, asthma, cardiovascular diseases, 
cerebrovascular diseases, inflammatory bowel syndrome, neurological diseases 





Several lines of evidence support the importance of n-3 PUFAs in brain disorders 
(Hibbeln et al., 2007; Su et al., 2008; Su et al., 2014). DHA and EPA are both 
essential for the brain and the body, and the deficiency of both may impair brain 
development and attribute to the development of several brain disorders such as 
depression. For example, the deficiency of DHA has been associated with 
neuronal membrane instability and dysfunctional transmission of serotonin, 
norepinephrine and dopamine (Chalon, 2006; Su, Huang, Chiu, & Shen, 2003), 
which might be connected to the aetiology of the mood and cognitive dysfunction 
of depression. Meanwhile, EPA is important in balancing the immune functions 
and physical health by reducing membrane AA (a n-6 PUFAs) and prostaglandin 
E2 (PGE2) synthesis (Farooqui, Ong, & Horrocks, 2006), and might be 
associated with medical comorbidity and somatic symptoms in depression (Su, 
2009). Moreover, EPA and DHA have been shown to increase anti-inflammatory 
action via inhibition of free radical generation and oxidant stress (Das, 2006), and 
to regulate neurotransmitter and immune functions via the modulation of lipid 
rafts signalling platforms on the cell membrane (Chang & Su, 2010). In addition, 
clinical trials showed that n-3 PUFAs helped to improve and prevent symptoms 
of depression (Lin & Su, 2007; Su et al., 2003; Su et al., 2008; Su et al., 2014) 
and cognitive function in mild cognitive impairment (Chiu et al., 2008). 
My PhD will investigate the effects of n-3 PUFAs in cognitive function and 
clinical symptoms in children with ADHD with a variety of approaches including 






Figure 5 Metabolism of the polyunsaturated fatty acids  






Figure 6 The PUFAs and the eicosanoids  





1.9 N-3 PUFAs in psychiatry 
N-3 PUFAs have been shown to be crucial during brain development, and its 
deficiency has been investigated in several psychiatric disorders, including 
anxiety disorders, ASD, dementia, early psychosis MDD, and post-stress 
traumatic disorder (PTSD) (Agostoni et al., 2017; Chang et al., 2015; Chang, 
Chen, & Su, 2009; Lin, Chiu, Huang, & Su, 2012; Matsuoka et al., 2015; Su et al. 
2018). 
 1.9.1 Deficiency of n-3 PUFAs and psychiatric disorders. 
Deficiency of n-3 PUFAs in mood disorders, especially depression has become a 
research focus of many countries in the recent year (Chang et al., 2015; Chang et 
al., 2009; Chang et al., 2018; Su et al., 2003). An epidemiologic study showed a 
negative correlation between the consumption of fish and the prevalence rate of 
depression in several countries, where countries with high consumption of fish 
such as Taiwan has a lower prevalence rate of depression, while a country with a 
low consumption of fish has a higher prevalence rate of depression (Hibbeln, 
1998). Moreover, a meta-analysis of blood PUFAs levels, either of erythrocytes 
or plasma, showed that patients with DSM-diagnosed depression have lower 
levels of n-3 PUFAs than patients without depression (Lin, Huang, & Su, 2010). 
Patients with cardiovascular diseases comorbid major depressive disorder (Chang 
et al., 2015) and patients with prenatal depression (Chang et al., 2018) and 
perinatal depression (Lin, Chang, Chong, Chen, & Su, 2017) also have lower 




Lower levels of n-3 PUFAs have also been reported in patients with other types 
of psychiatric disorders, including those with dementia (Lin et al., 2012) and 
those with developmental disorder such ASD (Mazahery et al., 2017). Moreover, 
lower levels of EPA have been associated with a higher risk of PTSD (Matsuoka, 
Nishi, & Hamazaki, 2013).  
1.9.2 N-3 PUFAs supplementation and psychiatric disorders 
Clinical trials with n-3 PUFAs supplementation have further supported the role of 
n-3 PUFAs in the pathogenesis of several psychiatric disorder. For example, an 8- 
week double-blind RCT showed that n-3 PUFAs supplementation compared with 
placebo had a greater improvement on depressive symptoms in pregnant women 
with prenatal depression; the n-3 PUFAs group had lower Hamilton Depression 
Rating Scale (HAM-D) scores at week 8 (p = .019) (Su et al., 2008). The meta-
analysis also showed that n-3 PUFAs have a better efficacy for treating 
depression if the supplementation contains > 60% EPA (Lin & Su, 2007). Not 
only do n-3 PUFAs treat depression, a prospective study was also able to show 
the protective effect of n-3 PUFAs, particularly EPA, in a group of patients with 
hepatitis C viral infection (HCV) receiving interferon-alpha treatment (Su et al., 
2014). The incidence rates of interferon-alpha-induced depression were 
significantly lower in EPA treated patients (10%), but not in DHA treated patients 
(28%) or in the placebo group (30%) (Su et al., 2014). 
N-3 PUFAs supplementation has also shown to improve cognitive function in 
those with mild cognitive impairment but not those with Alzheimer’s disease 




placebo, improved the social interaction and repetitive and restricted interests and 
behaviours in patients with ASD (Mazahery et al., 2017). A recent meta-analysis 
also reported a greater efficacy of n-3 PUFAs for anxiety symptoms if the anxiety 
symptoms are associated with a specific condition and that if the dosage of the n-
3 PUFAs supplementation is greater than or equal to 2000 mg/d (Su et al., 2018). 
On the other hand, although a meta-analysis including 10 clinical trials showed 
no effect of n-3 PUFAs on the emotional dysregulation in ADHD; the subanalysis 
of studies with strict inclusion criteria of ADHD (4 trials, 515 subjects with 
ADHD) showed a small effect size of n-3 PUFAs on emotional dysregulation 
(standardised mean difference, SMD = .25; CI = .08 to .43; p = .005) (Cooper, 
Tye, Kuntsi, Vassos, & Asherson, 2016). Lastly, n-3 PUFAs supplementation has 
also shown a beneficial effect for those with ultra-high risk for psychotic 
disorders. A 12-week intervention of 76 participants at ultra-high risk of 
psychotic disorder showed that 4.9% of the n-3 PUFAs group (1.2 g/d) compared 
with 27.5% of the placebo group had transitioned to psychotic disorder (p = .007) 
(Amminger et al., 2010). 
My PhD will investigate the effects of n-3 PUFAs in cognitive function and 
clinical symptoms in children with ADHD with a variety of approaches including 





1.10 N-3 PUFAs and ADHD 
Deficiency in omega-3 polyunsaturated fatty acids (n-3 PUFAs) has recently been 
investigated as a potential pathogenetic mechanism in ADHD (Stevens et al., 
1995). Although current pharmacotherapies, such as methylphenidate and 
atomoxetine, are able to improve ADHD symptoms (The MTA Cooperative 
Group, 1999; Quintana et al., 2007), there is still about 20-40% of patients with 
ADHD who do not benefit from these medications (Childress & Sallee, 2014). 
Therefore, novel treatments with clear efficacy and measurable biological 
mechanisms are essential.  
At cognitive levels, ADHD has been suggested to be a disorder involving an 
impaired inhibition control system (Barkley, 1997) and a disrupted feedback of 
the rewarding and motivational system (Barkley, 1997); on the other hand, n-3 
PUFAs have been associated with cognitive function and learning (Milte et al., 
2011), including in patients with ADHD (Sinn, Bryan, & Wilson, 2008; Vaisman 
et al., 2008; Voigt et al., 2001). Hence, n-3 PUFAs may be considered one of 
such novel treatments. 
1.10.1 Epidemiological studies and case control studies 
There is promising evidence that n-3 PUFAs may be relevant to ADHD. In 
epidemiological studies, children of mothers who have lower seafood intake 
during pregnancy are at risk of suboptimal outcomes for prosocial behaviours, 
fine motor coordination, verbal communication and social development (Hibbeln 
et al., 2007). Moreover, I have shown that children with ADHD have greater 




acid levels and comprising symptoms such as dry and scaly skin, eczema, and dry 
eyes (Chang, Jingling, Huang, Lu, & Su, 2016). In addition, EFA dietary 
deficiency in children with ADHD correlates negatively with plasma DHA levels 
(Stevens et al., 1995), and I have recently shown that EFA deficiency positively 
correlates with ADHD symptoms (Chang et al., 2016). However, several case-
control studies have reported no dietary differences, or even higher dietary 
PUFAs intake, in ADHD (Chen, Hsu, Hsu, Hwang, & Yang, 2004; Colter, Cutler, 
& Meckling, 2008; Gow et al., 2013; Stevens et al., 1995). 
In terms of PUFAs levels, lower red blood cells (RBCs) PUFAs (Stevens et al., 
1995) and a higher n-6/n-3 ratio (Stevens et al., 2003) have been reported in 
ADHD, and lower n-3 PUFAs levels are positively associated with the severity of 
ADHD symptoms in children (Colter et al., 2008; Stevens et al., 2003). However, 
some studies could not replicate the differences in n-3 PUFAs levels between 
children with ADHD and the controls (Gow et al., 2013; Stevens et al., 2003). 
1.10.2 Clinical trials 
The findings from clinical trials of n-3 PUFAs in children with ADHD have been 
controversial. Some clinical trials with n-3 PUFAs supplementation in ADHD 
have shown improvement in clinical symptoms (Manor et al., 2012; Perera, 
Jeewandara, Seneviratne, & Guruge, 2012; Richardson & Puri, 2002) and 
cognitive performances (Sinn et al., 2008; Vaisman et al., 2008; Voigt et al., 
2001), but others have found no beneficial effects (Widenhorn-Muller, Schwanda, 
Scholz, Spitzer, & Bode, 2014). Moreover, most of the trials used DHA as the 




Voigt et al., 2001), or used a rather low combined dosage of DHA and EPA (< 
500 mg/d) (Vaisman et al., 2008; Manor et al., 2012).  
In addition, although there were previous meta-analyses on this topic (Cooper et 
al, 2015; Gillies et al., 2012; Hawkey & Nigg, 2014; Puri & Martins, 2014; 
Sonuga-Barke et al., 2013), their findings might be confounded by heterogeneity 
in the clinical samples, including both children and adult subjects (Hawkey et al., 
2014) or subjects with diagnosis other than ADHD (Cooper et al., 2015; Puri et 
al., 2014), as well as by the inclusion of non-parallel trials (Hawkey et al., 2014; 
Puri et al., 2014), as well as  mixed supplementation interventions including n-3 
PUFAs together with vitamins and nutrients (Gillies et al., 2012; Sonuga-Barke et 
al., 2013).  
Due to its safety profile and anti-inflammatory effects, n-3 PUFAs have been of 
great interest as a potential treatment for ADHD. Moreover, a previous study 
examining 10 ADHD clinical trials with 699 children with ADHD 
(predominantly males, 60-87%) showed that a high dose of EPA (1-2g) 
supplementation was required to show significant improvement of clinical 
symptoms in ADHD (Bloch & Qawasmi, 2011). Thus, my PhD will investigate 
the effects of n-3 PUFAs in cognitive function and clinical symptoms in children 
with ADHD with a variety of approaches including meta-analyses, a cross-





1.11 Aims and hypotheses of the study 
The main hypothesis of my PhD is that n-3 PUFAs, 1.2 g EPA, when compared 
with placebo will improve cognitive function in children and adolescents with 
ADHD. In this section, I will provide the aims and hypotheses for my PhD, 
including the studies on the levels of salivary cortisol, blood inflammatory 
biomarkers, neurotrophins and PUFAs in ADHD, and the effect of n-3 PUFAs on 
clinical symptoms and cognitive functions.  
The studies on salivary cortisol levels in ADHD have been controversial, thus my 
PhD included a meta-analysis and a cross-sectional study on the salivary cortisol 
levels in ADHD. Moreover, previous study results on the blood inflammatory 
biomarkers and neurotrophins in ADHD have also been controversial. In my 
PhD, I have performed a cross-sectional study examining the blood levels of 
inflammatory biomarkers and neurotrophins between ADHD and TD youth 
(including both children and adolescents). Although there were previous meta-
analyses on n-3 PUFAs supplementation in ADHD (Cooper, Tye, Kuntsi, Vassos, 
& Asherson, 2015; Gillies, Sinn, Lad, Leach, & Ross, 2012; Hawkey & Nigg, 
2014; Puri & Martins, 2014; Sonuga-Barke et al., 2013), their findings might be 
confounded by heterogeneity in the clinical samples, including both children and 
adult subjects (Hawkey & Nigg, 2014) or subjects with diagnosis other than 
ADHD (Cooper et al., 2015; Puri & Martins, 2014), as well as by the inclusion of 
non-parallel trials  (Hawkey & Nigg, 2014; Puri & Martins, 2014), as well as 
mixed  supplementation interventions including n-3 PUFAs supplements and 




2013). To address these issues, I have performed a systematic review and meta-
analyses in my thesis to examine both the levels of n-3 PUFAs and the efficacy of 
n-3 PUFAs supplementation, and specifically in young (children and adolescents) 
subjects with ADHD. I have also examined the factors potentially modulating 
these findings, such as the EPA and DHA dosages in the supplementation trials, 
and the source tissue (RBCs, plasma, buccal cells) for the measurements of n-3 
PUFA levels. I have also performed a cross-sectional study examining the blood 
PUFAs levels between ADHD and TD youth. In addition, I have also conducted a 
double-blind randomized controlled trial of n-3 PUFAs (high dose EPA, 1.2 g/d) 
in ADHD, with the cognitive function as the primary outcome, and the blood 
levels of inflammatory biomarkers, neurotrophins and PUFAs, and emotional and 
clinical symptoms as the secondary outcome. 
1.11.1 First aim: Investigate the cortisol levels in ADHD 
There has been inconsistency in the finding of cortisol levels in ADHD. For 
example, one study comparing ADHD and TD children reported a lower morning 
salivary cortisol level in children with ADHD (Isaksson et al., 2012), while 
another study reported no such differences (van West et al., 2009). Moreover, 
while some studies were able to demonstrate a correlation between low basal 
cortisol levels and hyperactivity (Kaneko et al., 1993; Wang et al., 2011) and total 
ADHD symptoms (Wang et al., 2011), others failed to report such association 
(Pesonen et al., 2011). This leads to the first aim of my thesis, which is to 
investigate the cortisol levels in ADHD with a meta-analysis followed by a cross-
sectional study with four-time point (awakening, noon, 1800h and bedtime) 




• ADHD youth will have lower cortisol levels than TD youth in the meta-
analysis. 
• ADHD youth will have lower cortisol levels across all four-time points 
when compared with TD youth in the cross-sectional study. 
1.11.2 Second aim: Investigate the levels of inflammatory biomarkers in ADHD  
There has been inconsistency regarding the levels of inflammatory biomarkers in 
ADHD. While some study reported ADHD have a higher level of inflammatory 
biomarkers (Donfrancesco et al., 2016), other study reported no difference in 
levels when comparing ADHD with TD group (Oades et al., 2010b). Hence, my 
second aim is to investigate the levels of inflammatory biomarkers in ADHD in 
the cross-sectional study. Specifically, I hypothesised:  
• ADHD youth will have a higher level of pro-inflammatory biomarkers 
including IL-1b, IL-6, TNF-α, IFN-γ and hs-CRP, and a lower level of 
anti-inflammatory biomarker such as IL-10 than TD youth. 
1.11.3 Third aim: Investigate the levels of neurotrophins biomarkers in ADHD 
Although neurotrophins have been implicated in the pathogenesis of ADHD, the 
findings have been inconclusive (Amiri et al., 2013; Bilgic et al., 2017; 
Scassellati et al., 2014; Syed et al., 2007). Hence, the third aim of my PhD is to 
investigate the levels of neurotrophins in ADHD in the cross-sectional study. 
Specifically, I hypothesised:  
• ADHD youth will have a lower level of neurotrophins including BDNF, 




1.11.4 Fourth aim: Investigate the blood levels of n-3 PUFAs in ADHD 
There has been inconsistency in the literature regarding the blood n-3 PUFAs 
levels in ADHD. Where some literature reported a lower level of RBCs PUFAs 
(Stevens et al., 1995) and a higher n-6/n-3 ratio (Stevens et al., 2003) in ADHD, 
while other studies could not replicate the differences in n-3 PUFAs levels 
between children with ADHD and controls (Gow et al., 2013; L. Stevens et al., 
2003). Therefore, the fourth aim of my thesis is to investigate the n-3 PUFAs 
levels in youth in ADHD with a systematic review and meta-analysis followed by 
a cross-sectional study of n-3 PUFAs levels in ADHD and TD. Specifically, I 
hypothesised that 
• ADHD youth will have a lower level of DHA than TD youth in both 
the meta-analysis and cross-sectional study. 
• ADHD youth will have a lower level of EPA than TD youth in both the 
meta-analysis and cross-sectional study. 
• ADHD youth will have a lower level of total n-3 PUFAs than TD 
youth in both the meta-analysis and cross-sectional study. 
1.11.5 Fifth aim: Investigate the effect of n-3 PUFAs in the changes of the levels 
of inflammatory biomarkers 
The reports on the effects of n-3 PUFAs on inflammatory biomarkers have been 
inconsistent. While some study showed results in favour of n-3 PUFA in the 
reduction of the levels of inflammatory biomarkers such as CRP, erythrocyte 




Mohan, 2015; Hariri et al., 2012); other groups reported negative results on the 
effects of n-3 PUFAs on inflammatory biomarkers (Hoogeveen, Geleijnse, 
Kromhout, & Giltay, 2014; Smesny et al., 2017). Thus, the fifth aim of my PhD is 
to investigate the effects of n-3 PUFAs in the changes of the levels of 
inflammatory biomarkers. Specifically, I hypothesised:  
• The n-3 PUFAs group will have a greater decrease in the levels of pro-
inflammatory biomarkers including IL-1b, IL-6, TNF-α, IFN-γ and hs-
CRP, and an increase in anti-inflammatory IL-10 than placebo group. 
1.11.6 Six aim: Investigate the effect of n-3 PUFAs in the changes of the levels of 
neurotrophins 
A combination of vitamin B12 and n-3 PUFAs supplementation showed a higher 
DHA and NGF in the hippocampus and a higher BDF in both hippocampus and 
cortex in an animal study (Rathod, Khaire, Kale, & Joshi, 2016). Moreover, a 
positive correlation has been found between the n-3 PUFAs consumption and 
serum BDNF levels in TD adolescents (Ferreira et al., 2014). However, clinical 
studies in human have failed to show an effect of n-3 PUFAs, either DHA or 
EPA, on BDNF (Bot et al., 2011; Matsuoka, et al., 2015), while there had been no 
clinical study on the effects of n-3 PUFAs on bNGF, GDNF and NT-3 in general 
and no clinical study on the effects of n-3 PUFAs on BDNF in ADHD. Thus, the 
sixth aim of my study is to investigate the effect of n-3 PUFAs in the changes of 




• The n-3 PUFAs group will have a greater increase in the levels of 
neurotrophins including BDNF, bNGF, GDNF and NT-3 than the 
placebo group. 
1.11.7 Seventh aim: Investigate the effect of n-3 PUFAs in blood PUFAs levels 
My previous study showed the EPA supplementation increased both DHA and 
EPA blood levels, while DHA only increased DHA blood levels in adults with 
HCV (Su et al., 2014), while a combination with DHA and EPA improved both 
DHA and EPA in adolescents with mood disorders (Arnold et al., 2017). 
However, no study investigated the effect of EPA on the changes of PUFAs 
levels in children with ADHD. Thus, the seventh aim of my PhD is to investigate 
the effect of n-3 PUFAs on blood PUFAs levels in children with ADHD. 
Specifically, I hypothesised 
• N-3 PUFAs group will have a greater increase in DHA, EPA and total 
n-3 PUFAs than the placebo group in the RCT. 
1.11.8 Eighth aim: Investigate the effect of n-3 PUFAs on emotional symptoms in 
ADHD  
Youth with ADHD have a high comorbidity with mood disorders (Biederman et 
al., 1992), while n-3 PUFAs have been shown to improve depressive symptoms 
or prevent depression in adults (Su et al., 2008; Su et al., 2014). Moreover, meta-
analysis has shown a small effect of n-3 PUFAs on emotional dysregulation in 
ADHD if strict inclusion criteria are applied (Cooper et al., 2016). Thus, I will 
investigate the effect of n-3 PUFAs on the emotional symptoms in ADHD in the 




• N-3 PUFAs group will have decreased scores on the emotional problems 
and peer relationship problems and an increased score on the prosocial 
behavior than the placebo group. 
1.11.9 Ninth aim: Investigate the effect of n-3 PUFAs on clinical symptoms in 
ADHD  
Some clinical trials with n-3 PUFAs supplementation in ADHD have shown 
improvement in clinical symptoms (Manor et al., 2012; Perera et al., 2012; 
Richardson & Puri, 2002), but others have found no beneficial effects 
(Widenhorn-Muller et al., 2014). Due to the inconsistency in the literature, I will 
investigate the effect of n-3 PUFAs on clinical symptoms in ADHD with a meta-
analysis (parent- and teacher-reported clinical symptoms) followed by an RCT 
(parent-, teacher- and youth-reported clinical symptoms). Specifically, I 
hypothesised  
• N-3 PUFAs group will have a greater improvement in inattention 
symptoms in the meta-analysis (parent- and teacher- reported) and the 
RCT (parent-, teacher, and youth-reported) than the placebo group. 
• N-3 PUFAs group will have a greater improvement in hyperactivity-
impulsivity symptoms in the meta-analysis (parent- and teacher- reported) 





• N-3 PUFAs group will have a greater improvement in total ADHD 
symptoms in the meta-analysis (parent- and teacher- reported) and the 
RCT (parent-, teacher, and youth-reported) than the placebo group. 
1.11.10 Tenth aim: Investigate the effect of n-3 PUFAs on cognitive function in 
ADHD 
Clinical trials with n-3 PUFAs supplementation in ADHD have shown 
improvement in cognitive performances (Sinn et al., 2008; Vaisman et al., 2008; 
Widenhorn-Muller et al. 2014), and a previous meta-analysis has suggested the n-
3 PUFAs supplementation, particularly with higher doses of EPA, is modestly 
effective in treatment of ADHD (Bloch & Qawasmi, 2011). On the other hand, 
Voigt et al. (2001) have found no beneficial effects of n-3 PUFAs in ADHD. 
Thus, this inconsistency in the literature has prompted me to conduct a meta-
analysis followed by a double-blind RCT, particularly high dose EPA, to 
investigate the effects of n-3 PUFAs on cognitive function in ADHD as the tenth 
aim of my thesis. Specifically, I hypothesised that: 
• N-3 PUFAs group, when compared with the placebo group, will improve 
cognitive measures in the meta-analysis. 
• N-3 PUFAs group will have a greater improvement on the memory scores 
assessed with the Digit Span Subtest of the Weschler Intelligence Scale 





• N-3 PUFAs group will have a greater improvement on the CPT measures 
assessing focused attention: omission errors, HRTSD, variability, and 
detection than the placebo group. 
• N-3 PUFAs group will have a greater improvement on the CPT measures 
assessing impulsivity: commission errors, HRT and perseveration than the 
placebo group. 
• N-3 PUFAs group will have a greater improvement on the CPT measures 
assessing sustained attention: hit reaction time block changes (HRTBC) 
than the placebo group. 
• N-3 PUFAs group will have a greater improvement on the CPT measures 







My PhD consists of 2 systematic reviews and meta-analyses, a cross-sectional 
study and a double-blind randomized controlled trial. The systematic reviews and 
meta-analyses are on 1) salivary cortisol levels in ADHD and 2) n-3 PUFAs in 
ADHD focusing on the n-3 PUFAs blood levels and the effects of n-3 PUFAs 
supplementation on clinical symptoms and cognitive function. The cross-
sectional study investigates the levels of salivary cortisol, blood neurotrophins, 
inflammatory biomarkers and PUFAs between 98 ADHD youth and 21 TD 
youth. The double-blind RCT is a 12-week trial comparing the efficacy of 1.2 g 
EPA with placebo in 98 youth with ADHD, with cognitive function including 
Weschler Intelligence Scale for Children-Fourth Edition Digit Span subtest and 
CPT measures as the primary outcome and clinical symptom and levels of 
biomarkers as the secondary outcome. 
 
2.1 Meta-analysis of cortisol levels in ADHD 
I have conducted a systematic review and a meta-analysis in accordance with the 
Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 
guidelines (Moher, Liberati, Tetzlaff, & Altman, 2009). 
 2.1.1 Literature search 
To identify eligible studies in the systematic review and the meta-analysis, a 
computerized search was performed for studies available as of 5th of December 




The search was performed by using the search terms: (attention-deficit 
hyperactivity disorder, attention deficit disorder, hyperkinesis, hyperkinetic 
disorder, inattention, impulsivity, hyperactivity) and cortisol, with language 
limited to English. References lists from identified articles and relevant reviews 
were scrutinized for studies not indexed in the electronic databases. My initial 






Figure 7 PRISMA flow diagram for the meta-analysis of cortisol in ADHD 




2.1.2 Inclusion criteria of studies in the meta-analysis 
The studies included in this meta-analysis had to meet the following criteria: 1) 
measured levels of cortisol (either baseline cortisol levels before a stress test or 
task, or awakening morning cortisol levels); 2) participants were school-aged 
children (4-12 years) and adolescents (13-17 years) who had a diagnosis of 
ADHD; and 3) the data allowed to calculate an effect size. Studies that included 
and re-analysed the same data set as previously published studies were not 
regarded as independent, and in this case only the study with the highest number 
of participants was included. See Figure 8 for the flow-chart showing the 
selection of included studies.  
2.1.3 Meta-analytic methods 
In my analysis, the primary outcomes were comparisons of salivary cortisol levels 
between ADHD and controls. For each identified study, the ES expressing the 
difference in the cortisol levels between ADHD and controls, were described as 
the standardized mean difference (SMD) on the basis of Hedge’s adjusted g, in 
which a value greater than 0 indicated that cortisol levels were higher in ADHD 
subjects. When these data could not be retrieved from the publications, I 
contacted the authors to acquire the data of derived ES from other measures of 
variability. The results of individual studies were synthesized by the random 
effects model (Shadish, 1994), by which ESs were pooled and 95% confidence 
intervals (CIs) were calculated. The significance of the pooled effect size was 
determined by the z test. Sensitivity analyses were performed to determine 




moreover, each study was individually removed, and the significance was 
retested. The I2 statistic assessed heterogeneity between studies. Publication bias 
was assessed using the Egger regression asymmetry tests (and inspection of the 
regression asymmetry plot) and the Begg adjusted rank correlation test. Meta-
analyses were conducted by applying STATA (StataCorp, 2017) and Forest Plots 
were created by using Review Manager 5.3 (The Cochrane Collaboration, 2014). 
Two-sided p values < .05 were considered statistically significant. 
 
2.2 Meta-analysis of n-3 PUFAs in ADHD 
I have conducted a systematic review and meta-analysis in accordance with the 
PRISMA guidelines (Moher et al., 2009). 
2.2.1 Literature search 
To identify eligible studies for this meta-analysis, a computerized search was 
performed for all publications available up to 31st March 2017 through Cochrane 
Central Register of Controlled Trials, Embase, Ovid Medline, PsychInfo, limited 
to literature in English and human studies. The search terms used are listed in 
Table 3. References of eligible trials and appropriate reviews were searched for 
additional citations. Unpublished or ongoing trials were searched on 
ClinicalTrials.gov website and authors contacted to request relevant data. My 





Figure 8 PRISMA flow diagram of meta-analysis of n-3 PUFAs in ADHD 
AA, arachidonic acid; ADHD, attention-deficit hyperactivity disorder; BM, 
backward memory; Cog, cognition, Com, commission errors; DHA, 




hyperactivity-impulsivity; IA, inattention; IP, information processing; N-3, 
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2.2.1.1 N-3 PUFAs Levels 
My criteria were: the studies 1) measured level of DHA, EPA, AA, total n-3 or 
total n-6; and 2) used samples from RBCs membrane, blood phospholipids and 
cholesteryl esters, or buccal cells; 3) participants were school-aged children (4-12 
years) and adolescents (13-17 years) who had a diagnosis of ADHD; 4) the data 
allowed to calculate an effect size; and 5) the publications were in peer-reviewed 
journals.   
2.2.1.2 N-3 PUFAs Supplementations and Clinical Symptoms 
My criteria were: 1) studies were randomized, double-blind, placebo- controlled 
trials of n-3 PUFA supplementation with DHA and EPA alone or in combination; 
2) participants were school-aged children (4-12 years) and adolescents (13-17 
years) who had a diagnosis of ADHD; 3) the study measured clinical symptoms 
of ADHD as reported by parents; 4) the data allowed to calculate an effect size; 
and 5) the publications were in peer-reviewed journals.  
2.2.1.3 N-3 PUFAs Supplementation and Cognitive Performance 
My criteria were: 1) studies were randomized, double-blind, placebo- controlled 
trials of n-3 PUFA supplementation with DHA and EPA alone or in combination;  
2) participants were school-aged children (4-12 years) and adolescents (13-17 
years) who had a diagnosis of ADHD; 3) the studies measured cognitive 
performance defined as omission errors, commission errors, forward memory, 
backward memory, and information processing; 4) the data allowed to calculate 




Studies that included and reanalysed the same data set as previously published 
studies were not regarded as independent, and only the study with the highest 
number of participants was included. See Figure 8 for the flow chart showing the 
selection of included studies. 
2.2.2 Meta-analytic methods 
In my analysis, the primary outcomes were comparisons of 1) levels of DHA, 
EPA, AA, total n-3 PUFAs and total n-6 PUFAs, between ADHD and controls; 
and 2) clinical symptoms and cognitive performance in RCTs (omission errors, 
commission errors, memory and information processing) between n-3 and 
placebo groups. 
For each identified study, the ES expressing the difference in clinical symptoms 
and cognitive performance between n-3 and placebo group, or the difference in 
the PUFAs levels between ADHD and controls, were described as SMD on the 
basis of Hedge’s adjusted g, in which a value greater than 0 indicated levels were 
higher in ADHD subjects, or n-3 PUFAs were superior to placebo. When these 
data could not be retrieved from the publications, I have contacted the authors to 
acquire the data of derived ES from other measures of variability. The results of 
individual studies were synthesized by the random effects model (Shadish, 1994), 
but which ESs were pooled and 95% CIs were calculated. The significance of the 
pooled effect size was determined by the z test. Sensitivity analyses were 
performed to determine whether any individual study was responsible for the 
significant results. Moreover, each study was individually removed and the 




Publication bias was assessed using the Egger regression asymmetry tests (and 
inspection of the regression asymmetry plot) and the Begg adjusted rank 
correlation test. Meta-analyses were conducted by applying STATA (Stata Corp, 
2017) and Forest Plots were created by using Review Manager 5.3 (The Cochrane 
Collaboration, 2014). Two-sided p values < .05 were considered statistically 
significant. 
 
2.3 Study sample collection 
The Institutional Review Board of China Medical University Hospital (CMUH) 
approved this study (CMUH 104-REC-058, Appendix A) and written informed 
consent was obtained from the participants and their parents. I have recruited the 
youths with the DSM5 diagnosis of ADHD confirmed by a child and adolescent 
psychiatrist, age 6-18 years from the Department of Psychiatry, CMUH, Taiwan 
from July of 2016 to December of 2017. The participants also had to be drug 
naïve or had no medication use for the past 6 months. The exclusion criteria 
consisted of 1) intelligence quotient < 70, 2) Peabody Picture Vocabulary Test-
Revised (PPVT-R) percentile scores less than 5% (assessed in children age 6 to 
12 years of age; scores less than 5% may indicate speech delay or intellectual 
disability),  3) comorbid other psychiatric disorders, such as autism spectrum 
disorder, anxiety disorder, conduct disorder, and other major psychiatric 
disorders, 4) comorbid physical disorders, such as thyroid dysfunction, cerebral 




One hundred- and five were recruited and randomized into n-3 PUFAs (1.2g 
EPA) or placebo (1.2g soy bean oil) group for 12 weeks. The youth were assessed 
with the Digit Span Subset of Wechsler Intelligence Scale for Children-Fourth 
Edition (WISC-IV) and the Continuous Performance Test (CPT) and for 
cognitive function at baseline and after 12 weeks. The ADHD clinical symptoms 
of the child were assessed with the parent, teacher and youth (youth version only 
assessed in those older than or equal to 12 years of age) versions of Swanson, 
Nolan, & Pelham IV (SNAP-IV) at baseline and week 12; and the emotional 
problems of the child were assessed with the Strength and Difficulties 
Questionnaire (SDQ) at baseline and week 12. I have also assessed their dietary 
information and EFA deficiency severity with parental reports of the Food 
Frequency Questionnaire (FFQ) and of the Fatty Acid Deficiency Symptoms 
(FADS) Questionnaire at baseline. The saliva samples of the youth were collected 
for evaluation for cortisol levels, and blood samples were collected for evaluation 
of the levels of the inflammatory biomarkers including hs-CRP, IFN-γ IL-1b, IL6, 
IL-10, and TNF-α; the levels of the neurotrophins including BDNF, bNGF, 
GDNF and NT-3; and the levels of PUFAs at baseline and week 12.  
We performed power calculation for the sample size for the RCT. The ES of n-3 
PUFAs treatment in ADHD is around d = .2 to .3, but when we excluded the 
studies with less strictly defined diagnosis (only by rating scales) and those using 
low concentrations of EPA supplement (< 500 mg). We were to find the 
effect size of high dose EPA treatment in ADHD is to be around 0.38-0.81 
(Perera et al. 2012; Gustafsson et al, 2009; Widenhorn-Muller et al. 2014; Bos et 




diagnosis of ADHD will be made by board certified child and adolescent 
psychiatrist. Hence, the enrolment of 105 subjects will not be underpowered to 
detect a significant effect, since the enrolment criteria for ADHD will be strictly 
defined. The online sample size calculator is used to 
calculate sample size, https://www.ai-therapy.com/psychology-statistics/sample-
size-calculator. Significance level: 0.05, Power: 0.8, Effect size: 0.38 to 0.81, and 
the estimated sample sizes are between n = 246 to n = 50. 
Ninety-eight youth (mean age 9.32 + 3.05 years, 86% male) completed the 12-
week trial (See Figure 9 for enrolment process). I have also enrolled 21 age- and 
gender-matched typically developing (TD) youth (mean age 9.19 + 2.96 years, 
71.4 % male) without any past or current psychiatric disorders for the control 
group. I have assessed the cognitive function of TD youths with WISC-IV Digit 
Span subtest and CPT, their ADHD symptom severity with parent, teacher and 





   
Figure 9 The flow chart for RCT 
CPT, continuous performance test; EPA, eicosapentaenoic acid; mg, milligram; 




2.4 Clinical data collection at baseline (BL)  
These measures were administered at baseline to assess nutritional status, 
including omega-3 fatty acid intake level, and the fatty acid deficiency symptom 
severity of the subjects enrolled in the study. 
2.4.1 Social-demographic data 
I have collected social-demographic data at baseline. The data consists of age, 
gender, years of education and family history.  
2.4.2 Food Frequency Questionnaire (FFQ) 
Parents reported on the dietary patterns of the child. The FFQ is the most 
common dietary assessment tool used in large epidemiologic studies of diet and 
health (Burrows, Berthon, Garg, & Collins, 2012). The FFQ includes 13 
categories of nutritional food (e.g., vegetables, fruits, dairy, meat, seafood, 
internal organs, eggs, soybean products) and 9 categories of low-quality food 
(e.g., fried food, noodle cups, cakes and pastries, chips, cookies, ice cream, 
sweetened drinks) (See Appendix B). Similar foods were listed close to each 
other to prevent redundant recollection. Consumption was measured over a 
defined period of time (i.e., the past 3 months). The Chinese FFQ has been 
validated elsewhere (Chen et al., 2004). The questionnaire uses an 8-point scale 
from 0 (no intake of this food during the week) to 7 (eating this type of food on 
an everyday basis for 1 week); parents were asked to recall the frequency of 
different types of food intake of their child. FFQ scores have been positively 
correlated with current nutritional status (Burrows et al., 2012). The n-3 PUFA 




regarding consumption of fish, deep-sea fish, shrimp, oyster, crabs, and any type 
of seafood to account for n-3 PUFA intake. The high-quality (HQ) score was the 
sum of intake of the 13 nutritional food types of the FFQ. The low-quality (LQ) 
score was the sum of intake of 9 low nutritional value food types.  
2.4.3 Fatty Acid Deficiency Symptom Scale (FADS) 
Parents were asked to complete a health questionnaire about their child, which 
included questions about the existence and severity of each of the 20 FADS 
items. (See Appendix C). Some examples of the FADS items include excessive 
thirst, dry skin, brittle nails, and small bumps on the skin (Richardson et al., 
2000). The degree of each item was rated on a 3-point rating scale (0 = not at all, 
1 = just a little, 2 = somewhat, and 3 = very much). The lowest score is 0, and the 
highest score is 60. FADS score has been negatively correlated with blood n-3 
PUFAs concentration (Stevens et al., 1995).  
 
2.5 Laboratory methods  
2.5.1 Salivary cortisol levels 
Participants were provided with a verbal explanation and written instructions for 
collecting saliva samples at home (at the weekend or during the school holidays) 
using the Salivette swabs (Salivette; Sarstedt Inc., Rommelsdorf, Germany). The 
participants were instructed to place the swab in the mouth and chew it for about 
60 seconds to stimulate salivation, and then returned the swab with absorbed 
saliva to the container. The salivary samples were collected at 4 time-points 




1800h and before bed). The families were instructed to collect the samples before 
the youth brushed their teeth, at least 30 minutes after eating or drinking, and at 
least one hour after sports activities, and they were asked to record the time of 
sample collection on the recording sheet. The collected swabs were then placed in 
the sampling tubes and handed to the researchers, along with the sampling time 
records, after the completion of four collection time points. The tubes were stored 
at minus 80 °C until analysed and were vortexed and centrifuged at 1500 x g for 
15 minutes prior analysis. Cortisol was assessed using high sensitivity enzymatic 
immunoassay kit (Salimetrics®, State college, PA) with a lower limit of 
sensitivity of <0.007 micrograms per decilitre (μg/dL).  
Cortisol data were summarized using the Area Under the Curve (AUC) 
computation (Pruessner, Kirschbaum, Meinlschmid, & Hellhammer, 2003): AUC 
with respect to ground of cortisol levels during the morning (Wake to Noon: 
calculated using values for awakening and 1200h), during the afternoon (Noon to 
1800h: calculated using values for 1200h and 1800h), during the evening (1800h 
and before bedtime), and during the day (Wake to Bed: calculated using values 
for awakening, 1200h, 1800h, and before bedtime).  
2.5.2 Blood Inflammatory and neurotrophins biomarker levels 
Blood samples were obtained in the morning (0800h to1000h) after 12-hour 
fasting. Venous blood was extracted into 5mL K2 ethylenediaminetetraacetic acid 
tubes (BD, Franklin Lakes, NJ, USA) and were centrifuged at 1200 x g for 10 min 
(25°C) and the plasma were stored at -80°C until further analysis. Patients enrolled 




hs-CRP (DuoSet ELISA Development, R&D Systems, Inc., USA), cytokines 
including IL-1b, IL-6, IL-10, IFN-γ and TNF-α (DuoSet ELISA Development, 
R&D Systems, Inc., USA), and neurotrophins including BDNF, NT-3, GDNF, b-
NGF (DuoSet ELISA Development, R&D Systems, Inc., USA) by ELISA method. 
The samples were analysed with high specificity and sensitivity human ELISA kit 
and were analysed in duplicate according to the manufacturer's instructions. The 
cytokines (IL-1b, IL-6, IL-10, TNF-a, IFN-g) and neurotrophins (BDNF, NT-3, 
GDNF, b-NGF) levels were expressed in picogram per millilitre (pg/mL) and the 
plasma hs-CRP levels were expressed in milligram per Litre (mg/L). The lower 
limit sensitivity for IL-1b is 3.91 pg/mL, for IL-6 is 9.38 pg/mL, for IL-10 is 31.3 
pg/mL, for TNF-α and IFN γ is 15.6 pg/mL, for BDNF is 23.40 pg/mL, for NT-3, 
GDF and b-NGF is 31.3 pg/mL, and for hs-CRP is .00001 mg/L. 
2.5.3  Blood PUFAs levels 
The fatty acid composition of erythrocyte membranes was analyzed by thin-layer 
chromatography and the level of individual fatty acid was measured with gas 
chromatography of methyl esters (Lipid Standards, FAME, Sigma Co., St. Louis, 
MO, USA). Fatty acid profiles were identified by comparing the retention times 
with those of appropriate standard fatty acid methyl esters. The detailed step-by-
step procedures have been published and described elsewhere (Chiu et al., 2003). 
The levels of each fatty acid were expressed as a percentage of total fatty acids. 
Laboratory measures were conducted on coded samples by workers who were 





2.6 Clinical data collection at baseline and week 12 
2.6.1 Swanson, Nolan and Pelham Questionnaire, Fourth Edition (SNAP-IV) 
Parents, teachers and children (older than or equal to 12 years old) were asked to 
report the severity of the child’s ADHD symptoms with the SNAP-IV (Gau et al., 
2009; Gau et al., 2008; Nichols et al., 2017; Swanson et al., 2001) (See Appendix 
D). The parent, teacher and youth versions of SNAP-IV have been validated 
elsewhere (Gau et al., 2009; Gau et al., 2008; Nichols et al., 2017). SNAP-IV 
consists of 18 DSM-5 symptoms of ADHD, including inattention (items 1–9), 
hyperactivity (items 10–15), impulsivity (items 16–18), and symptoms of the 
criteria for the oppositional defiant disorder (ODD) (items 19–26). The sum of 
scores of items 1-18 indicates the total ADHD score. The symptom severity of 
each symptom item was rated on a 4-point rating scale (0 = not at all, 1 = just a 
little, 2 = quite a bit, and 3 = very much). A higher total score on items 1–18 
indicated a higher severity of ADHD symptoms. The ADHD group is further 
stratified by subtypes: inattention subtype (IA) is defined by SNAP-IV inattention 
subscale (IAs) > 12, the hyperactivity-impulsivity subtype (HI) is defined by 
SNAP-IV hyperactivity-impulsivity subscale (HIs) > 12, the combined subtype is 
defined by both SNPAP-IV IAs and HIs > 12, and subthreshold ADHD is defined 
by neither SNAP-IV IAs nor HIs score >12.  ODD is defined with an SNPA-IV 
ODD score > 13. 
2.6.2 Strength and Difficulties Questionnaire (SDQ) 
The parents reported on emotional problems of the child with the SDQ (See 




adolescents age 3-16 years old, and consists of 5 domains: emotional problems, 
conduct problems, hyperactivity, peer problems and prosocial behavior 
(Goodman, 1997). Each domain is composed of 5 items and each item is scored 
on a 3-point rating scale (0 = not true, 1 = somewhat true, 2 = certainly true). A 
higher score for emotional symptoms, conduct problems, hyperactivity, peer 
relationship problems, and a total of the four domains, represent total difficulties. 
On the other hand, a lower score for prosocial behavior subscale indicates a 
problem. The internalizing problems score is comprised of the scores of 
emotional and peer problems domains. The externalizing problems score is 
comprised of the scores of the conduct problems and hyperactivity domains. The 
reliability and validity of the Chinese version of the SDQ have been reported 
elsewhere (Liu et al., 2013). 
 
2.7 Cognitive assessment at baseline and week 12 
2.7.1 Peabody Picture Vocabulary Test-Revised (PPVT-R) 
Receptive vocabulary knowledge was measured with the PPVT-R (Dunn & 
Hottel, 1961; Wu et al., 2011) to screen for intellectual disability in children age 6 
to 12 years of age at baseline (scores less than 5% may indicate speech delay or 
intellectual disability). For this task, children were shown sets of four pictures and 
asked to point to the picture representing the word spoken by the examiner. The 
PPVT-R manual provides normative data that were collected from a sample of 
886 TD children with normal hearing from 3 to 12 years of age. The standard 




test developers. The standard scores were based on a mean of 100 and a standard 
deviation (SD) of 15.  
2.7.2 Wechsler Intelligence Scale-Fourth Edition (WISC-IV) Digit Span Subtest 
The memory for Digit Span assessment is a measure of short-term memory for 
children aged seven and over (Wechsler, 2003). There two parts to the Memory 
for Digit Span assessment: Digits Forward and Digits Backward. Each tap distinct 
but interdependent cognitive functions. Digit Forward primarily taps short-term 
memory, while Digits Span Backward measures the ability of the child to 
manipulate verbal information while in temporary storage. The higher the points 
indicate a better memory function of the child. 
2.7.3 Continuous Performance Test (CPT) 
The CPT is a 14-minute computerized task for children aged 8 years and older 
(Conners, 2014). It requires the individual to tap on the spacebar when any 
character except “X” is shown on the screen. There are 6 blocks in the CPT, 
including 3 sub-blocks that each contain 20 letter presentations, for a total of 360 
trials. The sub-blocks differ in interstimulus intervals (ISI) of 1, 2 and 4 s, and the 
sequence of ISI conditions is presented randomly. The domains of CPT 
performances include omission errors (the number of times not responding to a 
target), commission errors (the number of times responding to a nontarget), hit 
reaction time (HRT, the period of time between the presentation of the stimulus 
and the response), variability (intraindividual variability in HRT), perseveration 
(HRT<100 milliseconds (ms)), detectability or dprime (d’, the ability to 




consistency of RT), HRT changed by blocks (HRTBC, the slope of changes in 
RT over 6 blocks as the test progresses), HRT changed by ISIs (HRTISIC, 
whether performance decreases with longer ISIs). These domains can be grouped 
into 4 dimensions: focused attention, impulsivity, sustained attention, and 
vigilance (Egeland & Kovalik-Gran, 2010). Focused attention includes omission 
errors, HRTSD, variability, and detection; impulsivity includes commission 
errors, HRT and perseveration; sustained attention includes HRTBC; and 
vigilance includes HRTISIC. 
 
2.8 My contribution 
The study is designed by Dr. Jane Pei-Chen Chang and carried out after fully 
discussed with the supervisors Professor Carmine M. Pariante, Dr. Valeria 
Mondelli, and Professor Louise Arseneault and mentor Professor Kuan-Pin Su. 
The systematic reviews and meta-analyses were performed by Dr. Jane Pei-Chen 
Chang. Recruitment of patients was performed by Dr. Jane Pei-Chen Chang, the 
clinical assessments including the FADS, FFQ, SNAP-IV, PPVT-R, Continuous 
Performance Test and the WISC-IV Digit Span were performed by Dr. Jane Pei-
Chen Chang and Mrs. Hui-Tin Chen; the salivary and blood sample collections 
were performed by Dr. Jane Pei-Chen Chang and Mrs. Hui-Tin Chen; the blood 
processing (serum and plasma separation) were performed by Dr. Jane Pei-Chen 
Chang, Mrs. Grace Yu-Chuan Chen and Mr. Senthil Kumaran Satyanarayanan. 
The ELISA for the salivary cortisol levels, blood inflammatory markers and 




Kumaran Satyanarayanan; The blood PUFAs levels were analysed by Dr. Jane 
Pei-Chen Chang and Dr. Hui-Ting Yang. All other experiments were conducted 
by Dr. Jane Pei-Chen Chang under the supervision of Professor Carmine M. 
Pariante, Dr. Valeria Mondelli, and Professor Louise Arseneault. 
 
2.9 Data analysis 
All statistical analysis was carried out with Statistical Package for the Social 
Science (SPSS), version 25.0 for Windows (IBM Corp, Released 2017). 
Demographic, clinical characteristics, cognitive function measures, salivary 
cortisol levels, levels of blood inflammatory biomarkers, neurotrophins and 
PUFAs levels n ADHD and TD groups, and between the n-3 and placebo groups, 
were compared by t-test or Chi-Square test where appropriate. The enrolled 
subjects were stratified according to the tertiles of baseline EPA levels, where 
low EPA level was defined as < .91%, moderate EPA defined as .91 to 1.08% and 
high EPA was defined as > 1.08%. The enrolled subjects were also stratified 
according to the tertiles of baseline hs-CRP levels, where low hs-CRP was 
defined as < 1.45 mg/L, moderate hs-CRP defined as 1.45-2.22 mg/L and high 
hs-CRP defined as > 2.22 mg/L. The ES and 95% CIs were computed for the 
group comparisons between n-3 PUFAs and placebo group in the changes of the 
WISCDS scores and SDQ prosocial score among the different baseline hs-CRP 
level groups, and in the changes of the CPT scores among the different baseline 
EPA level groups, with the small, medium, and large ES as 0.2 to 0.5, 0.5 to 0.8, 





3.1 Meta-analysis  
In this section, I will report the findings from my systematic reviews and meta-
analyses on the 1) salivary cortisol levels in ADHD and 2) blood PUFAs levels in 
ADHD and the effects of n-3 PUFAs on clinical symptoms and cognitive 
function in ADHD. 
3.1.1 Cortisol levels in ADHD  
Fourteen studies (Angeli et al., 2018; Blomqvist et al., 2007; Christiansen, Oades, 
Psychogiou, Hauffa, & Sonuga-Barke, 2010; Freitag et al., 2009; Imeraj et al., 
2012; Isaksson et al., 2012; Jansen et al., 1999; Maldonado et al., 2009; 
McCarthy et al., 2011; Randazzo et al., 2008; Snoek et al., 2004; van West et al., 
2009; Wang et al., 2011; White & Mulligan, 2005) , were included in the meta-
analysis on cortisol levels, totalling 1538 subjects: 568 youth with ADHD and 
970 TD youth. Nine studies were included in the meta-analysis on morning 
cortisol levels, totalling 1322 subjects: 458 youth with ADHD and 864 TD youth. 
Five studies were included in the meta-analysis on afternoon cortisol levels, 
totalling 216 subjects, 110 youth with ADHD and 106 TD youth. Two studies 
were included in the meta-analysis of noon salivary cortisol levels, totalling 126 
subjects, 53 youth with ADHD and 73 TD youth. Three studies were included in 
the meta-analysis of bedtime salivary cortisol levels, totalling 530 subjects, 248 
youth with ADHD and 282 TD youth. If a study provided cortisol measurements 
from children with inattentive, hyperactivity-impulsivity and combine types of 




included in the meta-analysis, as the combined type is the most common and 
severe form of ADHD. When a study provided cortisol measurements collected 
from more than 2 settings for the same time block, for example, clinic and home, 
only the cortisol measurements collected from places other than home is included 
in the meta-analysis, as most of the studies collected cortisol measurements in 
settings other than home, except for those studies measuring awakening cortisol 
levels. The characteristics of the included articles are described in Table 4. The 





Table 4 Characteristics of studies included in the meta-analysis for salivary 
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Note: ADHD, attention deficit hyperactivity disorder; AM, morning; D, diurnal 
(including AM, noon, PM, bedtime); N, number; NL, Netherlands; NS, not 
specified; PM, afternoon; SD, standard deviation; T, time; TD, typically 






Table 5 Methods of sample collection, storage and analysis 
 
Study (yr) Collection  Storage 
Degree (°C) 
Analysis 
Jansen (1999) S; Citric acid 
induced; plastic tube 
-20 RIA 
Snoek (2004) S; Citric acid 
induced; plastic tube 
-20 RIA 
White (2005) S; straw -20 RIA 
Blomqvist (2007) S; swab -80 RIA 
Randazzo (2008) S; passive drool -20 EIA 
Freitag (2009) S; NS NS DELFIA 
Maldonado 
(2009) 
S; Salivette -20  DELFIA 





S; swab -20 RIA 
McCarthy Clinic 
(2011) 
S; Salivette -20 RIA 
Wang (2011) S; tube -30 ELISA 
Imeraj (2012) S; Salivette -26 RIA 
Isaksson (2012) S: Salivette -70 RIA 
Angeli (2018) S; Salivette -85 EIA* 
Note: °C, degree in Celsius; DELFIA, time-resolved immunoassay with 
fluorescence detection; EIA, immunoassay; ELISA, enzyme-linked 
immunosorbent assay; NS, not specified; RIA, radioimmunoassay; S, saliva; yr, 






The meta-analysis on 14 studies comparing basal cortisol levels in children with 
ADHD and TD children showed that ADHD youth have lower basal cortisol 
levels, independently from the time-point (g = -.77, p = .004, Figure 10). In 
addition, when I analysed the 9 studies that measured the morning cortisol levels, 
youth with ADHD continue to have a lower cortisol level than TD youth (n = 
1322 participants, g = -1.21, p = .002, Figure 11). On the other hand, the 
subanalysis of 5 studies with the afternoon salivary cortisol levels showed no 







Figure 10 Forest plots showing effect sizes (Hedges’s g) and 95% CIs from 
individual studies and pooled results comparing salivary cortisol levels 
between the ADHD population and control group 






I have repeated the analysis after only including the studies that took awakening 
cortisol measurements and found again that youth with ADHD have lower 







Figure 11 Forest plots showing effect sizes (Hedges’s g) and 95% CIs from 
individual studies and pooled results comparing morning salivary cortisol 
levels between the ADHD population and control group.  
Note: The forest plots also included awakening and non-awakening morning 
salivary cortisol levels. ADHD, attention deficit hyperactivity disorder; CI, 





The subanalysis of 2 studies measuring noon salivary cortisol levels also showed 
youth with ADHD have lower salivary cortisol levels than TD youth (n = 126, g 
= -0.47, p = .001, Figure 12), while the subanalysis of 3 studies measuring 
bedtime salivary cortisol levels showed no differences between youth with 
ADHD and TD youth (n = 530, p = .94, Figure 13). The sensitivity test showed 
that the main results of meta-analysis for the cortisol levels did not change after 
removal of any one of the included studies.   
 
 
Figure 12 Forest plots showing effect sizes (Hedges’s g) and 95% CIs from 
individual studies and pooled results comparing noon salivary cortisol levels 
between the ADHD population and control group.  







Figure 13 Forest plots showing effect sizes (Hedges’s g) and 95% CIs from 
individual studies and pooled results comparing bedtime salivary cortisol 
levels between the ADHD population and control group  






3.1.2 N-3 PUFAs levels in ADHD 
Nine studies were included in the meta-analysis on n-3 PUFAs levels (Bos et al., 
2015; Chen et al., 2004; Colter et al., 2008; Germano et al., 2007; Gow et al., 
2009; Gow et al., 2013; Mitchell, Aman, Turbott, & Manku, 1987; Stevens et al., 
2003; Stevens et al., 1995), totalling 558 subjects: 297 youths with ADHD and 
261 controls. Eight studies were included in the meta-analysis for DHA level 
(Bos et al., 2015; Chen et al., 2004; Colter et al., 2008; Germano et al., 2007; 
Gow et al., 2009; Mitchell et al., 1987; Stevens et al., 2003; Stevens et al., 1995), 
totalling 486 subjects: 268 youth with ADHD and 218 controls. Eight studies 
were included in the meta-analysis for EPA levels (Chen et al., 2004; Colter et al., 
2008; Germano et al., 2007; Gow et al., 2009; Gow et al., 2013; Mitchell et al., 
1987; Stevens et al., 2003; Stevens et al., 1995), totalling 542 subjects: 285 youth 
with ADHD and 257 controls. Seven studies were included in the meta-analysis 
for total n-3 PUFAs levels (Bos et al., 2015; Chen et al., 2004; Colter et al., 2008; 
Germano et al., 2007; Gow et al., 2013; Stevens et al., 2003; Stevens et al., 1995), 
totalling 470 subjects: 250 youth with ADHD and 220 controls. Eight studies 
were included in the meta-analysis for AA levels (Bos et al., 2015; Chen et al., 
2004; Colter et al., 2008; Germano et al., 2007; Gow et al., 2013; Mitchell et al., 
1987; Stevens et al., 2003; Stevens et al., 1995), totalling 567 subjects: 298 youth 
with ADHD and 269 controls. Eight studies were included in the meta-analysis 
for total n-6 PUFAs levels (Bos et al., 2015; Chen et al., 2004; Colter et al., 2008; 
Germano et al., 2007; Gow et al., 2009; Gow et al., 2013; Stevens et al., 2003; 
Stevens et al., 1995), totalling 499 subjects: 270 youth with ADHD and 229 




PUFAs (DHA, EPA, AA, n-3, n-6), only measurements of RBCs level were 
included in the meta-analysis, since plasma levels reflect more recent fluctuations 
(e.g., days) in phospholipids while RBCs levels reflect more long-term changes 















































3, N-6  
























































































DHA NE B 10.3(2.0) 
Note: ADHD, attention deficit hyperactivity disorder, AA, arachidonic acid; B, 
buccal cell; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; N, 
number; NE, Netherlands; N-3, omega-3; N-6, omega-6; P, plasma; R, red blood 
cells; SD, standard deviation; TD, typically developing youth; UK, United 






3.1.2.1 Youth with ADHD Have Lower Levels of N-3 PUFAs 
In the overall meta-analysis, irrespective of tissue source, youth with ADHD have 
lower levels of DHA (8 studies, n = 486, g = -.56, p = .05, Figure 14), but no 
group differences are present for EPA, AA, n-3 PUFAs and n-6 PUFAs levels 
(Figures 15 to 18).  
I also performed a secondary analysis by excluding the study by Stevens et al. 
(2003), which was different from all other studies in their participants inclusion 
criteria (see Figures 14 to 18 and Discussion 4.4.1). In this analysis, I found that 
youth with ADHD indeed have lower levels not only of DHA (7 studies, n = 412, 
g = -.76, p = .0002, Figure 14), but also of EPA (6 studies, n = 396, g = -.43, p 
= .0002, Figure 15), total n-3 (6 studies, n =396, g = -.58, p = .0001, Figure 16) 
and AA (7 studies, n = 493 , g = -.41, p < .0001, Figure 17) , but not of n-6 






Figure 14 Forest plots showing effect sizes (Hedges’s g) and 95% CIs from 
individual studies and pooled results comparing DHA levels between the 
ADHD population and control group  
Note: ADHD, attention deficit hyperactivity disorder; CI, confidence interval; 





Figure 15 Forest plots showing effect sizes (Hedges’s g) and 95% CIs from 
individual studies and pooled results comparing EPA Levels between the 
ADHD population and control group 
Note: ADHD, attention deficit hyperactivity disorder; CI, confidence interval; 





Figure 16 Forest plots showing effect sizes (Hedges’s g) and 95% CIs from 
individual studies and pooled results comparing n-3 PUFAs Levels between 
the ADHD population and control group  
Note: ADHD, attention deficit hyperactivity disorder; CI, confidence interval; 





Figure 17 Forest plots showing effect sizes (Hedges’s g) and 95% CIs from 
individual studies and pooled results comparing AA Levels between the 
ADHD population and control group 
Note: AA, arachidonic acids; ADHD, attention deficit hyperactivity disorder; CI, 





Figure 18 Forest plots showing effect sizes (Hedges’s g) and 95% CIs from 
individual studies and pooled results comparing n-6 PUFAs Levels between 
the ADHD population and control group 
Note: ADHD, attention deficit hyperactivity disorder; CI, confidence interval; 




I also performed subanalyses looking at levels of the RBCs and plasma PUFAs 
separately. Youth with ADHD have lower RBCs DHA (5 studies, n = 277, g = 
-.77, p < .0001, Figure 19), EPA (4 studies, n = 196, g = -.55, p = .01, Figure 20) 
and n-3 PUFAs (4 studies, n = 245, g = -.70, p = .0002, Figure 21). There were no 
differences in RBCs AA (p = .14, Figure 22) and n-6 PUFAs (p = .81, Figure 23). 
Moreover, the subanalysis showed that there is no difference in plasma PUFAs 
levels (Figures 24 to 28).  
 
 
Figure 19 Forest plots showing effect sizes (Hedges’s g) and 95% CIs from 
individual studies and pooled results comparing erythrocyte DHA levels 
between the ADHD population and control group  
Note: Stevens et al. 2003’s study was excluded in this met-analysis. ADHD, 
attention deficit hyperactivity disorder; CI, confidence interval; DHA, 






Figure 20 Forest plots showing effect sizes (Hedges’s g) and 95% CIs from 
individual studies and pooled results comparing erythrocyte EPA Levels 
between the ADHD population and control group 
Note: Stevens et al. 2003’s study was excluded in this met-analysis. ADHD, 
attention deficit hyperactivity disorder; CI, confidence interval; EPA, 






Figure 21 Forest plots showing effect sizes (Hedges’s g) and 95% CIs from 
individual studies and pooled results comparing erythrocyte n-3 PUFAs 
Levels between the ADHD population and control group 
Note: Stevens et al. 2003’s study was excluded in this met-analysis. ADHD, 
attention deficit hyperactivity disorder; CI, confidence interval; N3, n-3 or 







Figure 22 Forest plots showing effect sizes (Hedges’s g) and 95% CIs from 
individual studies and pooled results comparing erythrocyte AA Levels 
between the ADHD population and control group.  
Note: Stevens et al. 2003’s study was excluded in this met-analysis. AA, 
arachidonic acids; ADHD, attention deficit hyperactivity disorder; CI, confidence 





Figure 23 Forest plots showing effect sizes (Hedges’s g) and 95% CIs from 
individual studies and pooled results comparing erythrocyte n-6 PUFAs 
Levels between the ADHD population and control group 
Note: Stevens et al. 2003’s study was excluded in this met-analysis. ADHD, 
attention deficit hyperactivity disorder; CI, confidence interval; N6, n-6 or 






Figure 24 Forest plots showing effect sizes (Hedges’s g) and 95% CIs from 
individual studies and pooled results comparing plasma DHA Levels 
between the ADHD population and control group 
Note: Stevens et al. 2003’s study was excluded in this met-analysis. ADHD, 
attention deficit hyperactivity disorder; CI, confidence interval; DHA, 
docosahexaenoic acids; Std, standard. 
 
Figure 25 Forest plots showing effect sizes (Hedges’s g) and 95% CIs from 
individual studies and pooled results comparing plasma EPA Levels between 
the ADHD population and control group  
Note: Stevens et al. 2003’s study was excluded in this met-analysis. ADHD, 
attention deficit hyperactivity disorder; CI, confidence interval; EPA, 





Figure 26 Forest plots showing effect sizes (Hedges’s g) and 95% CIs from 
individual studies and pooled results comparing plasma n-3 PUFAs Levels 
between the ADHD population and control group 
Note: Stevens et al. 2003’s study was excluded in this met-analysis. ADHD, 
attention deficit hyperactivity disorder; CI, confidence interval; N3, n-3 or 






Figure 27 Forest plots showing effect sizes (Hedges’s g) and 95% CIs from 
individual studies and pooled results comparing plasma AA levels between 
the ADHD population and control group  
Note: Stevens et al. 2003’s study was excluded in this met-analysis. AA, 
arachidonic acids; ADHD, attention deficit hyperactivity disorder; CI, confidence 
interval; Std, standard. 
 
Figure 28 Forest plots showing effect sizes (Hedges’s g) and 95% CIs from 
individual studies and pooled results comparing plasma n-6 PUFAs Levels 
between the ADHD population and control group 
Note: Stevens et al. 2003’s study was excluded in this met-analysis. ADHD, 
attention deficit hyperactivity disorder; CI, confidence interval; N6, n-6 or 




3.1.3 N-3 PUFAs on clinical symptoms in ADHD 
I have identified 8 studies (Bos et al., 2015; Gustafsson et al., 2010; Manor et al., 
2012; Perera et al., 2012; Richardson & Puri, 2002; Sinn et al., 2008; Vaisman et 
al., 2008; Widenhorn-Muller et al., 2014), totalling 628 subjects: 366 received n-3 
PUFAs and 262 received placebo. Seven studies were included in the meta-
analysis for total ADHD clinical symptoms totalling 534 subjects: 318 received 
n-3 PUFAs and 216 received placebo. Seven studies were included in the meta-
analysis for inattention clinical symptoms (Bos et al., 2015; Gustafsson et al., 
2010; Manor et al., 2012; Perera et al., 2012; Richardson & Puri, 2002; Sinn et 
al., 2008; Widenhorn-Muller et al., 2014), totalling 590 subjects: 348 received n-3 
PUFAs and 242 received placebo. Six studies were included in the meta-analysis 
for hyperactivity clinical symptoms (Gustafsson et al., 2010; Manor et al., 2012; 
Perera et al., 2012; Richardson & Puri, 2002; Sinn et al., 2008; Widenhorn-
Muller et al., 2014), totalling 551 subjects: 328 received n-3 PUFAs and 223 






Table 7 Characteristics of studies included in the meta-analysis for effects of 
































































































































Note: ADHD, attention deficit hyperactivity disorder; CBCL, child behavior 
checklist; CHQ-PF50, child health questionnaire parent form 50; CPRS, Conners’ 
parenting rating scale; CPRS-L, Conners’ parent rating scale- long form; CRS, 
Conners’ rating scale; CTRS, Conners’ teacher rating scale; DHA, 
docosahexaenoic acid; EPA, eicosapentaenoic acid; n, number; NE, Netherlands; 
N-3, omega-3; NS, not specified; PUFA, polyunsaturated fatty acids; P, placebo; 
SD, standard deviation; SDQ, strengths and difficulties questionnaire; SNAP-IV, 
Swanson, Nolan and Pelham Questionnaire; SWAN, Strengths and weakness of 
ADHD symptoms and normal behavior rating scales; TRF, teacher report form; 





3.1.3.1 N-3 PUFAs Improves Clinical Symptoms in ADHD 
One of the major findings of my study is that n-3 PUFAs supplementation 
significantly improves parental reports of total symptom scores (7 studies, n = 
534, g = .38, p < .0001, Figure 31), inattention (7 studies, n = 590, g = .42, p 
< .0001, Figure 29), and hyperactivity (6 studies, n = 551, g = .48, p = .04) (see 
Figure 30). I also did a subanalysis looking at effects of n-3 PUFAs using two 
specific measurements, the Conner’s cognition subscale (Richardson & Puri, 
2002; Sinn et al., 2008) and the Conner’s DSM-IV inattention subscale (Manor et 
al., 2012; Richardson & Puri, 2002; Sinn et al., 2008): n-3 PUFAs have a 
significant effect on both scores (2 studies, n = 159, g = .49, p = .01; 3 studies, n 
= 306, g = .36, p =.007, respectively). For both inattention (Figure 29) and total 
ADHD score (Figure 31), these effects are significant also in the subgroup 
analyses testing separately studies with EPA dosage of 500mg/day or greater, and 
studies with EPA dosage less than 500mg. However, for hyperactivity (Figure 
30), only studies with EPA dosage of 500mg/day or greater (Gustafsson et al., 
2010; Perera et al., 2012; Widenhorn-Muller et al., 2014) show a significant 
effect, but not those with smaller dosages (Manor et al., 2012; Richardson & Puri, 
2002; Sinn et al., 2008). Interestingly, only one study (Perera et al., 2012) in my 
meta-analysis used EPA as the sole source for omega-3 supplementation, and 
showed a significant effect on both inattention (n = 93, g = .69, p = .001) and 





Figure 29 Forest plots showing effect sizes (Hedges’s g) and 95% CIs from 
individual studies and pooled results comparing parent-reported clinical 
ADHD- inattention symptom scores between n-3 and placebo group 
Note: ADHD, attention deficit hyperactivity disorder; CI, confidence interval; 
EPA, eicosapentaenoic acid ; N3 or n-3, omega-3 polyunsaturated fatty acids; 
Std, standard. >= 500, clinical trials with EPA dosage > 500 mg; < 500, clinical 






Figure 30 Forest plots showing effect sizes (Hedges’s g) and 95% CIs from 
individual studies and pooled results comparing parent-reported clinical 
ADHD- hyperactivity-impulsivity symptom scores between n-3 and placebo 
group.  
Note: ADHD, attention deficit hyperactivity disorder; CI, confidence interval; 
EPA, eicosapentaenoic acid ; N3 or n-3, omega-3 polyunsaturated fatty acids; 
Std, standard. >= 500, clinical trials with EPA dosage > 500 mg; < 500, clinical 





Figure 31 Forest plots showing effect sizes (Hedges’s g) and 95% CIs from 
individual studies and pooled results comparing parent-reported clinical 
total ADHD symptom scores between n-3 and placebo group  
Note: ADHD, attention deficit hyperactivity disorder; CI, confidence interval; 
EPA, eicosapentaenoic acid ; N3 or n-3, omega-3 polyunsaturated fatty acids; 
Std, standard. >= 500, clinical trials with EPA dosage > 500 mg; < 500, clinical 





Of note, n-3 PUFAs have no significant effect on teachers’ reports of inattention 
(3 studies, n = 319, p =.65, Figure 32), hyperactivity (3 studies, n = 317, p =.24, 
Figure 33) or total scores (3 studies, n = 321, p =.20, Figure 34) (Gustafsson et 
al., 2010; Manor et al., 2012; Widenhorn-Muller et al., 2014). 
 
 
Figure 32 Forest plots showing effect sizes (Hedges’s g) and 95%  CIs from 
individual studies and pooled results comparing teacher reported clinical 
ADHD- inattention symptom scores between n-3 and placebo group  
Note: ADHD, attention deficit hyperactivity disorder; CI, confidence interval; N3 






Figure 33 Forest plots showing effect sizes (Hedges’s g) and 95% CIs from 
individual studies and pooled results comparing teacher reported ADHD- 
hyperactivity-impulsivity symptom scores between n-3 and placebo group  
Note: ADHD, attention deficit hyperactivity disorder; CI, confidence interval; 
EPA, eicosapentaenoic acid; N3 or n-3, omega-3 polyunsaturated fatty acids; Std, 
standard.  
 
Figure 34 Forest plots showing effect sizes (Hedges’s g) and 95% CIs from 
individual studies and pooled results comparing teacher reported total 
ADHD symptoms scores between n-3 and placebo group 
Note: ADHD, attention deficit hyperactivity disorder; CI, confidence interval; 






3.1.4 N-3 PUFAs on cognitive function in ADHD 
I have identified 4 studies (Sinn et al., 2008; Vaisman et al., 2008; Voigt et al., 
2001; Widenhorn-Muller et al., 2014), totalling 309 subjects: 178 received n-3 
PUFAs and 131 received placebo. Three studies were included in the meta-
analysis for omission errors (Sinn et al., 2008; Vaisman et al., 2008; Voigt et al., 
2001), totalling 214 subjects: 134 received n-3 PUFAs and 80 received placebo. 
Two studies were included in the meta-analysis for commission errors totalling 
85 subjects: 43 received n-3 PUFAs and 42 received placebo. Two studies were 
included in the meta-analysis for memory (Sinn et al., 2008; Widenhorn-Muller et 
al., 2014), totalling 224 subjects: 137 received n-3 PUFAs and 87 received 
placebo. Four studies were included in the meta-analysis for information 
processing (Sinn et al., 2008; Vaisman et al., 2008; Voigt et al., 2001; 
Widenhorn-Muller et al., 2014), totalling 309 subjects: 178 received n-3 PUFAs 
and 131 received placebo. The characteristics of the included articles are 




Table 8 Characteristics of studies included in the meta-Analysis for effects of 



















































































8.91 (1.4) Memory, 
Information 
Processing 
Note: ADHD, attention deficit hyperactivity disorder; DHA, docosahexaenoic 
acid; EPA, eicosapentaenoic acid; n, number; N-3, omega-3; NS, not specified; 
PUFA, polyunsaturated fatty acids; P, placebo; SD, standard deviation; USA, 




3.1.4.1 N-3 PUFAs Improves Cognitive Performance in ADHD 
Another main finding of my meta-analysis is that n-3 PUFAs supplementation is 
superior to placebo in terms of cognitive performance for omission errors (3 
studies, n = 214, g = 1.09, p = .001, Figure 35) and commission errors (2 studies, 
n = 85, g = 2.14, p < .00001, Figure 36), but not forward memory (2 studies, n = 
224, p = .66, Figure 37), backward memory (2 studies, n = 224, p = 0.08, Figure 
38) or information processing (4 studies, n = 309, p = .23, Figure 39).  
 
Figure 35 Forest plots showing effect sizes (Hedges’s g) and 95% CIs from 
individual studies and pooled results comparing omission errors between n-3 
group and placebo group 
Note: CI, confidence interval; n3 or n-3, omega-3 polyunsaturated fatty acids; 






Figure 36 Forest plots showing effect sizes (Hedges’s g) and 95% CIs from 
individual studies and pooled results comparing commission errors between 
n-3 group and placebo group 
Note: CI, confidence interval; n3 or n-3, omega-3 polyunsaturated fatty acids; 
Std, stand.  
 
 
Figure 37 Forest plots showing effect sizes (Hedges’s g) and 95% CIs from 
individual studies and pooled results comparing forward memory between n-
3 group and placebo group 
Note: CI, confidence interval; n3 or n-3, omega-3 polyunsaturated fatty acids; 






Figure 38 Forest plots showing effect sizes (Hedges’s g) and 95% CIs from 
individual studies and pooled results comparing backward memory between 
n-3 group and placebo group 
Note: CI, confidence interval; n3 or n-3, omega-3 polyunsaturated fatty acids; 
Std, stand.  
 
Figure 39 Forest plots showing effect sizes (Hedges’s g) and 95% CIs from 
individual studies and pooled results comparing information processing 
between n-3 group and placebo group 
Note: CI, confidence interval; n3 or n-3, omega-3 polyunsaturated fatty acids; 





3.2 Cross-sectional study 
In this section, I will report the results from my cross-sectional study between 
youth with ADHD and TD youth on salivary cortisol levels, blood inflammatory 
biomarkers, neurotrophins, PUFAs levels, nutritional status (including food 
intake and fatty acid deficiency), emotional and clinical symptoms, and cognitive 
function. The ADHD group consists of 98 youth (mean age 9.32 + 3.05 years, 
86% male) with ADHD, and the TD group consists of 21 age- and gender-
matched youth (mean age 9.19 + 2.96 years, 71.4 % male) without ADHD and 
other major psychiatric disorders (Table 9). There was no difference in the 
education years between ADHD and TD group (p = .978), however, ADHD 
group has a higher rate of family history of psychiatric disorders when compared 
with TD (p = .007) (Table 9). 
3.2.1 Cortisol levels in ADHD 
There was no difference in age and gender between the ADHD and the TD 
groups. ADHD group had higher SNAP-IV inattention, hyperactivity and total 
ADHD symptom scores (p < .0001) than TD group (Table 9). ADHD youth also 
had lower bedtime salivary cortisol levels (p = .03) (Table 9, Figure 40). There 
were no differences in salivary cortisol AUC of periods from “wake to noon,” 






Table 9 Demographics of case-control cortisol in ADHD 
Mean (SD) ADHD (n=98) TD (n=21) P 
Age (yrs) 9.32 (3.05) 9.19 (2.96) .863 
Gender (male n, %) 84 (85.7) 15 (71.4) .106a 
Education (yrs) 3.98 (2.75) 4.00 (3.15) .978 
Family history# (%) 26.5% 0% .007** 
SNAP-IV     
IAs 17.37 (5.29) 6.90 (4.30) <.0001**** 
HIs 14.36 (6.32) 6.10(4.70) <.0001**** 
Totals 31.88 (9.62) 13.00 (8.62) <.0001**** 
ODD (n,%) 55 (56.1%) 0(0%) <.0001**** 
Awakening Time (n=98 
vs 21) 
 7:59 (1:00) 8:22 (1:00) .139 
Sleep Time  
(n=98 vs 20) 
22:18 (0:53) 22:27 
(0:45) 
.475 
Salivary Cortisol Levels ADHD (n=95) TD (n=21) P 
Wake .22(.13) .22(.07) .877 
Noon .10(.53) .10(.05) .809 
1800h .06(.06) .05(.01) .072 
Bed .03(.02) .04(.04) .026* 
Salivary Cortisol AUC    
Wake to 
Noon 
.68 (0.39) .64 (.28) .532 
Noon to 1800h .60(.31) .60 (.18) .967 
1800h to Bed .12(.13) .09 (.08) .348 




Note: ADHD, attention deficit hyperactivity disorder; AUC, Area under the 
curve; HIs, hyperactivity/impulsivity subscale scores of SNAP-IV items 10-18; 
hrs, hours; IAs, inattention subscale scores of SNAP-IV items 1 to 9; N, number; 
ODD, oppositional defiant disorder; SD, standard deviation; SNAP-IV, The 
Swanson, Nolan and Pelham Parent Rating Scale; TD, typically developing 
youth; Totals, the sum of IAs and HIs of SNAP-IV; yrs, years.* indicates a 
statistical significance of p-value < .05; ** indicates a statistical significance of p-
value < .10; **** indicates a significance of p-value <.0001. The p values are 
from Independent-sample t-test, unless X2 test result. aX2 test results. # indicates 








Figure 40 Cortisol levels across 4-time points between youth with ADHD and 
TD youth.  
Note: ADHD, attention deficit hyperactivity disorder; N, number; TD, typically 
developing youth. X-axis is the time points of cortisol collection; Y-axis is the 
cortisol levels across 4-time points, in units of μg/dL. *indicates statistical 
































3.2.1.1 ADHD subtypes and cortisol levels 
I then stratified the ADHD group by ADHD symptom severity and subtypes, 
including subthreshold ADHD, inattentive type (IA), hyperactive-impulsive type 
(HI) and combined type. HI group was the youngest, and IA group was the oldest 
(p = .003) (Table 10). The ADHD symptom scores were higher in all 3 ADHD 
subtypes, with combined type (the most severe form of ADHD) having the 
highest inattentive, hyperactivity-impulsivity and total ADHD symptom scores (p 
< .0001, Table 10). The ANOVA of the between-group differences for the 
awakening cortisol level was significant, p = .02 (Table 10, Figure 41); but there 
was no significant difference when looking at post-hoc analyses. The between-
group differences for the bedtime cortisol level were p = .001 (Table 10, Figure 
41); the post-hoc analysis showed that the youth with IA type ADHD and 
combined type ADHD have a lower bedtime cortisol level than youth with 
subthreshold ADHD (p = .041, .003, respectively). The post hoc test also showed 
that youth with combined type ADHD have a lower bedtime cortisol level than 
TD youth (p = .030). Moreover, combined subtype had the lowest awakening 
cortisol level (p = .022), lowest bedtime cortisol level (p = .001) (Figure 41), and 
a reduced cortisol AUC for “wake to noon” period (p = .012, Table 10), when 
compared with the other subtypes and with TD. There were no differences in 
Awakening time, Salivary Cortisol AUC of periods from “noon to 1800h,” 





Table 10 ADHD subtypes and the cortisol 
Mean 
(SD) 




























(male n, %) 
8 (72) 21 (88) 7 (88) 48 (87) 71 (58) .406a 



































































Awakening .29(.16) .26(.14) .21(.09) .19(.11) .22(.07) .022* 
Noon .12(.07) .10(.04) .12(.05) .09(.05) .10(.05) .495 
1800h .07(.06) .06(.03) .04(.02) .06(.07) .05(.01) .673 




      
Wake to 
Noon 






.76 (.48) .57 (.21) .63 (.25) .57 (.31) .60 (.18) .411 
1800h to 
Bed 
.14 (.14) .14 (.09) .08 (.05) .11 (.15) .09 (.08) .563 
Wake to 
Bed 




1.33 (.41) .087 
Note: ADHD, attention deficit hyperactivity disorder; AUC, Area under the 
curve; C, combined subtype with both IAs and HIs >12; HI, hyperactive-
impulsive subtype with HIs >12; HIs, hyperactivity-impulsivity subscale scores 
of SNAP-IV items 10-18; IA, inattentive subtype with IAs >12; IAs, inattention 
subscale scores of SNAP-IV items 1 to 9; N, number; standard deviation; SNAP-
IV, The Swanson, Nolan and Pelham Parent Rating Scale; TD, typically 
developing youth; Sub, subthreshold ADHD with neither IAs nor HIs >12; 
Totals, the sum of IAs and HIs of SNAP-IV; yrs, years. * indicates a significance 
of p-value < .05; **** indicates a significance of p-value < .0001. The p values 






Figure 41 Cortisol levels across 4-time points among ADHD subtypes and 



































Note: ADHD, attention deficit hyperactivity disorder; C, combined subtype; HI, 
hyperactive-impulsive subtype; IA, inattentive subtype; N, number; Sub, 
subthreshold ADHD; TD, typically developing youth. X-axis is the time points of 
cortisol collection; Y-axis is the cortisol levels across 4-time points, in units of 
μg/dL. * indicates statistical significance of p value < .05; ** indicates statistical 
significance of p value < .01. The between-group differences for the awakening 





3.2.1.2 ODD comorbidity and cortisol levels 
I also stratified youth with ADHD by comorbidity with (ADHD+ODD) or 
without ODD (ADHD-ODD); with ODD symptom severity > 13 as a cut-off 
point. About 56% of the youth with ADHD in my study comorbid with ODD, and 
none of the TD youth had ODD (Table 9). Regardless of ODD comorbidity, 
youth with ADHD had lower bedtime cortisol levels than TD youth (p = .030, 
Table 11). On the other hand, there were no differences in the levels of salivary 
cortisol at other time points, and no differences in the Salivary Cortisol AUC of 
periods from “wake to noon,” “noon to 1800h,” “1800h to bed,” and morning 






Table 11 AUC between ADHD+ODD, ADHD-ODD and TD 










8:10 (1:00) 7:47 (0:59) 8:22 (1:00) .079 




    
Awakening .21(.12) .22(.13) .22(.07) .900 
1200h .10(.05) .10(.05) .10(.05) .872 
1800h .06(.07) .06(.04) .05(.01) .636 
Bed .02(.01) .03(.03) .04(.04) .030* 
Cortisol 
AUC 
    
Wake to 
Noon 
.66(.36) .72(.43) .64(.28) .616 
Noon to 
1800h 
.63(.32) .57(.30) .60(.18) .549 
1800h to Bed .11(.13) .13(.13) .09(.08) .463 
Wake to Bed 1.40(.61) 1.41(.67) 1.33(.41) .878 
Note: ADHD, attention deficit hyperactivity disorder; ADHD+ODD, ADHD 
comorbid ODD; ADHD-ODD, ADHD without comorbid ODD; AUC, Area 
under the curve; N, number; ODD, oppositional defiant disorder, with SNAP-IV 
ODD score > 13; SD, standard deviation; TD, typically developing youth. * 




3.2.1.3 Puberty and cortisol levels 
I then stratified the youth by the puberty status. I defined puberty by age; puberty 
defined as older or equal to 10 years of age for girls and older or equal to 12 years 
of age for boys. My study showed that ADHD youth woke up almost an hour 
earlier than TD youth in the puberty group, but not in the prepuberty group (Table 
12). ADHD also had a higher 1800h salivary cortisol level (p < .05) in the 
puberty group (Figure 42). No differences were found in the 4-time point salivary 
cortisol levels between ADHD and TD groups in the prepuberty group (Figure 
43). There were also no differences in Awakening time, Salivary Cortisol AUC of 
periods from “wake to noon,” “noon to 1800h,” “1800h to bed,” regardless of 





Table 12 Puberty and cortisol 
Mean (SD) ADHD TD P 
Prepuberty  (n=75)  (n=13)  
Awakening Time 8:07(1:02) 8:22(1:02) .447 
Sleep Time 22:11(0:52) 22:20(0:43) .552 
Salivary Cortisol 
AUC 
(n=72) (n=13)  
Wake to Noon .62 (.36) .60 (.27) .853 
Noon to 18:00 .58 (.32) .57 (.14) .873 
18:00 to Bed .10 (.12) .09 (.09) .650 
Wake to Bed 1.30 (.61) 1.26 (.61) .788 
Puberty  (n=23)  (n=8) P 
Awakening Time 7:37(0:46) 8:21(0:59) .034* 
Sleep Time 22:40(0:52) 22:37(0:49) .870 
Salivary Cortisol 
AUC 
(n=23) (n=8)  
Wake to Noon .88 (.43) .70 (.31) .278 
Noon to 18:00 .65 (.29) .66 (.34) .951 
18:00 to Bed .18 (.15) .10 (.05) .147 
Wake to Bed 1.71 (.62) 1.45 (.47) .294 
Note: ADHD, attention deficit hyperactivity disorder; AUC, area under curve; n, 
number; Puberty defined as boys older than 12 years of age and girls older than 
10 years of age. SD, standard deviation; TD, typically developing youth. * 







Figure 42 Cortisol levels across 4-time points between ADHD and TD groups 
in puberty group  
Note: ADHD, attention deficit hyperactivity disorder; N, number; Prepuberty 
defined as boys age older than 12 years of age and girls older than 10 years of 
age; TD, typically developing youth. X-axis is the time points of cortisol 
collection; Y-axis is the cortisol levels across 4-time points, in units of μg/dL.      





Figure 43 Cortisol levels across 4-time points between ADHD and TD groups 
in prepuberty group 
Note: ADHD, attention deficit hyperactivity disorder; N, number; Prepuberty 
defined as boys age less than 12 years of age and girls less than 10 years of age; 
TD, typically developing youth. X-axis is the time points of cortisol collection; 




3.2.2 Inflammation associated biomarkers in ADHD 
I have the measurement of blood inflammatory markers and neurotrophins of 93 
youth (mean age 9.40 + 3.08 years, 87.1% males) with ADHD and 21 TD youth 
(mean age 91.9 + 2.96 years, 71.4 males). The ADHD group had a higher level of 
hs-CRP (p < .0001), IL-6 (p < .0001), but a lower level of TNFα (p = .009). 
However, there was no significant differences between the two groups in the 
levels of IL-1b (p = .362), IL-10 (p = .259) and IFN γ (p = .261) (Table 13). 
3.2.3 Neurotrophins in ADHD 
The ADHD group had a higher level of BDNF (p < .0001) than the TD group. 
However, there was no significant differences between the two groups in the 






Table 13 Inflammatory biomarkers and neurotrophins in ADHD 
Mean (SD) ADHD TD P  
 (n=93) (n=21)  
Age (yrs) 9.40 (3.08) 9.19 (2.96) .779 
Gender (male 
n, %) 
81(87.1) 15(71.4) .097 
BDNF  
(n=91 vs 21) 
778.81 (380.58) 1224.62(456.40)  <.0001**** 
bNGF  
(n=91 vs 21)  
235.54(372.32) 284.69(394.90) .671 
GDNF  
(n=54 vs 12)  
1538.81(2981.28) 1650.83(4475.27) .915 
hs-CRP$  
(n=89 vs 21) 
2.10(.95) 1.37(.04) <.0001**** 
IFN γ  
(n=45 vs 6)  
437.49(522.25) 692.17(453.44) .261 
IL-1b  
(n=71 vs 15) 
67.87(105.80) 99.60(181.55) .362 
IL-10  
(n=71 vs 15)  
1109.86(558.56) 936.53(586.22) .259 
IL-6  
(n=78 vs 20)  
266.65(176.52) 71.15(89.04) <.0001**** 
NT-3  
(n=59 vs 12)  
624.49(745.75) 1202.83(1504.87) .218 
TNFα  
(n=71 vs 18)  




Note: ADHD, attention deficit hyperactivity disorder, BDNF, brain-derived 
neurotrophic factor; bNGF, beta-nerve growth factor; GDNF, glia-derived 
neurotrophic factor; hs-CRP, high-sensitivity C-reactive protein; IFN γ, interferon 
gamma; IL, interleukin; L, litre; mg, milligram; mL, millilitre; n, number; pg, 
picogram; SD, standard deviation; NT-3, neurotrophin-3; TNFα, tumour necrosis 
factor alpha; yrs, years. The units of the inflammatory biomarkers and the 
neurotrophins are in pg/mL except for hs-CRP. $The units of hs-CRP is in 
mg/L.** indicates a statistical significance of p < .01; **** indicates a statistical 






3.2.4 N-3 PUFAs levels in ADHD 
There is no difference in the age (p = .753) and the gender (p = .118) distribution 
between the ADHD youth (n = 92, mean age 9.42 + 3.08 years, 85.9 % males) 
and the TD youth (n = 21, mean age 9.19 + 2.96, 71.4 % males). The ADHD 
youth have lower blood levels of linoleic acid (p = .003), AA (p = .008), DHA (p 
= .018) and total n-6 PUFAs (p = .016), and higher levels of gamma-Linolenic 
acid (p = .001), α-Linolenic acid (ALA) (p < .0001) than TD youth. On the other 
hand, there were no differences in blood levels of EPA (p = .496) and total n-3 






Table 14 The PUFAs levels between ADHD and TD 
Mean (SD) ADHD TD P  
 (n= 92) (n=21)  
Age 9.42(3.08) 9.19(2.96) .753 
Gender (male n, 
%) 
79(85.9) 15(71.4) .118a 
C18 2n6 (%) 13.97(2.08) 15.46(1.05) .003** 
C18 3n6 (%) .44(.12) .23(.26) .001** 
C18 3n3 (%) .71(.20) .40(.38) <.0001**** 
AA (%) 9.62(2.41) 11.11(1.65) .008* 
EPA (%) 1.12(0.51) 1.04(.55) .496 
DHA (%) 3.62(1.11) 4.24(.87) .018* 
Total n-3 (%) 5.46(1.37) 5.69(1.17) .482 
Total n-6 (%) 27.09(4.57) 28.59(1.73) .016* 
N-6/n-3 Ratio (%) 5.17(1.00) 5.46(1.35) .271 
 Note: C18 2n6, linoleic acid; C18 3n6, gamma-Linolenic acid; C18 3n3, α-
Linolenic acid; AA, arachidonic acid; ADHD, attention deficit hyperactivity 
disorder; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; n, number; n-
3, omega-3 polyunsaturated fatty acids; n-6, omega-6 polyunsaturated fatty acids; 
SD, standard deviation; TD, typical developing youth. * indicates a statistical 
significance of p < .05; ** indicates a statistical significance of p < .01; **** 
indicates a statistical significance of p < .0001. The p values are from 






3.2.5 Food frequency in ADHD 
The ADHD group have a lower intake of high-quality food intake, measured with 
food frequency questionnaire (FFQ), than the TD group (p < .0001). ADHD 
youth and TD youth have no differences when comparing the intakes for low-
quality food (p = .124) or n-3 PUFAs containing food (p = .680) (Table 15). 
3.2.6 Fatty acid deficiency in ADHD 
The ADHD group have a higher score on the fatty acid deficiency symptoms 
scale (FADS) than the TD group (p < .0001) (See Table 15) 
 
Table 15 The FFQ and FADS scores between ADHD and TD 
Mean (SD) ADHD (n=98) TD (n=21) P 
Age (yrs) 9.32 (3.05) 9.19 (2.96) .863 
Gender (male n, %) 84 (86) 15 (71) .106a 
FFQ Low 24.12 (7.21) 21.29(9.3) .124 
FFQ High 19.48(9.19) 28.43(6.09) <.0001**** 
FFQ N-3 5.58(5.24) 3.55(2.95) .680 
FADS 9.82(7.38) 3.81(3.74) <.0001**** 
Note: ADHD, attention deficit hyperactivity disorder; FADS, fatty acid 
deficiency symptom scale; FFQ, food frequency questionnaire; FFQ High, FFQ 
score of high-quality food; FFQ Low, FFQ score of low-quality food; FFQ N-3, 
FFQ score of n-3 PUFAs containing food; n, number; N-3, omega-3 
polyunsaturated fatty acids; SD, standard deviation; TD, typically developing 
youth; yrs, years.**** indicates a statistical significance of p value < .0001. The p 




3.2.7 Emotional problems in ADHD 
The ADHD group have a higher score of the parent-reported SDQ subscales, 
including Emotion (p < .0001), Conduct (p = .003), Hyperactivity (p < .0001), 
Peer Problems (p < .0001), Externalizing Problems (p < .0001) and Internalizing 
Problems, (p < .0001) than TD group. There was not difference in the parents 
reported SDQ Prosocial Behaviour Subscale scores between the ADHD and TD 
group (p = .470) (Table 16). 
 
Table 16 The SDQ scores between ADHD and TD 
Mean (SD) ADHD (n=98) TD (n=21) P 
SDQE 3.51(1.96) 1.67(1.20) <.0001**** 
SDQC 4.28(2.19) 2.76(1.61) .003** 
SDQH 8.05(1.70) 3.71(2.41) <.0001**** 
SDQPP 4.07(2.11) 2.00(1.27) <.0001**** 
SDQPS 6.19(2.29) 6.57(1.43) .470 
SDQEX 12.33(3.21) 6.48(3.23) <.0001**** 
SDQIN 7.58(3.12) 3.67(1.96) <.0001**** 
Note: ADHD, attention deficit hyperactivity disorder; n, number; SD, standard 
deviation; SDQ, Strength and Difficulties Questionnaire; SDQE, SDQ Emotion; 
SDQC, SDQ Conduct; SDQH, SDQ Hyperactivity; SDQPP, SDQ Peer Problems; 
SDQPS, SDQ Prosocial Behaviour; SDQEX, SDQ Externalizing Problems; 
SDQIN, SDQ Internalizing Problems; TD, typically developing youth. ** 
indicates a value of statistical significance of p < .01; **** indicates a value of 




3.2.8 Clinical symptoms in ADHD 
In this section, I will report the results cross-sectional study on the ADHD clinical 
symptoms of the parent, teacher and youth reports of the SNAP-IV scale between 
the ADHD and TD youth. 
3.2.8.1 Parental reports 
The parents of the ADHD youth reported a higher score of inattention, 
hyperactivity, total ADHD symptoms, and ODD symptoms than parents of the 
TD youth (p < .0001; See Table 17).  
 
Table 17 The parent-reported ADHD clinical symptoms between ADHD and 
TD 
Mean (SD) ADHD (n=98) TD (n=21) P 
SNpA 17.48(5.39) 6.90(4.30) <.0001**** 
SNpH 14.55(6.36) 6.00(4.70) <.0001**** 
SNpO 12.63(5.53) 6.38(4.76) <.0001**** 
SNpAH 32.03(9.91) 13.00 (8.61) <.0001**** 
Note: ADHD, attention deficit hyperactivity disorder; n, number; SD, standard 
deviation; SNAP-IV, Swanson, Nolan and Pelham (SNAP) Questionnaire-Fourth 
Edition; SNpA, inattentive subscale score of parent version of SNAP-IV; 
SNpAH, total ADHD score of parent version of SNAP-IV; SNpH, hyperactivity-
impulsivity subscale score of parent version of SNAP-IV; SNpO, oppositional 
defiant disorder subscale score of parent version of SNAP-IV; TD, typically 




3.2.8.2 Teacher reports 
I have the reports of teachers of 88 youth (mean age 9.46 + 3.08 years, 86.8% 
males) with ADHD and 19 TD youth (mean age 9.16 + 2.89 years, 68.4 % 
males). The teachers of the ADHD youth also reported a higher score of 
inattention, hyperactivity, total ADHD, and ODD subscales of the SNAP-IV than 
the teachers of TD youth (p < .0001; See Table 18).  
 
Table 18 The teacher-reported clinical ADHD symptoms between ADHD 
and TD 
Mean (SD) ADHD (n=88) TD(n=19) P 
Age (yrs) 9.07(2.85) 9.16(2.89) .09 
Gender (male n, 
%) 
75(85.2) 13(68.4) .08a 
SNtA 15.72(6.0) 6.16(6.34) <.0001**** 
SNtH 13.01(7.42) 4.68(6.67) <.0001**** 
SNtO 9.7(7.12) 2.26(2.86) <.0001**** 
SNtAH 28.73(11.55) 10.84(12.40) <.0001**** 
Note: ADHD, attention deficit hyperactivity disorder; n, number; SD, standard 
deviation; SNAP-IV, Swanson, Nolan and Pelham (SNAP) Questionnaire-Fourth 
Edition; SNtA, inattentive subscale score of teacher version of SNAP-IV; 
SNtAH, total ADHD score of teacher version of SNAP-IV; SNtH, hyperactivity-
impulsivity subscale score of teacher version of SNAP-IV; SNtO, oppositional 
defiant disorder subscale score of teacher version of SNAP-IV; TD, typically 










3.2.8.3 Youth self-reports 
The youth with ADHD older than or equal to 12 years-old (n = 23, mean age 
13.84 + 2.18 years, 87 % males) also reported a higher score of inattention (p 
= .005), hyperactivity (p = .038), and total ADHD scores (p = .008) on the SNAP-
IV than TD youth of the same age group (n = 3, mean age 14.00 + 2.65 years, 
100% males) (Table 19). There was no difference in the youth self-reported ODD 
subscale scores of the SNAP-IV between ADHD and TD youth (p = .161) (Table 
19). 
 
Table 19 The youth self-reported clinical ADHD symptoms between ADHD 
and TD 
Mean (SD) ADHD (n= 23) TD (n=3) P 
Age (yrs) 13.84(2.18) 14.00(2.65) .93 
Gender (male n, 
%) 
20(87.0) 3(100.0) .68a 
SNsA 14.65(5.18) 5.33(1.15) .005** 
SNsH 10.43(7.03) 1.33(1.15) .038* 
SNsO 11.04(5.94) 5.67(7.23) .161 
SNsAH 25.09(10.89) 6.67(1.15) .008** 
Note: ADHD, attention deficit hyperactivity disorder; n, number; SD, standard 
deviation; SNAP-IV, Swanson, Nolan and Pelham (SNAP) Questionnaire-Fourth 
Edition; SNsA, inattentive subscale score of youth version of SNAP-IV; SNsAH, 
total ADHD score of youth version of SNAP-IV; SNsH, hyperactivity-
impulsivity subscale score of youth version of SNAP-IV; SNsO, oppositional 




developing youth; * indicates a statistical significance of p < .05; ** indicates a 
statistical significance of p < .01. The p values are from Independent-sample t-






3.2.9 Cognitive function in ADHD 
In this section, I will report the results of the cognitive function measured by 
WISC-IV Digit Span and CPT between youth with ADHD and TD youth. 
3.2.9.1 WISC-IV Digit Span 
The ADHD youth have a lower WISC-IV Digit Span Total Score than TD youth 
(p < .0001) (Table 20). There were no differences between the ADHD and the  
TD groups in WISC-IV Longest Digit Span Forward score (p = .683), WISC-IV 
Digit Span Forward score (p = .871), WISC-IV Longest Digit Span Backward 
score (p = .075) and WISC-IV Digit Span Backward score (p = .074) (Table 20). 
 
Table 20 The WISCDS scores between ADHD and TD 
Mean (SD) ADHD (n=98) TD (n=21) P 
WISCLDSF 8.07(1.19) 7.98(1.32) .683 
WISCDSF 13.29(2.36) 13.19(2.74) .871 
WISCLDSB 3.99(1.5) 4.9(2.14) .075 
WISCDSB 6.94(2.72) 8.57(3.8) .074 
WISCDS Total 20.26(4.17) 34.62(4.17) <.0001**** 
Note: ADHD, attention deficit hyperactivity disorder; n, number; SD, standard 
deviation; TD, typically developing youth; WISC, Weschler Intelligence Scale 
for Children-Fourth Edition; WISCDS, WISC Digit Span; WISCDSB, WISC 
Digit Span Backward; WISCDSF, WISC Digit Span Forward; WISCDS Total, 




Backward; WISCLDSF, WISC Longest Digit Span Forward; **** indicates a 






The CPT is measured in youth older than or equal to 8 years of age, thus, I have 
the CPT data of 63 youth with ADHD (mean age 10.84 + 2.77 years, 87.3 % 
males) and 14 TD youth (mean age 10.64 + 2.56 years, 64.3% males) (Table 21). 
Youth with ADHD have poorer scores on the dprime (p < .0001), omission errors 
(p < .0001)), commission errors (p = .001), perseveration (p = .031), HRTSD (p 
< .0001), variability (p < .0001) and HRTISIC (p = .001) (Table 21). There were 
no differences between ADHD and TD groups in HRT (p = .346) and HRTBC (p 





Table 21 The CPT scores between ADHD and TD 
Mean (SD) ADHD(n=63) TD (n=14) P 
Age (yrs) 10.84(2.77) 10.64(2.56) .834 
Gender (male n, 
%) 
55(87.3) 9(64.3) .053a 
d’ -1.47(.91) -2.87(1.14) <.0001**** 
OM .05(.05) .01(.02) <.0001**** 
COM .54(.18) .34(.23) .001** 
PER .03(.04) .01(.02) .031* 
HRT 455.97(97.15) 430.33(56.58) .346 
HRTSD 226.67(124.64) 125.21(54042) <.0001**** 
VAR 107.0(77.48) 43.36(43.92) <.0001**** 
HRTBC 11.68(18.08) 4.89(9.89) .059 
HRTISIC 53.16(39.34) 29.18(18.18) .001** 
Note: ADHD, attention deficit hyperactivity disorder; COM, commission error; 
d’, dprime; PER, perseveration; HRT, hit reaction time; HRTSD, HRT standard 
deviation; VAR, variability; HRTBC, HRT block change; HRTISIC, HRT 
interstimulus interval change; n, number; SD, standard deviation; TD, typically 
developing youth; yrs, years. * indicates a value of statistical significance of p 
< .05; ** indicates a value of statistical significance of p < .01; **** indicates a 
value of statistical significance of p < .0001. The p values are from Independent-






3.3 Clinical trial 
A total of 98 youth with ADHD have completed the clinical trial, with 50 (mean 
age 9.22 + 3.10 years, 90 % males) receiving the n-3 PUFAs and 48 (mean age 
9.42 + 3.02 years, 81.3 % males) receiving placebo. In this section, I will report 
the findings from the RCT regarding the effects of n-3 PUFAs on the levels of 
inflammatory biomarkers, neurotrophins and PUFAs, the emotional problems, 
ADHD clinical symptoms and cognitive function. In the last section 3.3.7, I will 
also report the findings of n-3 PUFAs on cognitive function and prosocial 
behavior after stratification of the youth by baseline hs-CRP levels. 
 
3.3.1 N-3 PUFAs supplementation on the inflammatory biomarkers in ADHD 
There were no differences in the age and gender of the n-3 PUFAs (n = 46, mean 
age 9.41 + 3.14, 91.3 % males) and placebo group (n = 47, mean age 9.38 + 3.05, 
83 % males) (Table 22). There was no difference in the changes of the levels of 
hs-CRP (p = .788), IFN γ (p = .288), IL-1b (p = .196), IL-6 (p = .577), IL-10 (p 
= .751) and TNFα (p = .299) at 12 weeks from baseline between the n-3 PUFAs 






Table 22 The changes in the levels of inflammatory biomarkers at week 12 
from baseline between the n-3 PUFAs and placebo groups  





Age (yrs) 9.41 (3.14) 9.38 (3.05) .963 
Gender (male n, %) 42(91.3) 39(83.0) .188a 
hs-CRP Changes 
(mg/L)  
(n=45 vs 44) 
-.04 (.37) -.08(.80) .788 
IFN γ Changes 
(pg/mL)  
(n=20 vs 25) 
-37.8 (111.43) 22.00 (227.05) .288 
IL-1b Changes 
(pg/mL) 
(n=35 vs 36) 
-3.46 (16.31) 6.08 (40.34) .196 
IL-6 Changes 
(pg/mL) 
(n=37 vs 40) 
-22.38 (60.46) -8.68 (136.72) .577 
IL-10 Changes 
(pg/mL) 
(n=31 vs 38) 
-20.52 (137.69) -36.32 (245.68) .751 
TNFα Changes 
(pg/mL)  
(n=31 vs 38) 
-18.32 (56.36) -4.82 (50.79) .299 
Note: hs-CRP Changes, the changes of C-reactive protein levels at week 12 from 
baseline; IFN γ Changes, the changes of interferon gamma levels at week 12 from 
baseline; IL, interleukin; IL-1b Changes, changes of IL-1b levels at week 12 from 




Changes, changes of IL-10 levels at week 12 from baseline; L, litre; mg, 
milligram; mL, millilitre; n, number; N-3 PUFAs, omega-3 polyunsaturated fatty 
acids; pg, picogram; SD, standard deviation, TNFα Changes, changes of tumour 
necrosis factor-alpha levels at week 12 from baseline; yrs, years. The p values are 







3.3.2 N-3 PUFAs supplementation on the neurotrophins in ADHD 
There were no differences in the changes of the levels of BDNF (p = .071), bNGF 
(p = .393), GDNF (p = .748) and N-3 (p = .582) at week 12 from baseline 
between the n-3 PUFAs group and the placebo group (Table 23). 
 
Table 23 The changes in the levels of neurotrophins at week 12 from baseline 
between the n-3 PUFAs and placebo groups 
Mean (SD) N-3 PUFAs  Placebo P 
 (n=46) (n=47)  
Age (yrs) 9.41 (3.14) 9.38 (3.05) .963 
Gender (male n, 
%) 
42(91.3) 39(83.0) .188a 
BDNF Changes 
(pg/mL)  
(n=46 vs n=45) 
64.59(327.92) -51.76(277.85) .071 
bNGF Changes 
(pg/mL)  
(n=28 vs 31) 
-44.68(184.66) -14.77(54.66) .393 
GDNF Changes 
(pg/mL) 
(n=23 vs 31) 
-593.52(1745.92) -310.42(3917.65) .748 
NT-3 Changes 
(pg/mL) 
(n=28 vs 31) 
-55.96(156.76) -6.71(446.71) .582 
Note: BDNF Changes, changes of the levels of brain-derived neurotrophic factor 
at week 12 from baseline; bNGF Changes, changes of the levels of beta-nerve 




glial cell line-derived neurotrophic factor at week 12 from baseline; mL, 
millilitre; n, number; N-3 PUFAs, omega-3 polyunsaturated fatty acids; pg, 
picogram; SD, standard deviation; NT-3 Changes, changes of the levels of 
neurotrophin-3 at week 12 from baseline; yrs, years. The p values are from 





3.3.3 N-3 PUFAs supplementation on the PUFAs levels 
A total of 92 youth with ADHD have blood samples for the PUFAs levels at 
baseline and 12-week. After a 12-week n-3 PUFAs (EPA 1.2 g/d) 
supplementation, the n-3 PUFAs group (n = 47, mean age 9.34 + 3.14 years, 89.3 
% males) had a greater increase in EPA (p < .0001) and total n-3 PUFAs levels (p 
= .029) and a greater decrease of n-6/n-3 ratio (p = .011) at week 12 from 
baseline when compared with placebo group (n = 45, mean age 9.51 + 3.05 years, 





Table 24 The changes in the levels of PUFAs at week 12 from baseline 
between the n-3 PUFAs and placebo groups 





Age (yrs) 9.34(3.14) 9.51(3.05) .792 
Gender (male n, 
%) 
42(89.3) 37(82.2) .380a 
AA Changes (%) -.73(2.98) -.88(4.38) .855 
DHA Changes 
(%) 
-.17(1.49) -.43(2.00) .790 
EPA Changes 
(%) 
.75(1.10) -.08(.65) <.0001**** 
Total n-3 
Changes (%) 
.42(2.31) -.73(1.10) .029* 
Total n-6 
Changes (%) 
-1.82(5.68) -1.86(8.18) .98 
N-6/n-3 ratio 
Changes 
-.38(1.81) .85(2.68) .011* 
Note: AA, arachidonic acid; ADHD, attention deficit hyperactivity disorder; 
Changes, indicates the changes of levels from baseline at week 12; DHA, 
docosahexaenoic acid; EPA, eicosapentaenoic acid; n, number; n-3, omega-3 
polyunsaturated fatty acids; n-6, omega-6 polyunsaturated fatty acids; SD, 
standard deviation; TD, typical developing youth; yrs, years * indicates a 
statistical significance of p < .05; **** indicates a statistical significance of p 
< .0001. The p values are from Independent-sample t-test, unless X2 test result. 





3.3.4 N-3 PUFAs supplementation on emotional function in ADHD 
A total of 98 youth with ADHD have completed the clinical trial, with 50 (mean 
age 9.22 + 3.10 years, 90 % males) receiving the n-3 PUFAs and 48 (mean age 
9.42 + 3.02 years, 81.3 % males) receiving placebo (Table 25). There were no 
differences in the changes of the SDQ Emotion (p = .442), Conduct (p = .914), 
Hyperactivity (p = .536), Peer Problems (p = .515), Prosocial Behaviour (p 
= .230), Externalizing Problems (p = .706) and Internalizing Problems (p = .344) 





Table 25 The changes in SDQ scores at week 12 from baseline between the n-
3 PUFAs and placebo groups  





Age (yrs) 9.22(3.10) 9.42(3.02) .75 
Gender (male n, 
%) 
45(90.0) 39(81.3) .257a 
SDQE -.48(1.68) -.75(1.78) .442 
SDQC .72(1.43) -.69(1.53) .914 
SDQH -.88(2.14) -1.13(1.73) .536 
SDQPP -.1(1.68) -.31(1.53) .515 
SDQPS .42(1.69) 0(1.75) .230 
SDQEX -1.6(2.89) -1.8(2.65) .706 
SDQIN -.58(2.56) -1.06(2.45) .344 
Note: N, number; N-3 PUFAs, omega-3 polyunsaturated fatty acids; SD, standard 
deviation; SDQ, Strength and Difficulties Questionnaire; SDQE, SDQ Emotion; 
SDQC, SDQ Conduct; SDQH, SDQ Hyperactivity; SDQPP, SDQ Peer Problems; 
SDQPS, SDQ Prosocial Behaviour; SDQEX, SDQ Externalizing Problems; 
SDQIN, SDQ Internalizing Problems; yrs, years. The p values are from 






3.3.5 N-3 PUFAs supplementation on the clinical symptoms in ADHD 
I have investigated the effects of n-3 PUFAs on the clinical symptoms in ADHD 
by using parent-, teacher- and youth self-reported severity of ADHD symptoms 
using the SNAP-IV Questionnaire. 
3.3.5.1 Parent reports 
The placebo group have a greater reduction of total ADHD scores of the SNAP-
IV after 12 weeks than n-3 PUFAs group (p = .03) (Table 26). There was no 
difference in the changes of inattention (p = .06), hyperactivity (p = .05) or ODD 
(p = .158) subscale scores of SNAP-IV at 12 weeks from baseline between n-3 
PUFAs and placebo group (Table 26). There were also no differences between n-
3 PUFAs and placebo group in parent-reported clinical symptoms when I 





Table 26 The changes of parent-reported clinical ADHD symptoms at week 
12 from baseline between the n-3 and placebo groups  





SNpA Changes -1.98(6.07) -4.19(5.21) .06 
SNpH Changes -1.98(4.86) -3.94(4.96) .05 
SNpO Changes -1.76(4.96) -3.25(5.40) .159 
SNpAH Changes -3.96(9.54) -8.13(9.02) .03* 
Note: N, number; N-3 PUFAs, omega-3 polyunsaturated fatty acids; SD, standard 
deviation; SNAP-IV, Swanson, Nolan and Pelham (SNAP) Questionnaire-Fourth 
Edition; SNpA Changes, changes of the inattentive subscale score of parent 
version of SNAP-IV between baseline and week 12; SNpAH, changes of the total 
ADHD score of parent version of SNAP-IV between baseline and week 12; 
SNpH, changes of the hyperactivity-impulsivity subscale score of parent version 
of SNAP-IV between baseline and week 12; SNpO, changes of the oppositional 
defiant disorder subscale score of parent version of SNAP-IV between baseline 




3.3.5.2 Teacher reports 
A total of 88 youth with ADHD have data on teacher-reported ADHD symptoms, 
with 45 (mean age 9.00 + 2.92 years, 91.1 % males) receiving the n-3 PUFAs and 
43 (mean age 9.14 + 2.81 years, 79.1 % males) receiving placebo (Table 27). 
There were no differences in the changes of inattention (p = .05), hyperactivity (p 
= .841), ODD (p = .754) subscale scores and total ADHD symptoms scores (p 
=.176) of SNAP-IV at 12 weeks from baseline between n-3 PUFAs and placebo 
group (Table 27). There were also no differences between n-3 PUFAs and 
placebo group in teacher-reported clinical symptoms when I stratified the ADHD 





Table 27 The changes of teacher-reported clinical ADHD symptoms at week 
12 from baseline between the n-3 and placebo groups  





Age (yrs) 9.00(2.92) 9.14(2.81) .820 
Gender (male n, 
%) 
41(91.1) 43(79.1) .140a 
SNtaA Changes -.04(4.46) -1.67(3.04) .05 
SNtaH Changes -1.31(3.70) -1.47(3.47) .841 
SNtaO Changes -.8(4.25) -.52(3.60) .754 
SNtaAH Changes -1.36(2.81) -3.14(5.44) .176 
Note: N, number; n-3 PUFAs, omega-3 polyunsaturated fatty acids; SD, standard 
deviation; SNAP-IV, Swanson, Nolan and Pelham (SNAP) Questionnaire-Fourth 
Edition; SNtaA, inattentive subscale score of teacher version of SNAP-IV; 
SNtaAH, total ADHD score of teacher version of SNAP-IV; SNtaH, 
hyperactivity-impulsivity subscale score of teacher version of SNAP-IV; SNtaO, 
oppositional defiant disorder subscale score of teacher version of SNAP-IV; yrs, 
years. The p values are from Independent-sample t-test, unless X2 test result. aX2 






3.3.5.3 Youth self-reports 
A total of 22 youth with ADHD have data on self-reported changes of the ADHD 
symptoms, with 10 (mean age 13.42 + 2.07 years, 91.7 % males) receiving the n-
3 PUFAs and 8 (mean age 14.10 + 2.23 years, 80 % males) receiving placebo 
(Table 28). There were no differences in the changes of inattention (p = .586), 
hyperactivity (p = .803), ODD (p = .736) subscale scores and total ADHD 
symptoms scores (p = .958) of SNAP-IV at 12 weeks from baseline between n-3 
PUFAs and placebo group (Table 28). There were also no differences between n-
3 PUFAs and placebo group in youth self-reported clinical symptoms when I 





Table 28 The changes of youth self-reported clinical ADHD symptoms at 
week 12 from baseline between the n-3 and placebo groups  
  





Age (yrs) 13.42(2.07) 14.10(2.23) .465 
Gender (male n, 
%) 
11(91.7) 8(80.0) .571a 
SNsA Changes -4.17(5.32) -2.90(5.38) .586 
SNsH Changes -3.92(5.62) -4.60(7.09) .803 
SNsO Changes -3.58(3.65) -4.30(6.07) .736 
SNsAH Changes -7.25(10.04) -7.50(11.74) .958 
Note: N, number; n-3 PUFAs, omega-3 polyunsaturated fatty acids; SD, standard 
deviation; SNAP-IV, Swanson, Nolan and Pelham (SNAP) Questionnaire-Fourth 
Edition; SNsA, inattentive subscale score of youth version of SNAP-IV; SNsAH, 
total ADHD score of youth version of SNAP-IV; SNsH, hyperactivity-
impulsivity subscale score of youth version of SNAP-IV; SNsO, oppositional 
defiant disorder subscale score of youth version of SNAP-IV; yrs, years. The p 





3.3.6 N-3 PUFAs supplementation on the cognitive function in ADHD 
In this section, I will report the results from the RCT of n-3 PUFAs on cognitive 
function on WISCDS and CPT. Moreover, I will also report the effect of n-3 
PUFAs on CPT with the stratification of youth with ADHD by baseline EPA 
levels in 3.3.6.2. 
 
3.3.6.1 WISC-IV Digit Span 
There were no differences of the score changes of the WISC-IV longest digit span 
forward (p = .615), digit span forward (p = .671), longest digit span backward (p 
= .261), digit span backward (p = .124) and total scores (p = .194) at week 12 






Table 29 The changes in the WISCDS scores at week 12 from baseline 
between the n-3 PUFAs and placebo groups  





WISCLDSF Changes .50(1.16) .40(.84) .615 
WISCDSF Changes 1.14(1.43) .98(1.44) .671 
WISCLDSB Changes .60(1.05) .33(1.28) .261 
WISCDSB Changes .98(1.42) .44(2.00) .124 
WISCDS Total Changes 2.12(2.64) 1.42(2.69) .194 
Note: N, number; N-3 PUFAs, omega-3 polyunsaturated fatty acids; SD, standard 
deviation; TD, typically developing youth; WISC, Weschler Intelligence Scale 
for Children-Fourth Edition; WISCDS, WISC Digit Span; WISCDSB Changes, 
Changes of the WISC Digit Span Backward scores between baseline and week 
12; WISCDSF Changes, Changes of the WISC Digit Span Forward scores 
between baseline and week 12; WISCDS Total Changes, changes of the total 
score of WISC Digit Span subtest between baseline and week 12; WISCLDSB 
Changes, changes of the WISC Longest Digit Span Backward scores between 
baseline and week 12; WISCLDSF Changes, changes of the WISC Longest Digit 






Overall, sixty-three youth with ADHD who were older than 8 years-old and have 
completed the 12-week trial with CPT assessment at baseline and at 12 weeks. 
Thirty-two youth with ADHD received n-3 PUFAs (mean age 10.75 + 2.70 years, 
90.6 % males) and 31 received placebo (mean age 10.94 + 2.70 years, 83.9 % 
males). I found that there were no differences in CPT measurements including 
dprime (p = .154), omission errors (p = .560), commission errors (p = .116), 
perseveration (p = .309), HRT (p = .320), HRTSD (p = .914), HRTBC (p = .651) 





Table 30 The changes in CPT scores at week 12 from baseline between the n-
3 PUFAs and placebo groups  





Age (yrs) 10.75(2.70) 10.94(2.70) .793 
Gender (male n, 
%) 
29(90.6) 26(83.9) .474a 
d’ -.17(.63) -.41(.67) .154 
OM .00(.05) -.00(.06) .560 
COM -.06(.14) -.11(.12) .116 
PER -.00(.03) -.01(.04) .309 
HRT 6.35(60.27) 21.71(61.30) .320 
HRTSD 6.40(84.81) 9.40(130.28) .914 
VAR -6.89(76.22) 14.18(65.18) .248 
HRTBC 2.13(18.92) -.19(21.58) .652 
HRTISIC 5.09(36.87) 5.10(36.01) .999 
Note: COM, commission error; d’, dprime; PER, perseveration; HRT, hit reaction 
time; HRTSD, HRT standard deviation; VAR, variability; HRTBC, HRT block 
change; HRTISIC, HRT interstimulus interval change; n, number; N-3, omega-3 
polyunsaturated fatty acids; SD, standard deviation; TD, typically developing 
youth; yrs, years. The p values are from Independent-sample t-test, unless X2 test 







 Next, I stratified the groups according to their baseline EPA levels, where 61 
youth have both CPT and baseline EPA measurements. The EPA is categorized 
into low EPA (EPA < .91%, n = 23), moderate EPA (EPA= .91 to 1.08%, n = 15) 
and high EPA (EPA > 1.08%, n = 23) groups. I found that in the low EPA groups, 
n-3 PUFAs have greater effect on HRT (ES = 1.21, confidence intervals (CIs) = 
.28 to 2.05, p = .009, Figure 44), HRTSD (ES = .90, CIs = .01 to 1.72, p = .043, 
Figure 45) and HRTISIC (ES= 1.30, CIs= .35 to 2.14, p = .005, Figure 46) when 
compared with placebo. However, I did not find similar findings in the moderate 






Figure 44 The effect size of n-3 PUFAs on HRT with stratification of baseline 
EPA levels 
N-3 PUFAs have a greater effect on HRT than placebo in the Low EPA group, 
with an effect size of 1.21, the confidence intervals of .28 to 2.05, p = .009 The x-
axis is the effect size. The were no differences between the n-3 PUFAs group and 
placebo group on HRT of CPT in the overall, High EPA and Mod EPA group. 
Note, EPA, eicosapentaenoic acid; High EPA; Mod EPA; Low EPA; HRT, hit 






Figure 45 The effect size of n-3 PUFAs on HRTSD with stratification of 
baseline EPA levels. 
N-3 PUFAs have a greater effect on HRTSD than placebo in the Low EPA group, 
with an effect size of .9, the confidence intervals of .01 to 1.72, p = .043. The x-
axis is the effect size. The were no differences between the n-3 PUFAs group and 
placebo group on HRTSD of CPT in the overall, High EPA and Mod EPA group. 




reaction time; HRTSD, HRT standard deviation; n, number; N-3 PUFAs, omega-





Figure 46 The effect size of n-3 PUFAs on HRTISIC with stratification of 
baseline EPA levels 
N-3 PUFAs have a greater effect on HRTISIC than placebo in the Low EPA 
group, with an effect size of 1.3, the confidence intervals of .35 to 2.14, p = .005. 
The x-axis is the effect size. The were no differences between the n-3 PUFAs 
group and placebo group on HRT of CPT in the overall, High EPA and Mod EPA 
group. Note, EPA, eicosapentaenoic acid; High EPA; Mod EPA; Low EPA; 
HRT, hit reaction time; HRTISIC, HRT interstimulus interval change; n, number; 




3.3.7 Stratification based on baseline hs-CRP levels 
I then stratified the youth into high hs-CRP (> 2.23 mg/L, n = 29), moderate hs-
CRP (> 1.45 to 2.22 mg/L, n = 31) and low hs-CRP (<1.45 mg/L, n = 29) groups 
according to their baseline CRP levels. There is a total of 89 youth with both 
SDQ/WISCDS and hs-CRP measures; although there are 29 youth with high 
baseline hs-CRP and 23 youth with low baseline EPA, there are only 8 youth with 
both high baseline hs-CRP and low baseline EPA. I found that in the youth with 
high hs-CRP levels (n = 29), the n-3 PUFAs group have a greater improvement 
on the SDQ Prosocial Behaviour scores (ES = .91, CIs = .12 to 1.65, p = .021, 
Figure 47), WISC-IV longest digit span back ward (ES = 1.54, CIs= .67 to 2.32, p 
< .001, Figure 48), WISC-IV digit span backward (ES = 1.40, CIs = .55 to 2.17, p 
= .001, Figure 49) and WISC-IV digit span total scores (ES = .84, CIs = .16 to 
1.49, p = .026, Figure 50). However, I did not find similar findings in youth with 
low and moderate hs-CRP levels. 
 






Figure 47 The effect size of n-3 PUFAs on prosocial behaviours with 
stratification of baseline hs-CRP levels. 
N-3 PUFAs have a greater effect on SDQ Prosocial Behaviour scores than 
placebo in the High hs-CRP group (diamond), with an effect size of .91, the 
confidence intervals of .12 to 1.65, p = .021. The x-axis is the effect size. The 
were no differences between the n-3 PUFAs group and placebo group on SDQ 
Prosocial Behaviour scores in the overall (square), Low hs-CRP (circle) and Mod 
hs-CRP group (triangle). Note: hs-CRP, high-sensitivity C-reactive protein; N, 





Figure 48 The effect size of n-3 PUFAs on WISC-IV longest digit span 
backward scores with stratification of baseline hs-CRP levels 
N-3 PUFAs have a greater effect on WISC-IV longest digit span backward scores 
than placebo in the High hs-CRP group (diamond), with an effect size of 1.54, 
confidence intervals of .67 to 2.32, p< .0001. The x-axis is the effect size. The 
were no differences between the n-3 PUFAs group and placebo group on WISC-
IV longest digit span backward scores in the overall (square), Low hs-CRP 
(circle) and Mod hs-CRP group (triangle). Note: hs-CRP, high sensitivity C-





Figure 49 The effect size of n-3 PUFAs on WISC-IV digit span backward 
score with stratification of baseline hs-CRP levels 
N-3 PUFAs have a greater effect on WISC-IV digit span backward scores than 
placebo in the High hs-CRP group (diamond), with an effect size of 1.4, the 
confidence intervals of .55 to 2.17, p = .0001. The x-axis is the effect size. The 
were no differences between the n-3 PUFAs group and placebo group on WISC-
IV digit span backward scores in the overall (square), Low hs-CRP (circle) and 
Mod hs-CRP group (triangle). Note, hs-CRP, high-sensitivity C-reactive protein; 





Figure 50 The effect size of n-3 PUFAs on WISC-IV digit span total scores 
with stratification of baseline hs-CRP levels 
N-3 PUFAs have a greater effect on WISC-IV digit span total scores than placebo 
in the High hs-CRP group (diamond), with an effect size of .84, the confidence 
interval of .16 to 1.49, p = .026. The x-axis is the effect size. The were no 
differences between the n-3 PUFAs group and placebo group on WISC-IV digit 
span total scores in the overall (square), Low hs-CRP (circle) and Mod hs-CRP 
group (triangle). Note, hs-CRP, high-sensitivity C-reactive protein; N, number; 






Summary of the findings 
The aims of my PhD are to investigate the salivary cortisol and blood PUFAs 
levels in ADHD and the effects of n-3 PUFAs supplementation on inflammatory 
biomarkers, neurotrophins, PUFAs levels, emotional symptoms, ADHD clinical 
symptoms and cognitive function in ADHD using a variety of approaches 
including meta-anlayses, a cross-sectional study and an RCT. The meta-analysis 
showed that ADHD youth have a lower level of salivary cortisol, DHA, EPA and 
total n-3 PUFAs than TD youth. The cross-sectional study showed that ADHD 
youth also had lower bedtime salivary cortisol levels, lower blood levels of AA, 
DHA and total n-6 PUFAs than TD youth. Moreover, The ADHD group have a 
higher level of pro-inflammatory biomarkers such as hs-CRP and IL-6, but a 
lower level of BDNF. Lastly, the RCT showed that a high dose of the n-3 PUFAs, 
EPA, is superior to placebo on the cognitive function associated with focused 
attention, response consistency and vigilance, but only in ADHD youth with the 
lowest baseline EPA level. The RCT also showed that EPA is superior to placebo 
on the prosocial behavior and working memory, but again only in ADHD youth 





4.1 ADHD and Hypothalamic-Pituitary-Adrenal (HPA) Axis 
dysfunction 
My meta-analysis found that youth with ADHD have lower salivary cortisol 
levels than TD youth, particularly morning awakening cortisol levels. On the 
other hand, my cross-sectional study showed that youth with ADHD have a lower 
bed-time cortisol level than TD youth, and the combined type has the lowest 
bedtime cortisol levels when compared with the inattention and the hyperactivity-
impulsivity subtypes and the TD group. Moreover, the cross-sectional study also 
showed that in the group of youth who entered puberty, youth with ADHD have a 
higher cortisol level at 1800h than TD group. In the following section, I will 
discuss the possible mechanisms that contribute to the abnormal HPA axis 
activity in ADHD. 
4.1.1 Meta-analysis 
The major finding of my meta-analysis is that ADHD youth have lower salivary 
basal cortisol levels at any time point and lower morning, particularly morning 
awakening, salivary cortisol levels, and noon salivary cortisol levels when 
compared with TD youth. My results may provide a partial explanation of why 
youth with ADHD may feel tired and have a later rise time in the morning 
(Chiang et al., 2010), since their cortisol levels may require a longer time to peak. 
Morning awakening salivary cortisol level may be a potential biomarker for 
children with ADHD, since it provides a non-invasive alternative to serum 
cortisol levels and closely correlates with plasma free cortisol (Calixto, Martinez, 




An altered diurnal rhythm of cortisol levels may further contribute to the low 
morning cortisol levels in children with ADHD. A phase delay of cortisol rhythms 
in ADHD has been further supported by a study of adults with ADHD (Baird, 
Coogan, Siddiqui, Donev, & Thome, 2012), where adults with ADHD had a 
delayed phase of cortisol rhythm by 2 hours. Incidentally, the lack of difference in 
the afternoon salivary cortisol levels between youth with ADHD and TD youth, 
even in the potential presence of a low cortisol output, may be explained by the 
higher degree of exposure to stressors, including familial conflicts, in the youth 
with ADHD throughout the day (Chang & Gau, 2017).  
There had only been three systematic review and meta-analyses of biomarkers, 
including cortisol, in ADHD: one did not perform subanalysis in regard to the 
timing of sample collection (Scassellati et al., 2012), one only included adult 
subjects (Bonvicini, Faraone, & Scassellati, 2016), and one examined the cortisol 
awakening response rather than the cortisol levels (Kamradt et al., 2018). My 
study finding is overall consistent with Scassellati’s meta-analysis of 8 studies of 
salivary cortisol levels, where patients with ADHD have lower cortisol levels 
when compared to TD subjects (p = .0001) (Scassellati et al., 2012). I have 
updated this meta-analysis by adding three more recent studies measuring 
salivary cortisol levels (Angeli et al., 2018; Imeraj et al., 2012; Isaksson et al., 
2012) and also by including the clinical data from McCarthy et al. (2011), which 
was excluded by Scassellati et al.’s meta-analysis due to use of medication in 
subjects with ADHD. Moreover, it is also of note that although Bonvicini et al.’s 
meta-analysis of 3 studies of adults with ADHD (n = 117) showed no difference 




numerical trend showing adults with ADHD had lower salivary cortisol levels 
(Bonvicini et al., 2016).  
I will further elaborate on the potential factors, including an under-active 
Behaviour Inhibition System and psychiatric comorbidity, affecting cortisol levels 
in ADHD in section 4.1.3 and 4.1.4.  
4.1.2 Cross-sectional study 
The major finding of my cross-sectional study is that youth with ADHD, as a 
group, have a lower bedtime cortisol values than TD youth, with the combined 
subtype (the most severe form of ADHD) having the lowest awakening cortisol 
level and a reduced cortisol AUC for “wake to noon” period than other ADHD 
subtypes and TD. My findings are consistent with specific aspects of the 
literature. For example, a recent study also shows that ADHD combined subtype 
have a lower AUC ‘wake to bed’ period (Angeli et al., 2018), even if this study 
did not have individual time recordings (as I did in my study), which was a major 
limitation. On the other hand, my finding is different from previous study 
findings (Imeraj et al., 2012), where they found no differences in bedtime cortisol 
levels between ADHD and TD youth. My study is different from the previous 
studies in aspects as discussed in section 4.1.2.1. 
4.1.2.1 Factors affecting cortisol levels between studies 
Several factors may affect cortisol levels between studies including the method 
for sample collection. However, this may not be a robust explanation for my 
study since previous studies and my study all used Salivette for sample collection. 




due to other factors including the gender ratio and puberty status of the studied 
population, medication use, the timing for awakening and bedtime and perceived 
stressful events. For example, my study had a similar gender distribution in 
ADHD and TD group (males; 86% vs 71%) as that of Imeraj et al. (2012) (82% 
vs 79%) and of Angeli et al. (2018) (78.6 % vs 62.5%); but a different gender 
distribution when compared with Isaksson et al. (2012) (75.6 vs 41.6 %). 
Another factor influencing cortisol levels may be the use of medication for 
ADHD. The ADHD subjects in my study are either drug naïve or had been drug-
free for 6 months, which is similar to that of Angeli et al. (2018). On the other 
hand, the ADHD subjects in the study by Imeraj et al. (2012) had been asked to 
stop medication such as methylphenidate 72 hours prior to the cortisol sample 
collection, while 89% of the ADHD group in the study by Isaksson et al. (2012) 
were on medication. Medications for ADHD, such as methylphenidate, have been 
shown to increase cortisol level by triggering dopamine release in the central 
nervous system (Wilens, 2008). Moreover, methylphenidate administration has 
been associated with greater impulse control in a cognitive test such as 
Continuous Performance Test in ADHD (Wang, Huang, Hsiao, & Chen, 2017), 
possibly by enhancing the effects of dopamine in the meso-limbic system 
(Marinelli & Piazza, 2002). In addition, treatment with stimulant medication has 
been suggested to normalize baseline cortisol levels in ADHD (Wang et al., 
2017). Methylphenidate may be able to indirectly affect the cortisol levels by 
either weakening or strengthening the impact of external events and subjective 





4.1.2.2 HPA axis and Sleep in ADHD 
Studies have demonstrated bidirectional effects between sleep and HPA axis 
(Buckley & Schatzberg, 2005; Steiger, 2002). Cortisol levels theoretically peak 
during the awakening time between 0600h to 0900h and decline steadily during 
the day and will be at the lowest at night between 2400h to 0200h (Krishnan et 
al., 1990). However, this may not be the case for ADHD; ADHD has been 
associated with more eveningness, altered melatonin rhythmicity and a phase 
delay of about 2 hours of the cortisol rhythm (Baird et al., 2012). Thus, 
differences in sampling time between studies may also attribute to the differences 
in the study findings of cortisol levels. The mean sampling time for the 
awakening and cortisol of ADHD and TD group in my study is similar to the 
sampling time on weekends for the study by Imeraj et al. (2012), where the 
awakening time is between 0800h to 0830h; however, the subjects in my group 
had a later bedtime of around 2200h than the bedtime of around 2100h of the 
other two studies (Imeraj et al., 2012; Isaksson et al., 2012). Moreover, I found 
that in the pubertal group of my study, ADHD youth woke up about an hour 
earlier and had a higher 1800h cortisol level than TD youth.  
Based on these findings, it is possible to speculate that, although youth with 
ADHD had to fulfill the demand of early awakening for school, their awakening 
cortisol levels may not be able to peak in time to respond to such demand, due to 
a dysregulated HPA axis. Moreover, youth with ADHD may have an incongruent 
diurnal cortisol pattern that may not provide them with enough motivation and 




going to sleep, which may partially explain the difficulties in awakening, 
circadian rhythm problems and insomnia associated with ADHD (Chiang et al., 
2010). A lack of sleep efficiency has also been associated with an increased 
cortisol reactivity (Pesonen et al., 2012), which further aggravates the vicious 
cycle of poor sleep and HPA axis dysregulation. In addition, the low bedtime 
cortisol levels may be driven by the low morning cortisol levels in ADHD, 
commonly seen in studies investigating children and my meta-analysis. 
4.1.2.3 Ethnicity and cortisol differences 
Another factor, which is less explored by current literature, to explain the 
inconsistency is the ethnic differences in cortisol metabolism. Although patients 
of South Asian ethnicity have been reported to have lower cortisol levels than 
patients with European ethnicity (Reynolds et al., 2006), there had been no 
studies reporting on the differences in cortisol metabolism in children and 
adolescents. Future studies examining bedtime cortisol levels in youth with 
ADHD of different ethnicities are warranted to support this speculation. 
4.1.2.4 Puberty and cortisol levels 
The second major finding of my cross-sectional study was that ADHD youth who 
had entered puberty had a higher 1800h cortisol than TD youth. The rise in the 
1800h cortisol levels in the older ADHD youth may be secondary to the hormonal 
changes associated with puberty (Panagiotakopoulos & Neigh, 2014), where a 
switch from cortisol hyporeactivity to cortisol hyperreactivity has occurred 
(Hankin, Badanes, Abela, & Watamura, 2010). The developmental stage of 




early childhood years, is similar to the ‘stress hyporesponsive period’ observed in 
the rodent HPA axis (Lupien, McEwen, Gunnar, & Heim, 2009), where it is 
difficult to produce elevations in cortisol levels (Gunnar & Quevedo, 2007; 
Walker, Sapolsky, Meaney, Vale, & Rivier, 1986). Moreover, youth with ADHD 
often have a higher exposure to a number of adversities (Combs, Canu, Broman-
Fulks, Rocheleau, & Nieman, 2015), including poor peer and family interactions 
and having more problems at school (Wu & Gau, 2013) and at home (Chang & 
Gau, 2017; Gau & Chang, 2013), than TD youth; and the number of adversities 
encountered in late childhood have been associated with a higher level of cortisol 
levels later in life (Bosch et al., 2012). Thus, it is possible to speculate that the 
accumulated daily stressors can ‘hyper-activate’ the post-pubertal HPA axis, 
which is now stress-responsive, leading to the higher 1800h cortisol levels. 
4.1.3 Behaviour Inhibition System (BIS) hypoactivity, hypocortisol and ADHD 
An under-active BIS provides another potential explanation for the low cortisol 
levels in ADHD youth. An under-active BIS has been closely associated with 
deficits in cognitive functions such as working memory, self-regulation of affect, 
internalization of speech, and reconstitution of goal-directed behavior in ADHD 
(Barkley, 1997). Moreover, these cognitive functions are crucial for stress 
management (Williams, Suchy, & Rau, 2009), yet they are often impaired in 
ADHD (Willcutt et al., 2005). The low cortisol levels associated with an under-
active BIS also further disrupt the reward and adaptation regulatory systems, 
which are mediated by the interactions of cortisol and dopamine (Van 
Craenenbroeck, De Bosscher, Vanden Berghe, Vanhoenacker, & Haegeman, 




control and goal-directed behavior problems commonly observed in ADHD 
(Barkley, 1997).  
Another factor that may contribute to HPA axis abnormality in ADHD is the 
psychosocial adversity and prenatal stress experienced by ADHD youth 
(Biederman et al., 1995). Early exposure to adversity and chronic stress can lead 
to low cortisol levels (Yehuda et al., 2005), which later result in the 
hyporeactivity of the HPA axis to help the individual adapt to the chronic stress 
(Moss, Vanyukov, Yao, & Kirillova, 1999). Youth with ADHD often have a lack 
of fear and a lack of physiological arousal when facing challenges, and this low 
level of physiological arousal may then drive the child to search for sensations 
that could eventually trigger a decrease in cortisol response to stressors, after 
repeated activations (Alink et al., 2008). Thus, blunting of the HPA axis perhaps 
initially served as a protective strategy for ADHD youth who were subjected to 
chronically high cortisol levels, however, research has suggested that too high or 
too low levels of cortisol are both unfavorable for the brain (Lupien et al., 2005). 
4.1.4 Comorbidity with ODD and cortisol 
Comorbidity with an oppositional defiant disorder (ODD) has also been 
suggested to contribute to HPA axis abnormality in ADHD (Freitag et al., 2009; 
Snoek et al., 2004). Children with ADHD comorbid ODD (ADHD+ODD) have 
an attenuated cortisol awakening response (CAR), a marker for HPA axis 
response during stress (Roberts, Wessely, Chalder, Papadopoulos, & Cleare, 
2004), and a low cortisol reactivity during stress when compared with ADHD 




In contrast, my PhD, which examined cortisol levels rather than reactivity to 
awakening or other stressors, showed that regardless of ODD comorbidity, 
ADHD youth had lower bedtime salivary cortisol levels than TD youth. My study 
finding is further supported by a study reporting that ADHD symptom severity 
predicted reduced basal cortisol level, while conduct disorder (CD) symptom 
severity predicted increased basal cortisol levels, in ADHD with and without CD 
(Northover, Thapar, Langley, Fairchild, & van Goozen, 2016). Moreover, the co-
occurrence of internalizing problems, including depression and anxiety, may also 
interplay in the relation of externalizing problems and cortisol levels. For 
example, children with CD comorbid anxiety had higher levels of salivary 
cortisol than children with CD but without comorbid anxiety (McBurnett et al., 
1991).  
In summary, I find, in my meta-analysis, that children with ADHD have lower 
basal cortisol levels, especially morning cortisol levels, than TD youth. The lower 
cortisol levels in ADHD further imply the role of HPA axis hypoactivity in 
ADHD pathogenesis. In addition, since salivary cortisol levels are often 
normalized after the child receive treatments, such as stimulant medications, 
further attention is warranted for development of potential treatment strategies 





4.2 ADHD and inflammation 
I found that youth with ADHD have higher levels of inflammatory biomarkers 
including hs-CRP and IL-6, but a lower TNFα than TD youth. I also found that n-
3 PUFAs did not affect the levels of the inflammatory biomarkers in the RCT, 
although I did find that n-3 PUFAs have a greater effect on the social behavior 
and cognitive function in youth with a high baseline hs-CRP level than those with 
low baseline hs-CRP level. Interestingly, according to my knowledge, there was 
only one other study measuring inflammatory biomarkers in children with 
ADHD, thus the impossibility to conduct a meta-analysis on this topic. I will 
discuss the mechanism linking inflammation and ADHD in the following section 
and the effect of n-3 PUFAs on cognitive function via its anti-inflammatory 
effects. 
4.2.1 Cross-sectional study 
The major finding of the cross-sectional study on inflammatory biomarkers is that 
youth with ADHD have a higher level of hs-CRP and IL-6 than TD youth. To my 
knowledge, this is the first study reporting a higher hs-CRP level in youth with 
ADHD. In contrast to the previous study, where no association was found 
between ADHD symptomatology and CRP levels in 2307 adult subjects who 
participated in the Netherlands Study of Depression and Anxiety (Vogel et al., 
2017). Moreover, my finding of the IL-6 levels further supported two recent 
studies reporting a higher level of IL-6 in youth with ADHD than TD youth 
(Darwish, Elgohary, & Nosair, 2019; Donfrancesco et al., 2016). As I have 




develop allergic and immune-mediated diseases at young age, which may allow 
systematic inflammation associated inflammatory cytokines to pass through the 
BBB and activate neuroimmune mechanisms that may affect the neurocircuits 
regulating behaviours and emotions, predisposing the child to the development of 
ADHD (Buske-Kirschbaum et al., 2013). Thus, a subgroup of children with 
ADHD may be in a state of low-grade chronic inflammation. Moreover, youth 
with ADHD may have higher levels of inflammatory cytokines due to the 
elevated levels of psychological stress in early life that may affect the maturation 
of the prefrontal cortex areas in ADHD (Buske-Kirschbaum et al., 2013). Another 
study further demonstrated the association between inflammation and attention 
problems by reporting that children born prematurely, and with a recurrent or 
persistent elevation of inflammatory proteins, such as IL-6, during the first two 
postnatal weeks, show attention problems at 2 years of age (O'Shea et al., 2014). 
Of note, youth with ADHD have lower TNFα levels than TD youth in my cross-
sectional study. This finding is different from the study by Oades et al. (2010a) 
showing no difference in TNFα levels in ADHD youth and TD; another study 
also showed no differences in TNFα levels between ADHD and controls in adults 
(Corominas-Roso et al., 2017). On the other hand, a negative correlation has been 
shown between cortisol awakening response and TNFα in adults with inattentive 
type ADHD but not in adults with other subtypes (Corominas-Roso et al., 2017). 
More studies with a larger sample will be needed to further clarify the role of 





The RCT showed that n-3 PUFAs did not have an impact on the levels of 
inflammatory biomarkers. My finding is different from a previous study reporting 
a decrease in IL-6 and CRP levels in n-3 PUFAs group when compared with the 
placebo group in children with ADHD (Hariri et al., 2012). Hariri et al. (2012) 
showed that there was a significant decrease in both plasma IL-6 and CRP levels 
in an 8-week study of 103 children with ADHD age 6-12 years-old treated with 
900 mg PUFAs per day (DHA165 mg + EPA 635mg) when compared with 
placebo. Comparing to Hariri et al. (2012), my study has a smaller sample size 
(thirty-seven in the N-3 PUFAs group and 40 in the placebo group), a wider age 
range (6 to18 years old), and the treatment group received EPA 1200 mg/d and no 
DHA. Although there was no statistical significance of the changes of the IL-6 
levels between the n-3 PUFAs and the placebo group, my study did show a 
numerical trend where youth treated with n-3 PUFAs has a greater decrease in IL-
6 levels than youth in the placebo group (Table 22). To my knowledge, this is the 
first study on the effects of n-3 PUFAs on IFN γ, IL-1b, IL-10 and TNFα in 
children with ADHD.  
The effects of n-3 PUFAs on the changes of inflammatory biomarkers have been 
inconsistent. One study showed that 1.2 g n-3 PUFAs (DHA 480 mg + EPA 700 
mg) did not have an effect on plasma IL-6 soluble alpha subunit of IL-2 receptor, 
but an increase in the soluble form of the intracellular adhesion molecule one 
(sICAM-1) in adolescents at ultra-high risk for psychosis (Smesny et al., 2017). 




affect hs-CRP levels in patients with a history of myocardial infarction 
(Hoogeveen et al., 2014). On the other hand, serum ESR and IL-12 levels were 
significantly reduced in patients with Systemic Lupus Erythematous (SLE) 
receiving n-3 PUFAs when compared with those receiving placebo (Arriens et al., 
2015). 
In addition, there has been only a small number of studies investigating the 
changes of inflammatory biomarkers in children and adolescents after n-3 PUFAs 
supplementation. One study showed that a two 6-month supplementation of n-3 
PUFAs 390-1170 mg decreased the LTB4/LTB5 ratio in youth with cystic 
fibrosis when compared with placebo (p < .01) (Panchaud et al., 2006). Another 
study showed that a supplementation of n-3 PUFAs syrup of 700 mg to 900 mg to 
enteral feeding in children with mild to moderate sepsis for 7 days decreased 
serum CRP, ESR and IL-6 levels (p < .0001) when compared to children without 
the n-3 PUFAs supplementation (Al-Biltagi, Abo-Elezz, Abd-Elhafez, Mabrouk, 
& Suliman, 2017). Moreover, studies with n-3 PUFAs supplementation during 
pregnancy and lactation showed a reduction of pro-inflammatory cytokines in 
newborns (Rodriguez-Santana et al., 2017) and a decrease in the incidence of 
respiratory symptoms in children with a history of maternal atopy (Escamilla-
Nunez et al., 2014). 
 
4.3 ADHD and neurotrophins 
My PhD showed that youth with ADHD have a lower BDNF level, but not other 




supplementation did not affect the levels of neurotrophins when compared with 
placebo. To date, this is the first study looking at the effects of n-3 PUFAs on the 
neurotrophins in youth with ADHD. 
4.3.1 Cross-sectional study 
The cross-sectional study showed that youth with ADHD have a lower BDNF 
level than TD youth. This is consistent with previous literature supporting the role 
of BDNF in the pathogenesis of ADHD (Tsai, 2017). For example, BDNF 
conditional knockout mice manifested with certain characteristics such as 
learning deficiencies, aggressiveness and locomotor activity that has been 
associated with ADHD (Rios et al., 2001). BDNF is important for normal brain 
development and has been shown to modulate the release of dopamine release via 
the activation of tyrosine kinase B (TrkB) receptor (Blochl & Sirrenberg, 1996). 
Moreover, BDNF has been shown to play a crucial role in the differentiation of 
midbrain dopaminergic neurons (Spina, Squinto, Miller, Lindsay, & Hyman, 
1992), while midbrain dopaminergic system has been implicated in ADHD 
pathogenesis (Solanto, 2002). In addition, BDNF has been shown to be involved 
in the release of dopamine and dopamine-related behaviours induced by 
methylamphetamine, a medication used to treat ADHD (Narita, Aoki, Takagi, 
Yajima, & Suzuki, 2003). 
Of note, I did not find a difference in the levels of bNGF, GDNF and NT-3 
between youth with ADHD youth and TD youth. My finding of bNGF is different 
from the study by Guney et al. (2014), where they found a higher level of serum 




association between NGF and ADHD (Ribases et al., 2008). My finding of 
GDNF in ADHD is consistent with the study findings of Syed et al. (2007), 
where they also did not find an association between GDNF and ADHD. Although 
two case-control genetic studies (Conner et al., 2008; Ribases et al., 2008) and 
case-control studies found an association between NT-3 and ADHD, other studies 
like mine failed to show such link (Cho et al., 2010; Syed et al., 2007). 
4.3.2 RCT 
The levels of neurotrophins including BDNF, bNGF, GDNF and NT-3 were not 
affected by n-3 PUFAs, while there is a numerical trend showing an increase of 
BDNF in the n-3 PUFAs group when compared with the placebo group at the end 
of the study. Studies have demonstrated that treatments for ADHD such as 
methylphenidate (Amiri et al., 2013) and atomoxetine (Ramos-Quiroga et al., 
2014) may have its therapeutic effect via modulation of the levels of BDNF. A 
study showed that plasma BDNF levels increased after 6 weeks treatment of 
methylphenidate in 28 children, ranging from 3.5 to 10 years of age, with ADHD 
(p = .002) (Amiri et al., 2013). On the other hand, a study in adults with ADHD, 
(mean age 33.43 + 8.99 years, 68.5% males) showed a decrease in serum BDNF 
after 3 months of treatment with atomoxetine (p = .05) (Ramos-Quiroga et al., 
2014).  
An animal study further suggested that n-3 PUFAs provide neuroprotection for 
parkinsonism via the modulation of BDNF expression in the striatum (Bousquet 
et al., 2009). Moreover, a recent animal study showed that n-3 PUFAs with the 




memory-related ability by increasing BDNF in metabolic syndrome (Hashimoto 
et al., 2013). Meanwhile, long-term EPA administration may provide 
neuroprotection by increasing brain DHA level and exert a direct effect on the 
neurons and glial cells resulting in hippocampal synaptic plasticity (Kawashima 
et al., 2010). Thus, a larger sample size with a longer follow-up period may be 
able to provide a more conclusive effect of high dose EPA on the changes of 
BDNF. 
The study findings on the associations between n-3 PUFAs intake and blood 
BDNF levels have been inconsistent. For example, although a positive association 
has been reported between n-3 PUFAs consumption and serum BDNF levels in 
137 adolescents (Ferreira et al., 2014), clinical trials did not find an effect of n-3 
PUFAs on the BDNF levels in traumatized adults vulnerable to developing 
psychological distress nor in in adults with diabetes mellitus with MDD (Bot et 
al., 2011). To my knowledge, until my PhD, there had been no study on the 
effects of n-3 PUFAs on the changes of BDNF levels in ADHD and no study on 
the effects of n-3 PUFAs on the changes of bNGF, GDNF and NT-3 levels in 
humans. 
 
4.4 N-3 PUFAs levels in ADHD 
My meta-analysis showed that youth with ADHD have lower levels of AA, DHA, 
EPA and total n-3 PUFAs than TD youth. The cross-sectional study further 






My overall meta-analysis, including all studies and irrespective of tissue source, 
shows that youth with ADHD have lower levels of DHA. DHA has been 
implicated in the brain development of infants and children, since lower maternal 
intake of n-3 PUFAs during pregnancy is associated with worse developmental 
outcomes in the offspring, including lower fine motor and communication scores 
and lower social development scores (Hibbeln et al., 2007). Children with 
developmental disorders also have lower levels of DHA (Milte et al., 2011). 
Overall, I did not find a lower level of EPA, n-3 PUFAs and AA in ADHD when 
compared with TD; however, I also conducted analysis by excluding the study by 
Stevens et al. 2003 (Stevens et al., 2003) from the meta-analysis, and I found that 
youth with ADHD also have lower EPA, n-3 PUFAs and AA levels. In the study 
by Stevens et al. (2003), children with ADHD had higher RBCs levels of AA and 
DHA when compared with healthy children, which is different from all other 
studies. I would argue that I am justified to exclude Stevens et al. (2003), as in 
this study the diagnosis of ADHD was not strictly defined, and the subjects self-
referred and enrolled in the ADHD group if they reported to have been given a 
diagnosis of ADHD from a paediatrician, psychologist or psychiatrist. In contrast, 
in all the other studies the diagnosis was confirmed by standardised clinical 
interviews and/or subjects had an ADHD symptoms rating scale score of 
moderate severity. In fact, the enrolment criteria in Steven et al. (2003) are also 
different from a previous study from the same authors (Stevens et al., 1995), 




the Parent/Teacher Conner’s Rating Questionnaire; and indeed, in this previous 
study they found that ADHD children do have lower levels of plasma and/or 
RBCs DHA, EPA, n-3 PUFAs and AA. Taken together, these lines of evidence 
justify my decision to present the findings with and without this study (Stevens et 
al., 2003).    
It is also of note that a subanalysis of RBCs levels of n-3 PUFAs shows that 
youth with ADHD have lower levels of RBCs, but not plasma, DHA, EPA, n-3 
and AA. Both RBCs and plasma PUFAs are common biomarkers used to reflect 
fatty acid intake/status in clinical studies (Chang et al., 2015; Chang et al. 2017; 
Lin et al., 2010; Su et al., 2014). However, RBCs PUFAs are more strongly 
correlated with dietary intake (Sun, Ma, Campos, Hankinson, & Hu, 2007), and 
reflect longer-term fatty acid consumption (Sun et al., 2007). I also included 
buccal cells PUFAs measurements, a non-invasive measurement that correlates 
significantly with RBCs, plasma and brain PUFAs (Lapillonne, DeMar, 
Nannegari, & Heird, 2002). However, since only one study (Bos et al., 2015) in 
the meta-analysis used buccal cells PUFAs measurement, more studies using this 
method will be needed to support its role as a biomarker. 
4.4.2 Cross-sectional study 
The cross-sectional study further showed that youth with ADHD have lower 
levels of linoleic acid (precursor of n-6 PUFAs), AA, DHA, and total n-6 and 
higher levels of gamma-Linolenic acid (precursors of n-6 PUFAs), α-Linolenic 
acid (precursor of n-3 PUFAs). The results of the cross-sectional study are 




levels of AA and DHA than TD youth. Moreover, although youth with ADHD 
have higher levels of precursors of n-3 PUFAs, α-Linolenic acid, they have lower 
levels of DHA when compared with TD youth. On the other hand, although youth 
with ADHD have a higher level of n-6 PUFAs precursors (gamma-Linolenic 
acid), they have lower levels of AA and n-6 PUFAs when compared with TD 
youth. This may suggest that although youth with ADHD have plenty of 
precursors of both n-3 and n-6 PUFAs, they may have impaired PUFAs 
metabolism, such as a defective FADS2 (corresponds to delta-6 desaturase) 
enzyme, which is the key enzyme responsible for the conversion from EPA to 
DHA (Lee, Lee, Kang, & Park, 2016), and responsible for the conversion linoleic 
acid and α-Linolenic acid to their metabolites, such as AA, EPA and DHA. Study 
has shown that the carriers of the minor alleles of fatty acid desaturase 2 gene 
(FADS2) would have a deficiency in DHA (Lee et al., 2016); while ADHD has 
been associated with SNP rs498793 in the FADS2 gene (Brookes et al., 2006). 
4.4.3 RCT 
The RCT showed the youth receiving n-3 PUFAs, in this case 1200mg EPA, has 
an increase in EPA, total n-3 PUFAs and a decrease in the n-6/n-3 ratio at the end 
of the 12 weeks. This is somehow an expected finding, although it confirms the 
children’s compliance with treatment, and is similar to another study in ADHD 
youth showing that a supplementation of n-3 PUFAs (DHA 174 mg + EPA 558 
mg) increases total n-3 PUFAs (p < .001)) and EPA (p < .001) levels at the end of 




4.5 N-3 supplementation and emotional problems in ADHD 
Overall, my PhD did not show a beneficial effect of n-3 PUFAs on the emotional 
problems in ADHD measured with the SDQ. However, when I stratified the 
youth with ADHD into low, moderate and high inflammatory status with the 
baseline hs-CRP levels, I found that n-3 PUFAs improved prosocial behavior in 
the high inflammatory status group when compared with placebo, while such 
effect is not present in the low or the moderate inflammatory status group. I have 
used this approach based on the studies by Raison et al. (2013) and Rappaport et 
al. (2016). Raison et al. did not find an overall difference in change of HAM-D 
scores after 12 weeks between the treatment group (TNF antagonist infliximab 
(5mg/kg) and placebo group in patients with MDD, but found that patients with 
baseline hs-CRP concentration of > 5mg/L treated with infliximab had a 
significant improvement on the HAM-D scores when compared with those with 
high baseline hs-CRP but received placebo (Raison et al., 2013). Rappaport et al. 
overall found an insignificant effect of n-3 PUFAs (EPA 1060 mg or DHA 900 
mg) on the changes of 17-item HAM-D scores when compared with placebo after 
8 weeks in patients with MDD; however, when they stratified the patients 
according to inflammation biomarkers at baseline, they found the group with high 
inflammation (high IL-1 receptor a, or hs-CRP or low adiponectin) improved 
more on EPA than placebo or DHA (Rapaport et al., 2016). Moreover, subjects 
with high inflammation had medium ES decreases in HADM-D-17 score when 




Youth with ADHD often comorbid emotional and behavioral problems (Lin, 
Yang, & Gau, 2016). They often have poor peer (Wu & Gau, 2013) and family 
(Chang & Gau, 2017; Gau & Chang, 2013) relationships. Moreover, a higher 
CRP level has been associated with aggression and hostility in personality 
disorders (Coccaro, 2006), and Hamazaki et al. (1996) showed that n-3 PUFAs 
was able to decrease aggression in college students. In addition, a recent meta-
analysis supported the effect of n-3 PUFAs in reduction emotional lability and 
oppositional behaviours in subgroups of children with ADHD (Cooper et al., 
2016). Thus, it is possible to speculate that the high-inflammation ADHD 
represents a subgroup of more emotionally unstable youth whose emotional 
symptoms respond better to PUFAs. Thus, n-3 PUFAs, especially EPA, help 
improve prosocial behavior in youth with ADHD, particularly those with a high 
hs-CRP level at baseline. EPA may help ameliorate inflammation by exerting its 
anti-inflammatory action through the inhibition of free radical generation and 
oxidant stress (Das, 2006), which may help improve social behaviours in youth 
with ADHD. 
 
4.6 N-3 supplementation and clinical symptoms in ADHD 
My meta-analysis showed that n-3 supplementation improved parent reported 
inattention, hyperactivity and total ADHD symptoms in youth with ADHD. On 
the other hand, the RCT did not show differences in the improvement of parent-, 




baseline hs-CRP or EPA levels. I will discuss the role of n-3 PUFAs in ADHD 
clinical symptoms in the next section. 
4.6.1 Meta-analysis 
My meta-analysis also showed that n-3 PUFAs supplementation improves clinical 
symptoms in youth with ADHD, measured as parental reports of total ADHD, 
inattention and hyperactivity symptom scores. In comparison, I found no effects 
of PUFAs on the teacher-reported ADHD severity (Gustafsson et al., 2010; 
Manor et al., 2012; Widenhorn-Muller et al., 2014), but this may due to the small 
cumulative sample size (n = 344 with teacher reports vs. n = 534-590 with 
parental reports). Moreover, parental reports, commonly used in clinical practice, 
have high sensitivity in detecting changes in ADHD symptoms in clinical trials 
(Biederman, Faraone, Monuteaux, & Grossbard, 2004). Overall, I think that the 
effects of n-3 PUFAs on parental reports are clinically significant.  
4.6.2 RCT 
Considering the results of the meta-analysis, it was surprising that the RCT did 
not find a difference between n-3 PUFAs and placebo when examining the 
changes of parent-, teacher-, and self-reported clinical ADHD symptoms at 12 
weeks from baseline. The reason may be that changes in the brain functions may 
be detected as early as 12 weeks after EPA supplementation, while the child’s 
symptoms and behaviours may require a longer follow-up period, more than 3 
months, to be observable. For example, the mean duration of the studies included 
in my meta-analysis is 15.63 + 3.74 weeks, ranging from 12 weeks to 24 weeks 




EPA supplementation are warranted to support my finding. Moreover, another 
factor contributing to the limited effects of EPA on parent-report ADHD 
symptoms may be due to the heterogeneity of the ADHD core symptoms in the 
youth enrolled in the study. In addition, about 56% of the youth in my study have 
a comorbidity with ODD, which may contribute to the limited effect of EPA on 
the ADHD clinical symptoms; ADHD is generally viewed as a neurobiologically 
mediated problem, while ODD tends to have a stronger link to environmental risk 
factors and psycho-social stressors.  
The utilization (conversion) ability of EPA to DHA should also be considered, as 
mentioned above. Indeed, we surprisingly did not find higher DHA levels in the 
EPA group, even if EPA is physiologically converted in DHA. For example, the 
carriers of the minor alleles of fatty acid desaturase 2 gene (FADS2) would have a 
deficiency in DHA despite being provided a high dose of EPA, since FADS2 
(corresponds to delta-6 desaturase) is the key enzyme responsible for the 
conversion from EPA to DHA (Lee et al., 2016). Indeed, a single nucleotide 
polymorphism (SNP) in FADS2 has been significantly associated with ADHD 
(Brookes et al., 2006). Lastly, the limited effects of EPA monotherapy on the 
clinical ADHD symptoms may further suggest that the synergic effects of EPA 
and DHA would surpass the effect of EPA alone, as being suggested in MDD and 
Alzheimer’s disease (Song et al., 2016). Indeed, this is a major difference 
between my study and most of the other studies included in the meta-analysis, 





4.7 N-3 Supplementation and cognitive function in ADHD 
My meta-analysis showed the n-3 PUFAs improved omission and commission 
errors, but not memory or information processing, in children with ADHD when 
compared with placebo. Moreover, the RCT did not show a superior effect of the 
n-3 PUFAs on WISCDS scores and CPT measures when compared with placebo. 
However, subgroup analysis showed that n-3 PUFAs improved WISCDS scores, 
or working memory, in youth with high baseline hs-CRP levels, and improved 
inattention, inconsistency and vigilance in youth with low baseline EPA levels. 
4.7.1 Meta-analysis 
My meta-analysis found that n-3 PUFAs supplementation shows efficacy in 
improving omission and commission errors, but not memory and information 
processing, in children with ADHD. This is consistent with epidemiological 
studies, where EFA deficiency correlates with cognitive impairment and 
increased impulsivity, which is usually associated with commission errors (Chang 
et al., 2016). N-3 PUFAs are crucial for optimal brain function and regulate 
neurotransmitter function: for example, incorporating more EPA and DHA in the 
cell membrane can increase cholesterol efflux (Chang & Su, 2010), modulate 
lipid raft clustering and disruption (Chang & Su, 2010), and affect the function of 
the dopamine transporter (DAT) (Foster, Adkins, Lever, & Vaughan, 2008), 
which in turn may affect attention and executive function, by regulating synaptic 





In the following section, I will discuss the effects of n-3 PUFAs on cognitive 
function based on the stratification of baseline hs-CRP levels and baseline EPA 
levels. 
4.7.2.1 Stratification by baseline hs-CRP levels 
EPA have a greater improvement on the WISC-IV Digit Span Scores, especially 
the Backward Digit Span, than placebo, in youth with high baseline hs-CRP 
levels. Higher levels of hs-CRP had been associated with worse performance in 
executive function and changes in associated areas in healthy adults (Wersching 
et al., 2010) and a marker for memory impairment in the elderly (Noble et al., 
2010). On the other hand, my study finding indicates that that n-3 PUFAs may 
benefit the cognitive function of those with a higher level of inflammation. As 
mentioned previously in section 4.5, I have used this approach based on the 
studies by Raison et al. (2013) and Rapaport et al. (2016) who found a positive 
effect of anti-inflammatory agents and omega-3 PUFAs on depressive symptoms 
in patients with high baseline inflammation profile. Our finding is supported by a 
recent animal study showing that n-3 deficient diet exacerbated inflammation in 
an animal model of maternal immune activation, where the pregnant mice were 
injected with lipopolysaccharide to induce inflammation reaction, and induces 
spatial memory deficits in the adult offspring; while the adult offspring of the 
mice fed with n-3 balanced diet during gestation had no memory deficits 
(Labrousse et al., 2018). Moreover, a study investigating the effects of anti-




dose aspirin 600 mg/d improved backward digit span when compared with those 
in the low dose aspirin 300 mg/d and placebo group (p = .025) (Watson et al., 
2009). Hence, n-3 PUFAs, in this case of high dose EPA, may improve working 
memory in children with ADHD with high inflammatory status via its anti-
inflammatory actions. 
4.7.2.2 Stratification by baseline EPA levels 
I decided to stratify based on EPA levels, since I expect EPA to have an 
important role in cognition and ADHD via its anti-inflammatory actions. EPA can 
be metabolized into DHA and our previous study showed that supplementation 
with EPA can increase both DHA and EPA levels (Su et al., 2014). EPA has been 
suggested as the active component in the antidepressant effect of n-3 PUFAs. 
Meta-analysis had shown that n-3 PUFAs with a composition of > 60% EPA have 
a greater effect on depressive symptoms when compared with those with < 60% 
EPA (Lin & Su, 2007). Of note, my previous study in interferon-alpha induced 
depression showed that EPA reduces the incidences of interferon-induced-
depression, while DHA can only delay the onset of depression (Su et al., 2014). 
EPA is able to exert several anti-inflammatory actions via antagonizing 
membrane AA formation and inhibition of synthesis of pro-inflammatory 
mediators (Su, 2009). In addition, Bloch & Qawasmi (2011) demonstrated an 
association between efficacy and EPA dosage in their meta-analysis of omega-3 
fatty acid supplementation in children with ADHD. Thus, a deficiency in EPA 





EPA improved HRT, HRTSD, HRTISIC in youth with low baseline EPA level in 
my RCT. To my knowledge, this is the first study report the effects of EPA 
supplementation in youth with ADHD stratified by baseline EPA levels. This is 
compatible with the previous study showing that a higher fatty-fish intake is 
associated with a higher improvement on cognitive function scores (Oyen et al., 
2018), and supported with a previous meta-analysis showing that n-3 PUFAs 
improved cognitive function in those with low n-3 PUFAs status (Cooper et al., 
2015). Moreover, an increase in erythrocyte EPA and DHA after n-3 PUFAs has 
been associated with improved attention and behavior in children with ADHD 
(Milte et al., 2015). Moreover, EPA may help improve impulsivity and vigilance 
via its ability to modulate neurotransmission through its conversion to DHA 
(Burdge & Wootton, 2002). DHA will then regulate attention-dependent 
dopamine and serotonin neurotransmission via alteration of neuronal cell 
membrane fluidity (Chalon, 2006) and lipid rafts. Lipid rafts are the mediators in 
neurotransmission signaling system located within the cell membrane (Chang & 
Su, 2010). For example, n-3 PUFAs, especially DHA, enrichment in cell 
membrane will affect signal transductions through changing the fluidity and 
rigidity of cell membranes and correct lipid raft clustering and disrupted signal 






4.8 Strengths and limitations 
The strength of my PhD is that it provides a comprehensive investigation of n-3 
PUFAs in ADHD using meta-analyses, a cross-sectional study and an RCT. 
Moreover, my PhD is the first meta-analysis to look at different time points of 
salivary cortisol collection and the first to examine the PUFAs levels from 
different sources (erythrocytes, plasma and salivary) in children with ADHD. 
Moreover, for the RCT, I have collected detailed history of the n-3 PUFAs intake, 
fatty acid deficiency symptom severity and blood PUFAs prior to the n-3 
supplementation, which is of value when examining the effects of n-3 
supplementation in any disorder. In addition, my PhD examined the effects of n-3 
PUFAs on cognitive function with stratification of inflammation levels, which to 
my knowledge is the first in ADHD. This is extremely important in establishing 
personalized medicine in ADHD, focusing on the effects of n-3 PUFAs. 
My PhD, although with several strengths, is not without limitations. One of the 
limitations of the cross-sectional study is that only a small number of TD is 
recruited, however, the control group is age- and gender-matched. Moreover, 
there are significant differences between the ADHD and TD in both clinical 
symptom ratings and cognitive function. Another limitation is that the ADHD 
population for the RCT is heterogeneous, where the age ranges from 6-18 years 
old and over half has a comorbidity with ODD. Moreover, I have included all 
three types of ADHD in the study. However, the characteristic of the ADHD 
population is similar to the ADHD population in the clinical setting, which may 




of my PhD is the duration of the RCT. The duration of the RCT in my PhD is 12 
weeks, while most of the studies included in my meta-analysis of n-3 PUFAs on 
clinical symptoms have durations longer than 12 weeks with a mean of 15.63 
weeks. Although we were able to find a favourable outcome of n-3 PUFAs on 
cognitive function when compared with placebo, we did not find a similar 
outcome in the clinical symptoms. Perhaps a longer duration of RCT, more than 
15 weeks, may help to provide more information of the effect of n-3 PUFAs on 
the clinical symptoms in ADHD. 
Overall, my study showed that HPA axis dysfunction and inflammation may play 
a crucial role in ADHD and provided more evidence on their associations. My 
study showed that youth with ADHD has lower levels of cortisol and plasma 
BDNF and higher levels of inflammation biomarkers than TD youth. Moreover, 
my PhD further supported the role of n-3 PUFAs in ADHD. Children with 
ADHD have lower levels in DHA, EPA and total n-3 PUFAs than TD children. In 
addition, high dose EPA also improved prosocial behavior and cognitive function 
in children with ADHD with high inflammation. EPA may improve behaviour 
and cognitive function via counteracting the pro-inflammatory actions of n-6 
PUFAs.  
From a clinical point of view, my study helped to provide further insight into 
personalized medicine with n-3 PUFAs in children with ADHD. I found that EPA 
is not effective in all children with ADHD and is only effective in the 
subpopulation of children with high inflammation, either with a low baseline EPA 




PUFAs supplementation to provide for a better effect of n-3 PUFAs on the 
clinical symptoms of ADHD, since some of the children with ADHD may carry 
the FADS2 SNP that is associated with the lack of conversation enzyme between 
EPA and DHA. Future studies should incorporate a longer study period e.g. 6 to 
12 months to compare the effects of DHA, EPA, DHA+DHA supplementation 
with placebo in children with ADHD. Moreover, a study with a larger sample size 
in children with ADHD with high inflammation, e.g., low EPA or high hs-CRP, 
is warranted to repeat my PhD findings. 
 
4.9 Conclusion 
My PhD provide evidence that ADHD youth have lower cortisol, BDNF and 
PUFAs levels and a higher state of inflammation than TD youth. My finding also 
supported the efficacy of n-3 PUFAs, especially EPA, in improving inattention, 
response consistency and vigilance associated cognitive measures in ADHD, 
particularly in youth with a low baseline EPA. My PhD also found that youth 
with a high baseline hs-CRP benefit more from high dose EPA supplementation, 
particularly on prosocial behavior and working memory. Further research is 
needed to explore the effects of EPA on the clinical symptoms of ADHD 
targeting a larger sample size of youth with high inflammation. In conclusion, my 
PhD supports n-3 PUFAs, particularly EPA, as a potential treatment in improving 
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Please indicate the frequency of the symptoms of your child by circling the 
number corresponding to the frequency of the symptom (0 is not at all and 3 is 
very much) 
 Frequency 
Symptoms Not at all Just a little Pretty much Very much 
Dry skin 0 1 2 3 
Scaling skin 0 1 2 3 
Eczema 0 1 2 3 
Chapped Skin, skin 
peeling 
0 1 2 3 




Dull skin without 
glow 
0 1 2 3 
Small skin bumps 0 1 2 3 
Mixed oily and dry 
skin 
0 1 2 3 
Thick scabs 0 1 2 3 
Slow growth of hair 0 1 2 3 
Cracked nails 0 1 2 3 
Dull nails 0 1 2 3 
Dry mouth/throat 0 1 2 3 
Easily thirsty 0 1 2 3 
Dry eye 0 1 2 3 
Increased in amount 
of ear wax 
0 1 2 3 
Allergy 0 1 2 3 
Fatigue 0 1 2 3 
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